Slashdot Mirror


The Law of Unintended Consequences: Patents

An anonymous reader writes "Fortune has an interesting article about the relationship between patent law and innovation. It compares the biotech industry with the computer industry and discusses the effects of the Bayh-Dole amdendment, which has allowed universities to make a lot of cash. But in the process innovation and scientific collaboration seem to have been stifled."

304 comments

  1. What Are They Talking About? by TheComputerMutt.ca · · Score: 4, Funny

    Of course patents help science and tech! If patents hadn't existed, The Great E could never have gotten a job at the patent office, and may never have ended up making his amazing findings, or maybe never publishing them.

    Where would we be then?

    1. Re:What Are They Talking About? by halcyon1234 · · Score: 4, Funny
      Of course patents help science and tech! If patents hadn't existed, The Great E could never have gotten a job at the patent office, and may never have ended up making his amazing findings, or maybe never publishing them.

      Where would we be then?

      Moving faster than the speed of light, that's where we'd be.

    2. Re:What Are They Talking About? by TheComputerMutt.ca · · Score: 2

      And back in time?

    3. Re:What Are They Talking About? by syousef · · Score: 2, Informative

      I hope this was meant to be funny. I'm sure he'd have gotten a job elsewhere. Whether it allowed him the time to develop his theories is a different matter, but make no mistake someone would have developed them very soon thereafter because all the context was there waiting for an enquiring mind with a slightly quirky and rebelious way of looking at things to work out what was happening.

      --
      These posts express my own personal views, not those of my employer
    4. Re:What Are They Talking About? by halcyon1234 · · Score: 4, Funny
      And back in time?

      In theory. But then you might accidently reinvent the Patent process and *bang* we've got Einstien again (re-again?)... AND a paradox.

      Are you happy, now... urr... then?... um...

    5. Re:What Are They Talking About? by TheComputerMutt.ca · · Score: 1

      It was meant as a joke, mainly. Although you never know, it's possible that it could never have been discovered if not for patents -- it's just not very likely. :P

    6. Re:What Are They Talking About? by Austerity+Empowers · · Score: 1

      and if we let castro play baseball maybe I could vacation in sunny cuba.

    7. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      You don't happen to know his current /. handle, do you?

    8. Re:What Are They Talking About? by tambo · · Score: 3, Informative
      Ah yes, another good "let's bash patents" thread on Slashdot.

      The irony in this case is that the Bayh-Dole Act has almost nothing to do with patents. The overlap is essentially nil. Before the Bayh-Dole Act of 1980, universities could patent inventions; after the Act, universities can still patent inventions, in exactly the same manner (foregoing the completely unrelated changes in patent law.)

      What the Bayh-Dole Act changed is who gets to commercialize federally-funded inventions.

      Before the Act, all inventions created by federal grants, which of course are almost all academically-created inventions, were owned by the federal government. But the government had a terrible track record of commercialization. As a result, the technologies and patents just got locked away inside the government and went unused. Eventually, the patents expired; but no company was willing to spend R&D developing a brand-new but unpatented product - if it succeeded, competitors would just copy it.

      The Bayh-Dole Act recognized and remedied this functional problem. Universities were allowed to keep and commercialize the rights to inventions created by their employees. That commercialization usually entails patenting the invention, and then exclusively licensing the patent(s) to a single company, so that they can develop a product. In fact, the Bayh-Dole Act places affirmative obligations on the university to commercialize it in a timely manner: if they don't, the federal government can seize the rights to the invention and patents.

      Now let's talk results. If you want to see the benefits of the Bayh-Dole Act, look at pharmaceuticals. How many new, extremely useful drugs have hit the market in the last 25 years? I am not a defender of big pharma - their enormous lobbying efforts and enormous profit margins reflect an obese and gluttonous industry - but it's undeniable that they have created a host of useful drugs since the Bayh-Dole Act passed.

      So that's the Bayh-Dole Act in a nutshell. Hopefully it's apparent that this has essentially nothing to do with patents. It pertains to who is responsible for commercializing an invention: the university that created it, or the federal government. We can certainly discuss the positive and, yes, the negative aspects to pressuring universities to commercialize their technologies; but that's a completely different discussion than the effect of patents on innovation.

      (One common but flawed Slashdot comment that I'd like to head off at the pass: the ridiculous notion that taxpayers are somehow "paying for the invention twice" by first funding the research, and then paying monopoly prices for the drugs. That reasoning is specious, because the public is paying once for two discrete steps. First, an institution creates an idea for curing a disease, like "let's inhibit this protein as a cure multiple sclerosis." Taxpayer dollars cover that step. Second, a company takes that idea and spends $$$$$$$ to develop a drug that executes this principle. That's paid for by customer purchases and health insurance. They're two distinct steps - not "the same thing" being bought twice.)

      - David Stein

      --
      Computer over. Virus = very yes.
    9. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 5, Insightful


      As usual, you didn't read the article or get the point.

      While Bayh-Dole was about commercialization of products developed with federal funding by universities (not particularly onerous a concept if you accept the basic concept of the state in the first place), the "unintended consequence" was patent legal wars - which are a direct result of there being patents.

      And then you have the nerve to talk about pharma - which is exactly the point and example of the article.

      RTFA next time.

      And yes, you DO pay twice (or X or multiple times X) when the company is granted a monopoly on a drug invented by someone else. The issue - and the point of the problem the article has with Bayh-Dole - is that those with patent monopolies tend NOT to license or cross-license their products - which raises the cost of those products to monopoly rates and limits the spread of the IP - which is supposed to be the point of patents in the first place.

      Just because patents are supposed to grant you a monopoly, that monopoly is supposed to be limited in time and subject to the provision that the IP gets licensed to all comers, so invention and distribution are both served.

      Of course, it doesn't work that way. Monopoly is monopoly - I get it all, you get nothing. That's how humans work when they can use the coercive power of the state in their favor.

      In a TRUE free market, you take your chances and the only thing keeping you from bankruptcy is smarts and speed.

      And that's how it SHOULD be - raw evolution in action.

      You monkeys just can't handle that, however.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    10. Re:What Are They Talking About? by soundofthemoon · · Score: 4, Interesting

      First off, mod parent up. That was a wonderfully cogent explanation.

      However, I think there is still a case to be made that drug companies are getting something of a free ride at taxpayers' expense. Sure, they still have to invest money in bringing a drug to market, and paying for the trials to do that is expensive. But they do get a big break by the taxpayer footing the bill for much of the basic research. Perhaps drug companies that market medications based on publically funded research should have to pay back the cost of the research into the fund, so it can be used to pay for further research. That seems like a start at fair compensation for lowering their product development risk by several orders of magnitude.

    11. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      Parent not off topic!

    12. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      You don't happen to know his current /. handle, do you?

      Anonymous Coward

    13. Re:What Are They Talking About? by tambo · · Score: 5, Insightful
      ...and I'll follow up that post with some observations about the problems with academic research.

      Basic academic research is a phenomenally important beast - perhaps the most important component of our long-term economy and the long-term health of our nation. It's impossible to overstate this or to use enough hyperbole here.

      And contrary to the tiresome pop-culture tirades, America doesn't have a terrible shortage of scientists. We could use more, sure, but our labs are jam-packed with Ph.D.s and incoming students. In fact, we have a slight overabundance of them, which is reflected in their unappreciatively low salaries.

      When I talk to scientists about the factors holding back their research - which I do frequently, in fact, as part of my job - I get a pretty consistent answer.

      Grants are getting more competitive. While federal funding overall is growing, it hasn't kept pace with the explosion in life sciences research in labs across the country. Life sciences research complexity and data have experienced Moore's-Law-like rates of growth; just look at the sizes of GenBank and the Protein Data Bank over time. But because all universities are increasingly focusing on federal research dollars (in part because their academic rankings are based on it), it's becoming harder every year to get a grant funded. Scientists must show more data, and argue more convincingly that the research is useful.

      Contributing factors:

      The federal government has taken a stronger role in guiding research. A growing proportion of federal funds is earmarked for research on specific topics - e.g., AIDS or bioterrorism defenses. This necessarily diverts funds away from other areas of research.

      Also, the administrative oversight of federal grants has grown. Universities are now held to much stricter rules about how those federal funds are spent. If a grant proposal indicates that a scientist will commit 40% of his employment to a project, he must actually commit that 40%. Funds must be carefully tracked by university admins - no more "I want to buy a Light Cycler with my unrelated grant money" discretionary BS.

      These are real rules, and are strictly enforced. The penalties for violating them include paying the grant money back to the federal government, large penalty fines, and potentially getting barred from future federal funding. As a result, scientists and university admins have to spend tremendous time on administrative tasks - which detracts from research.

      Those are the factors that scientists most frequently cite. Surely there are others.

      - David Stein

      --
      Computer over. Virus = very yes.
    14. Re:What Are They Talking About? by Nutty_Irishman · · Score: 1

      Bah, it never was Einstein's theory in the first place, didn't you see the family guy episode?


      Albert Einstein: And what is it you want to patent, Herr Smith?
      Herr Smith: I call it "Smith's Theory of Relativity."
      Albert Einstein: Hey, look at this.
      Herr Smith: What?
      Slams guys head with shutter and runs off with the theory

    15. Re:What Are They Talking About? by tambo · · Score: 4, Interesting
      RTFA next time.

      I did RTFA. Like all Fortune articles, it's ten pages long, comprising four pages of anecdotes, two pages of buzz-clip quotes, four pages of unsupported supposition, and zero pages of logical reasoning. Fortune caters to the C?O set, so it eschews attention-span-draining critical analysis for talking points.

      And yes, you DO pay twice (or X or multiple times X) when the company is granted a monopoly on a drug invented by someone else. The issue - and the point of the problem the article has with Bayh-Dole - is that those with patent monopolies tend NOT to license or cross-license their products - which raises the cost of those products to monopoly rates and limits the spread of the IP - which is supposed to be the point of patents in the first place.

      Of course they don't license their products. If you spent $5 billion developing and testing a new drug, would you let your competitors buy the rights to sell their own versions? And if you did, how quickly do you think your company's investors - the people who paid money to help build your company - would sell their stocks and run?

      Again, I'm not here to defend the pharmaceutical industry, which I view as undeniably corrupt. But their product strategy is simple reality, owing to the very simple fact that copying is easier than innovating. Isn't that why everyone (rightly) criticizes Microsoft - because it lets everyone else take the R&D risks, and then just copies their ideas? (Stacker/DoubleSpace, Netscape/IE, Eudora/Outlook, WordPerfect/Word, etc.)

      - David Stein

      --
      Computer over. Virus = very yes.
    16. Re:What Are They Talking About? by tambo · · Score: 2, Insightful
      I think there is still a case to be made that drug companies are getting something of a free ride at taxpayers' expense.

      In general, I agree with you. Like oil companies, pharmaceutical companies achieve annual net profits that can only be described as indefensible.

      I like your idea about channeling some big pharma profits back into basic research. But I think that's an indirect route to solving the core problem with big pharma: the complete lack of a normal capitalist buyer/seller market for prescription drugs. No patient in America knows or cares how much drug companies actually get paid for their prescription, since they never pay the price directly; the costs are completely hidden by the impenetrable bureaucrasies of health insurance and federal healthcare payments. It's a ridiculous scandal, but one that most Americans will only see in retrospect after it has collapsed.

      Pressuring big pharma to sell drugs at more realistic prices would tremendously reduce the crushing healthcare burden on the federal government. Those spare tax dollars could be used in many other ways - for instance, more federal funding of basic research.

      - David Stein

      --
      Computer over. Virus = very yes.
    17. Re:What Are They Talking About? by laughingcoyote · · Score: 1

      But I think you're missing something-if that idea was developed using public money, mine and yours, isn't that idea publically owned, mine and yours? It'd be ridiculous for government funds to be used to build a road, and then the contractor who already received the money be allowed to set up toll booths to collect more from the taxpayers who drive on it. Can you explain to me how this is somehow different (tax money funding the initial product, then the private entity who -already- benefited from the tax money being able to charge more money for the product)? The organization doing the developing of the final product is still, directly or indirectly, receiving the tax money or the fruits thereof.

      --
      To fight the war on terror, stop being afraid.
    18. Re:What Are They Talking About? by parvati · · Score: 4, Interesting

      There are most definitely other problems, many of which are overlooked during all the hand-wringing of "we don't have enough (US) scientists".

      A) Over the past 5 years, there are a huge increase in federal funding for basic research. Unfortunately, most of the money went to fund a few large-scale projects run by well-investigators--we're talking about guys who are already at the peak of the funding heap and don't really have to worry about their salary and their entire labs' salary and jobs depending on whether the grant submission scores in the top 9% (probably be funded), or outside of the top 12-15% (probably not funded). What I'm saying, long-windedly, is that much of the recent increase in NIH money made a few large-scale, high-profile projects even larger, at the very same time that young invenstigators were seeing a precipituous drop in the percent of acceptance for the smaller new investigator grants.

      b) 6 years of grad school, a doctorate, and then you find out that you really aren't paid any better than losers straight from Party U--and THEY probably get health care. Raise your hand if you're ready to quit yet, since your first grant is going to be rejected anyway.

      c) it never fucking ends. You can be president of the school and a nobel prize winner and so important that they've decided to make you the first human cloned, and your grant STILL only has a 10-18% chance of being funded.

      So, um, I can't remember how this pertains to the patent thing. The key to remember, however, is that the Pharmas tend not to do the most productive basic research, so many of the potential drugs arise from federally-funded work a universities, where people are pursuing utterly novel stuff. It's good for the rest of us to provide a mechanism for the school to approach a biotech and offer that novel product in exchange for any possible royalties.

      The only bad patents are patents on genes or part of the genome. Those are fucking stupid and people should be beaten.

    19. Re:What Are They Talking About? by tambo · · Score: 1
      I think you're missing something-if that idea was developed using public money, mine and yours, isn't that idea publically owned, mine and yours?

      That's what we had before the Bayh-Dole Act: such inventions were owned by the federal government on behalf of the people. It didn't work out too well. No company could afford to step up to the plate, take the idea off of the shelf, and develop it into a successful product - not without the ability to prevent competitors from immediately copying it. It was a completely unfeasible business model. It was so bad that it prompted massive federal legislation, in the form of the Bayh-Dole Act, to repair it.

      In essence, if you want to dispense with the monopoly-drug business model, you'll have to replace the entire second half of the development track for drugs. You'll have hundreds or thousands of raw, freely usable ideas for diagnosing and curing disease. It will be up to you to figure out how to use them. And good luck with that - it's usually a pretty hard technical problem, taking several man-decades of experimentation. Alternatively, you can just buy a formulation on the store shelf with no FDA testing... perhaps a Wikipedia page containing dozens of (anonymous) recommendations of which drugs cure which diseases....

      - David Stein

      --
      Computer over. Virus = very yes.
    20. Re:What Are They Talking About? by cyberon22 · · Score: 5, Interesting

      Hear hear! Grandparent post has clearly not read the article, the basic logic of which is as follows:

      (1) Inventions are now patented which would not have been patented previously because researchers could not *automatically* get patents for federally-funded research. There was a complex process that wasn't invoked for relatively trivial or cumulative research.

      (2) The change in law led to a cash grab, and a research culture in which universities encouraged staff to patent any new developments, even those growing out of collaborative research. This led to commercial barriers being formed (licensing) which inhibited research and industrial application.

      (3) As a result of #2, the amount of research flowing back into the academic commons is being sharply reduced. This is also inhibiting research.

      (4) As a result of #2 and #3, there is a visible and statistically significant reduction in the amount of innovation in the drug industry since 1980, measured in terms of the amount of significant new drugs being made available to the public, and those which are significant enough to merit fast-tracked approval.

      So parent post is correct. You *do* pay twice, because you are paying licenses to use technology which was never previously patented because it grew out of the public domain and so there were greater barriers to patenting it because a bureaucratic approval process was required.

      The argument is that the law made it possible to commercialize things which were not commonly commercialized before.

    21. Re:What Are They Talking About? by symbolic · · Score: 3, Insightful

      but it's undeniable that they have created a host of useful drugs since the Bayh-Dole Act passed.

      This implies that none of these drugs would have been developed without the act. Pharma wasn't exactly hurting before the act, and it's defintely not hurting now. Who wins? The American consumer doesn't, as they are subject to inflated drug prices.

    22. Re:What Are They Talking About? by laughingcoyote · · Score: 3, Insightful

      If your premise is correct, why were new drugs and treatments coming out before 1980? If your premise is correct that we'd be reduced to "a Wikipedia page" without this rampant patenting of everything, shouldn't that have been the state of things before it?

      --
      To fight the war on terror, stop being afraid.
    23. Re:What Are They Talking About? by SerpentMage · · Score: 5, Insightful

      I personally think you skimmed the article.

      However, lets get to the reality of patents. First there is no NEED whatsoever to spend 5 billion to develop a test a drug! 5 billion is 5 billion! The argument that you need so much money to bring out a drug is bogus! The biotech industry can do with less, but because it is so easy to pump the clientel it is done!

      I detest patents because they don't promote innovation. Cars became popular because a Mr Henry Ford broke the car patent and mass produced a car! It is possible to earn money in an pure competition world.

      The reason why biotech is different is because it deals with the lives of humans, and that is why I don't agree with patenting of drugs. I like capitalism, but bio-tech is a vulture preying on the lives of humans. They say, "Oh you want to live? Well here is a drug, but guess what it is going to cost you!" That, my friend, is very scummy! Again not against those that want to earn money, but reasonable money like all other industries!

      I am glad that you mentioned Microsoft. First yeah sure Microsoft copies, but Netscape was not the original maker of the web browser, neither was Eudora, neither was WordPerfect. If you accurately check your history books before Netscape was what Tim Berners Lee wrote, before WordPerfect was Wordstart, and the list continues.

      In other words you have proved the argument that by copying we get a vibrant industry! You get real innovation! Because copying is evolution as multiple ideas are combined to create a new idea!

      --

      "You can't make a race horse of a pig"
      "No," said Samuel, "but you can make very fast pig"
    24. Re:What Are They Talking About? by Vicissidude · · Score: 3, Insightful

      You *do* pay twice, because you are paying licenses to use technology which was never previously patented because it grew out of the public domain and so there were greater barriers to patenting it because a bureaucratic approval process was required.

      To put it clearly, US taxpayers pay twice from the taxpayer money the government earmarks for drug research AND the money that the taxpayer then spends on drugs.

      What makes this even worse is that the drug companies then sell the drugs in countries such as Canada for less than what they sell it in the US. In that way, the US taxpayer is triple screwed over.

    25. Re:What Are They Talking About? by zby · · Score: 2, Interesting

      The main idea behind patents was that companies don't hold the ideas secret so that other can build further inventions upon them. If you admit that companies don't licence their inventions to others than it means that you agree that patents dont support their reason d'etre. Perhaps it is not that all patents are wrong, perhaps we only should change the law so that companies can profit from licencing patents more than from keeping them for themselves.

    26. Re:What Are They Talking About? by geminidomino · · Score: 1

      No patient in America knows or cares how much drug companies actually get paid for their prescription, since they never pay the price directly; the costs are completely hidden by the impenetrable bureaucrasies of health insurance and federal healthcare payments

      As someone who has spent most of the last 10 years with either utterly shitty prescription coverage or no coverage at all, allow me to say this:

      Bullshit. Some of us know that Imitrex is $18/dose for a medication that seems to be about 40% effective (IME). And that's LIGHT compared to some of the active-patent drugs out there.

      Because they can fleece the insurance companies by giving a headache pill 5x the street price of cocaine (gram for gram), the have no qualms leaving the ones without decent insurance to suffer.

    27. Re:What Are They Talking About? by John+Newman · · Score: 1
      In essence, if you want to dispense with the monopoly-drug business model, you'll have to replace the entire second half of the development track for drugs. You'll have hundreds or thousands of raw, freely usable ideas for diagnosing and curing disease. It will be up to you to figure out how to use them. And good luck with that - it's usually a pretty hard technical problem, taking several man-decades of experimentation.
      You're right, that sounds like an utterly intractable problem. If only there were some other way, some way of organizing people...lots of people. Using their money, together, to hire impartial experts to work for them. And then making the results available to all. I don't just mean a few dozen people, or a few thousand, I mean MILLIONS AND MILLIONS. Heck, why not just bring *everybody* in? We can all band together and do incredible things that would be out of reach of any of us individually. We can even select our own leaders to decide how our money gets spent, and have public debates about whether they're doing a good job. Everything will be transparent and accountable, and all working to the benefit of all of us! I shall start this great organization. I shall create it, for all of us. And I shall call it...

      government.
    28. Re:What Are They Talking About? by HuguesT · · Score: 3, Insightful

      Hi,

      In fact, this:

      > c) it never fucking ends. You can be president of
      > the school and a nobel prize winner and so
      > important that they've decided to make you the
      > first human cloned, and your grant STILL only has
      > a 10-18% chance of being funded.

      this is good! Grants should be awarded on merit and not on who they are for.

    29. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 4, Insightful

      "If you spent $5 billion developing and testing a new drug, would you let your competitors buy the rights to sell their own versions?"

      What part of LICENSING don't you understand?

      You license so you can partake of the profits of everybody else selling your invention as well or better than you can yourself.

      By not licensing, all you do is stimulate everyone else to come up with a better product - under a different patent - and put you out of business.

      Read my lips. Patents don't last. No form of IP lasts. Monopolies that are not coercively protected by the state do not last. If you rely on a patent to make you money, you will shortly go out of business or spend most of your monopoly profits fighting legal battles in court.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    30. Re:What Are They Talking About? by banana+fiend · · Score: 3, Informative

      "but it's undeniable that they have created a host of useful drugs since the Bayh-Dole Act passed."

      Nonsense! Nothing stated without proof is undeniable. As a matter of fact, the exact opposite of that statement was made in the article - they state that these "useful" (new, better - esp. for cancer, not just rehashes) drugs are coming out at a SLOW rate, not in "hosts" . (honestly now, did you actually read it?).

      Where are you getting these figures from? You're going to have to do better than that. How about the NME's or high-priority drugs (If you don't know the term RTFA)? Granted, the article states that 2004 was a bonanza year (without stating how much so) - but the previous years?

      Let's get some figures from you.

      --
      Johns: Well, how does it look now? Riddick: Looks clear.
    31. Re:What Are They Talking About? by Anspen · · Score: 1

      I've never understood why it is legal to license patents only to a single company (or for a company to keep a patent for itself). Seems to me that the fundamental advantage of patents (making invents more profitable and spreading knowledge) would be served better by giving inventors the rights to inventions but also the requirement to licence them for a fair price.

    32. Re:What Are They Talking About? by Fragglebabe · · Score: 0, Offtopic

      I wish I had mod points today. I haven't seen such an excellently argued and well-rounded point in a long long time. Well done, hopefully someone with the hallowed mod points will notice your comment and give you the recognition you deserve.

      --
      Insane people are always sure they are fine. It is only the sane people who are willing to admit that they are crazy.
    33. Re:What Are They Talking About? by smittyoneeach · · Score: 2, Interesting
      First there is no NEED whatsoever to spend 5 billion to develop a test a drug! 5 billion is 5 billion! The argument that you need so much money to bring out a drug is bogus! The biotech industry can do with less, but because it is so easy to pump the clientel it is done!
      Oh, come on.
      There is so much money in pharma, that everyone, at every level of the economy, from the FDA, to lobbyists, to insurance companies, to advertisers, to sharks, to doctors, to resorts hosting boondoggles is in on the act. Of course it's going to cost 5 billion.
      Welcome to the scam.
      Oh, and the actual product does about as much as Dr. Foobar's Miracle Cure-All from the early 1900's? You can't expect anything costing that much to be worthwhile, can you?
      --
      Get thee glass eyes, and, like a scurvy politician, seem to see things thou dost not.--King Lear
    34. Re:What Are They Talking About? by salesgeek · · Score: 1

      As a result, the technologies and patents just got locked away inside the government and went unused.

      This is a crock. Government research into basic technologies for the space program, NASA, military (especially aviation) programs and the department of energy have delivered incredible advancements without 25 years of waiting for greedy bastards to loose their monopolistic attitude. The issue now isn't the patent. It's the fact that I can use patents to shelf a technology or prevent it's application, period. We really need better definition of reasonable license fees and possible shortening the length of time something can be patented... then there's the issue of what is actually patentable.

      First, an institution creates an idea for curing a disease, like "let's inhibit this protein as a cure multiple sclerosis." Taxpayer dollars cover that step. Second, a company takes that idea and spends $$$$$$$ to develop a drug that executes this principle.

      Two bad things happen under this model:

      1) I am being forced to invest in your company by paying your R&D costs.

      2) You are patenting a scientific fact (the principal by which a medication or class of medications works).

      The result is that pharma companies / university "partners" operate without having to make real economic R&D decisions (as long as you can fool the agency writing your grant) and are incented to force research just for the sake of getting patentable grants. Second, because you've locked up the scientific facts that are used to engineer an invention, not just how your specific invention actually works, you lock out more than just a few competitors. The result is that state of the art in MS medication is late 70s early 80s era interferon based protiens that help a little bit and cost a metric ton (my father is a doctor with MS - and has and will continue to suffer because research moves at a snails pace). So much so that most of those insurers you suggest will pay for it will not. So I get to pay again with my tax money via medicaid/medicare or the VA.

      Patents in their current for:

      1) Stifle innovation by locking away facts instead of protecting inventions. See genetic patents and software patents as examples.
      2) Are in force for too long a time. Many patents are obsolete before the 25 years expire.
      3) Allow technologies that could have great benefit to mankind to be shelved for 25 years or more for no other reason than greeed.
      4) Allow one person to patent the application of a nother's actual invention. My patented software requires IBM's computer to work. WTF is this?
      5) Are way, way too expensive to litigate.

      Don't defend greed.

      --
      -- $G
    35. Re:What Are They Talking About? by Znork · · Score: 4, Insightful

      "If you spent $5 billion developing and testing a new drug"

      The vast majority of the pharm money is not spent on R&D. It's wasted on marketing, administration and inefficient production.

      "But their product strategy is simple reality, owing to the very simple fact that copying is easier than innovating."

      The very simple fact is that once you have a monopoly, marketing, lobbying and litigating is easier than either copying or innovating.

      The very simple fact is that we're not getting even 20% efficiency out of the monopoly money we're paying.

      The very simple fact is that we'd get more than five times as much R&D done for the same money we're spending today if we simply got rid of the patents, paid for the R&D outright and let generic producers run a competetive industry instead.

    36. Re:What Are They Talking About? by Anonymous Coward · · Score: 1, Interesting

      If you think that developing biotech drugs in our modern society, with the current amount of litigation, clinical trials, reagents, and production costs is cheap, then you really are quite ignorant of how biotech research is conducted, and how biotech drugs are produced. It is very likely that drug (particularly biotech where patents aren't as important) companies will be able to stay in business if IP protections were removed, but they would shrink to a fraction of their current size, and the pace of research would slow drastically. If you took the time to look at what is going through Phas II and III clinical trials in the US (even just in the biotech industry) you would see that there are a LOT of potentially very powerful drugs about to come out. The pace of research has not slowed, the approvals process certainly has though.

    37. Re:What Are They Talking About? by Morrolan · · Score: 1
      However, lets get to the reality of patents. First there is no NEED whatsoever to spend 5 billion to develop a test a drug! 5 billion is 5 billion! The argument that you need so much money to bring out a drug is bogus! The biotech industry can do with less, but because it is so easy to pump the clientel it is done!

      Really bad argument... 5 billion (or whatever) is money... You believe that a hard core capitalist corporation will burn money just because it is sooooo easy to get more...

      You expect others to believe it too...

    38. Re:What Are They Talking About? by hcob$ · · Score: 1

      Probably still counting the dead from invading japan without a nuke.

      --
      Cliff Claven
      K.E.G. Party Chairman
      Founding Leader of: Koncerned for Egalitarin Governance
    39. Re:What Are They Talking About? by doradox · · Score: 1

      Say someone invents a new drug that could save lives. If a person doesn't buy it they aren't any worse off than before the drug was invented when the drug couldn't be purchased for any price. Without the profit motive and patent protection this new life saving drug would never even exist. You think it cost too much, then don't buy it. Or make your own damn drug.

      --
      If he really thinks we're the Devil, then let's send him to Hell.
    40. Re:What Are They Talking About? by SnapShot · · Score: 1
      This is the same logic that said, "Get in your SUVs and evacute New Orleans" and reflects a lack of understanding that a great number of Americans are not sitting in cushy office jobs with great drug benefits in their health insurance.

      Today, the Census Bureau reported that 45 million Americans lacked health insurance in 2003, up by 1.4 million from 2002 and 5.2 million from 2000. The report states that this increase is "statistically significant." *


      As an unrelated point, since I don't feel like posting a separate response elsewhere, does anyone think Fortune would bother writing this article if it were Merck or some other publicly traded drug company making these profits? I think their major issue is that you can't exactly buy stock in MIT (can you?).
      --
      Waltz, nymph, for quick jigs vex Bud.
    41. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      Whoever or whatever project gets the grant, at least in pharma, 90% of it goes to salaries anyway.

    42. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      this is good! Grants should be awarded on merit and not on who they are for.

      If I'm a university professor, I've been carefully selected based on being good at research. I can't educate graduate students unless I have funding for my research. So there needs to be some funding for this purpose. I believe the Canadian system operates along these lines. Put another way: you decide, do you want professors writing grant proposals or educating students?

    43. Re:What Are They Talking About? by KingEomer · · Score: 1

      How can you come up with a new and innovative way to cure a genetic disability if the proteins and genes responsible for that disability are patented?

    44. Re:What Are They Talking About? by Eccles · · Score: 1

      That's what we had before the Bayh-Dole Act: such inventions were owned by the federal government on behalf of the people. It didn't work out too well. No company could afford to step up to the plate, take the idea off of the shelf, and develop it into a successful product - not without the ability to prevent competitors from immediately copying it.

      So perhaps we should modify the system so the development and licensing rights go to the highest bidder?

      --
      Ooh, a sarcasm detector. Oh, that's a real useful invention.
    45. Re:What Are They Talking About? by tambo · · Score: 3, Interesting
      The argument that you need so much money to bring out a drug is bogus! The biotech industry can do with less, but because it is so easy to pump the clientel it is done!

      Seriously. Do you do any kind of research before you make such ridiculous statements?

      Do you know anything about the path between licensing a drug concept from a university, and actually putting a drug on the market? In part, it involves:

      • Research into chemicals that can effectuate the idea licensed from the university.
      • Research into the potential side-effects of this drug in the human body in a wide variety of circumstances.
      • Research into potentially adverse interactions with every other drug on the market.
      • Research into drug formulation: assessing various chemical structures for maximum effectiveness, dosage and frequency tweaking, additives to prevent spoilage, and additives to reduce side effects (upset stomach, etc.)
      • All of the infrastructure for actually manufacturing the drug on a very large scale.
      • Costly experimentation of the drug in cell lines and animals to make sure it works as expected.
      • Phase I clinical trials: tests of low doses in a small group of humans to test for serious adverse events - stuff like, you know, death.
      • Phase II clinical trials: months or years of long-term testing on hundreds of patients, as a long-term efficacy test. And since these are double-blinded, they require a large control group of patients to receive placebos.
      • Phase III clinical trials: several years of testing on thousands of patients for more thorough testing and tweaking before the product goes on the market.
      • And, of course, the infrastructure to submit all of this data to the FDA and to push for approval of the drug for clinical use.

      By necessity, this is a lengthy, complex, costly process. If you shortcut the process, you get, you know, thalidomide.

      I detest patents because they don't promote innovation. Cars became popular because a Mr Henry Ford broke the car patent and mass produced a car!

      Your example is not an example of a "patent-free world." It's an example of a deceptive patent system that lures a company to develop a product by a promise of monopoly that turns out to be illusory. And you're right - that works very well... until those developer companies realize that it's consistently illusory, and stop developing new products. Then you're screwed.

      I like capitalism, but bio-tech is a vulture preying on the lives of humans. They say, "Oh you want to live? Well here is a drug, but guess what it is going to cost you!"

      For most Americans, the answer is: very little. Usually it's like a $2 co-pay, thanks to the miracles of health insurance and Medicare prescription drug benefits.

      Of course, it's nowhere near this cheap. It's just that the costs are defrayed through other mechanisms. Those mechanisms absolutely need an overhaul - they're buckling under the weight of pharmaceutical company markups and other sleaziness - and we need to extend them to all Americans. But the drama you see in the sitution just doesn't exist for most Americans.

      In other words you have proved the argument that by copying we get a vibrant industry! You get real innovation!

      That's a more plausible argument in software, where the development costs are essentially nil. It's less persuasive in biotech because of the large initial costs.

      In fact, the field of pharmaceuticals proves your suggestion catastrophically wrong. Do you have any idea how many great ideas for drug targets are unpatented, unexploited, and ready to be tried? Many thousands - probably closer to a million. We have hundreds of ideas for drugs that would probably cure every disease on the planet. They're not patentable, so they can be freely used!

      In light of this fact, do smaller drug companies choose to develop new drugs based on them? No. They create knockoffs of Viagra and

      --
      Computer over. Virus = very yes.
    46. Re:What Are They Talking About? by tambo · · Score: 1
      What part of LICENSING don't you understand?

      Very little, I believe - as I have executed approximately 2,000 IP-related licenses for an academic institution. (My experience is irrelevant to this discussion, but since you brought it into play, I figured I'd answer it.)

      To get to the heart of your response: Let's say Merck develops a great new drug. Now they have two options: they can develop it themselves under a patent monopoly, or they can develop their version and license it to other companies to develop alternatives. Which one makes them more money? If it's the latter, why aren't they doing it already? And if it's the former, wouldn't the latter violate the company's fiscal obligation to give stockholders a return on their investments?

      If you rely on a patent to make you money, you will shortly go out of business or spend most of your monopoly profits fighting legal battles in court.

      That's awfully funny. Yeah, I'm sure that's why companies have tremendously cranked up their patent investments in recent decades - because patents completely don't work. A simple glance at the state of any large industry will demonstrate how wrong you are. I could explain why, but you wouldn't read the explanation.

      - David Stein

      --
      Computer over. Virus = very yes.
    47. Re:What Are They Talking About? by tambo · · Score: 1
      Inventions are now patented which would not have been patented previously because researchers could not *automatically* get patents for federally-funded research. There was a complex process that wasn't invoked for relatively trivial or cumulative research.

      I have no idea what you mean here. The process of getting a patent has not fundamentally changed since the Patent Act of 1952. Researchers had to jump through exactly the same hurdles to get a patent in 1979 as they did in 1981 (and today.)

      The change in law led to a cash grab, and a research culture in which universities encouraged staff to patent any new developments, even those growing out of collaborative research. This led to commercial barriers being formed (licensing) which inhibited research and industrial application.

      It hasn't impacted research much because (a) it's extraordinarily difficult to enforce any patent against the private research of another company, (b) there's little incentive to do so anyway, and (c) those other companies enjoy an "experimental use" exemption to patent infringement (which is narrow, but is being expanded.)

      And while it did create barriers to industrial application, it had the result of giving all of the rights to one company, instead of spreading them so thinly across a field that no company has an interest in developing it. That was the whole point - even though everyone had a right to use those inventions, no one was actually using them. The Bayh-Dole Act changed that.

      The amount of research flowing back into the academic commons is being sharply reduced.

      Completely untrue. The amount of federal funding flowing into the academic commons has grown over time - particularly in the last ten years. It's not keeping pace with the growth of research in academia, but by no metric has it been "sharply curtailed" - quite the opposite.

      You *do* pay twice, because you are paying licenses to use technology which was never previously patented because it grew out of the public domain and so there were greater barriers to patenting it because a bureaucratic approval process was required.

      Okay - tell you what. Pick a disease, any disease, for which there is a patented drug. I guarantee that you can spend some time in PubMed and find a few dozen other ideas for biological mechanisms for curing the disease. They don't infringe the patent, and you can freely use them! All you have to do is develop your own drug applying that concept. Or, you can buy some kind of non-FDA-approved herbal supplement that the Acme Corporation swears is effective for that purpose. Some ginsana for your cancer, perhaps?

      - David Stein

      --
      Computer over. Virus = very yes.
    48. Re:What Are They Talking About? by tambo · · Score: 1
      As someone who has spent most of the last 10 years with either utterly shitty prescription coverage or no coverage at all...

      I think that's terrible and needs to be fixed immediately. But according to the U.S. Census, 85% of Americans have some form of health insurance. Many who don't can receive prescription drug assitance from the federal government. So most Americans are not in your situation.

      - David Stein

      --
      Computer over. Virus = very yes.
    49. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1

      "I have executed approximately 2,000 IP-related licenses for an academic institution"

      Okay, obviously we see your bias here!

      "Which one makes them more money? If it's the latter, why aren't they doing it already? And if it's the former, wouldn't the latter violate the company's fiscal obligation to give stockholders a return on their investments?"

      Clearly you know nothing. The latter - licensing - obviously makes them more money (although there could be cases where it doesn't.) Spreading an invention wide and participating in the profits of numerous companies will return more income, over time, to the inventor than being the sole source of it.

      Why aren't they doing it? Greed and incompetent management usually explains most corporate actions adequately.

      Violate fiscal responsibility? Gimme a break. That is the LAST thing ANY corporate management gives a shit about. The only thing corporate management cares about is the stock value of their shares and their personal power in the corporation. There is no such thing as "fiscal responsibility". Anybody who says there is is a manager who is lying his ass off.

      As for the state of any large industry, kindly reread the article which compares the computer industry to the pharma industry. The computer industry widely cross-licenses. The cranking up of patent protection in that industry is merely another example of greedy incompetent management like Microsoft trying to defend against open source.

      And I didn't say patents didn't work to make money for a corporation. Clearly they do in many cases. What I'm saying is first, that patent monopolies don't make as MUCH money for the company as licensing does, and second, patents have a negative effect on inventing, both for a company and for the industry of which it is a part as well as other industries that might use the technology, which means companies end up not inventing as much because they're milking their patents instead. This is another way patents put a damper on the company's income - less invention output equals less income.

      That simple.

      You're just another clueless management type that can't comprehend that risk equals reward.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    50. Re:What Are They Talking About? by aug24 · · Score: 1
      6 years of grad school, a doctorate, and then you find out that you really aren't paid any better than losers straight from Party U--and THEY probably get health care.

      Frankly, if you didn't work this out sooner, you don't deserve that doctorate.

      Justin.
      (I decided not to do a doctorate when I found out I could earn a shit-load more playing with computers)

      --
      You're only jealous cos the little penguins are talking to me.
    51. Re:What Are They Talking About? by tambo · · Score: 1
      Government research into basic technologies for the space program, NASA, military (especially aviation) programs and the department of energy...

      ...which, together, produced a total of zero new prescription drugs. The Bayh-Dole Act is primarily aimed at basic biological research with the goal of creating new diagnostic and therapeutic drugs. Last I checked, neither NASA, the defense department, nor the department of energy was much interested in manufacturing pharmaceuticals.

      I am being forced to invest in your company by paying your R&D costs.

      No one is ever going to force you to buy a pharmaceutical. You always have the choice of not buying it.

      You are patenting a scientific fact (the principal by which a medication or class of medications works).

      Nope. You can't patent scientific facts. Every patent application must demonstrate that the invention is useful for a specific purpose. In fact, this is particularly true for biological compounds - recently, the USPTO and the courts have raised the threshold for patenting new drugs. Applicants can't just state "may be useful to treat cancer, or MS, or diabetes, or Lyme disease, or HIV, or ingrown toenails, or..." Rather, they have to present some data that would persuade "one of ordinary skill in the art" that it might actually work for a specific purpose.

      - David Stein

      --
      Computer over. Virus = very yes.
    52. Re:What Are They Talking About? by tambo · · Score: 1
      I shall start this great organization. I shall create it, for all of us. And I shall call it... government.

      And the current system is completely amenable to that.

      The federal government has a right to use, and even develop products for, every invention developed with federal funds - whether patented or not. If it so decided, it could develop a drug to compete with Viagra; it could even license the right to do so to another company.

      It has that power today. It could start doing it immediately.

      So why doesn't it? Answer: Because the federal government is not interested in developing drugs. That obvious fact, and obvious failure of the government to commercialize inventions, was the whole reason for the Bayh-Dole Act.

      If you want to change the situation, then I encourage you to do so. Enter the ranks of the NIH, reach some level of prominence where you can compel change, and create a program for federal-government-brand pharmaceuticals. The legal system is amenable to this, and it might be an interesting result. Good luck! We'll look forward to your success.

      - David Stein

      --
      Computer over. Virus = very yes.
    53. Re:What Are They Talking About? by tambo · · Score: 1
      The latter - licensing - obviously makes them more money...

      Yes, I'm sure you know more about the economics of licensing than the collective wisdom of the entire pharmaceutical industry combined. We'll just accept your statements at face value.

      Since you have this brilliant idea for a new method of marketing pharmaceuticals, then you should go start a new pharmaceutical company - maybe Open-Source Drugs, Inc. I presume I'll hear your name in 10 years as the man who revolutionized pharmaceuticals, and when I do, I'll come back to this thread and admit defeat. Good luck with that!

      Violate fiscal responsibility? Gimme a break. That is the LAST thing ANY corporate management gives a shit about.

      Right. That's why they spend so much time monitoring the stock price and financials of their companies. Not every company is Enron, you know.

      You're just another clueless management type that can't comprehend that risk equals reward.

      Wrong. I've never managed anyone in my life. I am in the trenches. I do the actual nuts-and-bolts work of negotiating licenses. And I do it on the side of academia, not big pharma - I have plenty of vitriol for the pharmaceutical industry, and I could go into great detail about how they maliciously oppress innovation and academia. Where you and I differ is that I don't see them as just monolithic Bad Guys - my overall view of the licensing process is that it's logical and it works, even if they have distorted it in several ways for personal gain.

      But you've seen fit to question my credentials, and now you know them. Might I ask you to return the favor, and share with us some of your credentials? Turnabout is fair play.

      - David Stein

      --
      Computer over. Virus = very yes.
    54. Re:What Are They Talking About? by Red+Flayer · · Score: 1

      "Just because patents are supposed to grant you a monopoly, that monopoly is supposed to be limited in time and subject to the provision that the IP gets licensed to all comers, so invention and distribution are both served. " (emphasis mine)

      BS. Licensing is at the discretion of the patent holder, as it was intended to be. The point of licensing was/is to allow inventors to profit from their ideas while not having to produce the tech themselves.

      "The issue - and the point of the problem the article has with Bayh-Dole - is that those with patent monopolies tend NOT to license or cross-license their products - which raises the cost of those products to monopoly rates and limits the spread of the IP - which is supposed to be the point of patents in the first place. " (emphasis mine)

      BS again. Lack of licensing != lack of IP distribution. Pharma for example -- the information is available to everyone, by law: composition of drug delivery vehicle (tablet, etc), molecular structure of the drug, etc. Why do you think that when one company releases a drug that acts via a new mechanism, there are similar drugs on the market from other companies as soon as the testing and FDA approval can get done?

      The problem with the patent laws is the duration.

      "In a TRUE free market, you take your chances and the only thing keeping you from bankruptcy is smarts and speed."

      And secrecy. Keep the valuable info to myself.

      "And that's how it SHOULD be - raw evolution in action.
      You monkeys just can't handle that, however.
      "

      Nice troll. What you appear to miss is that without patents, there is no profit incentive to share your discoveries. Where would your innovation come from then? Or would you prefer to limit technological growth? Obviously, you wouldn't want government to fund research, sincew that's not free market. So why would anyone invest hundreds of millions in research and research facilities when they will not earn the money back?

      In a TRUE free market, monopolies exist and bleed their customers dry. Yet, you think reverting to a true free market will reduce monopolies?

      --
      "Trolls they were, but filled with the evil will of their master: a fell race..." -- J.R.R. Tolkien on Olog-hai
    55. Re:What Are They Talking About? by tambo · · Score: 1
      So perhaps we should modify the system so the development and licensing rights go to the highest bidder?

      In theory, that's exactly what happens. The university holds the rights to the technology, shops it around, and licenses it to the company willing to pay the most. And the licensing revenue gets reinvested in the academic research of that university.

      In practice, it's not quite that effective. First, pharmaceutical companies often strong-arm their way into cheaper deals. Frequently, they donate a little bit of money or some reagents to a researcher, in exchange for rights to any invention that comes out of the research. Unless the researcher or the university's technology transfer office sees this as a problem and fights against it, the university gets very little revenue from the invention.

      Also, when it comes to licensing, there's a clear gap of expertise between pharmaceutical companies and academic institutions. Universities can't pay their licensing officers much, so they usually get guys fresh out of school who know very little about IP, biotech, and licensing. Many pharmaceutical companies take advantage of this.

      - David Stein

      --
      Computer over. Virus = very yes.
    56. Re:What Are They Talking About? by tambo · · Score: 1
      Today, the Census Bureau reported that 45 million Americans lacked health insurance in 2003, up by 1.4 million from 2002 and 5.2 million from 2000. The report states that this increase is "statistically significant." *

      45 million people = 15% of the population. The other 255 million Americans are the ones who, by and large, have no idea how much drugs cost.

      They probably vaguely know that drugs are expensive, and that healthcare costs are crushing America, but they really don't see much connection with their drugs. It's the same as with taxes: everyone knows we have a huge federal deficit, but no one is personally willing to pay $1 more in federal taxes (or give up $1 in federal benefits) to fix it.

      - David Stein

      --
      Computer over. Virus = very yes.
    57. Re:What Are They Talking About? by Eccles · · Score: 1

      In theory, that's exactly what happens.

      No it isn't. The differences are quite dramatic.

      By having the university be the license seller, it puts universities and researchers in competition with each other. Which means they don't want to share interim results, sue each other, act like corporations, etc.

      If the *Feds* were the license sellers, the profits would (ok, could) go back into all universities' research. No competitions, suits, etc. But there's still an incentive for the pharmaceutical companies to develop the ideas that, it is claimed, would otherwise not get developed.

      We want academic researchers to be working together, not against each other.

      --
      Ooh, a sarcasm detector. Oh, that's a real useful invention.
    58. Re:What Are They Talking About? by jafac · · Score: 1

      Read my lips. Patents don't last. No form of IP lasts. Monopolies that are not coercively protected by the state do not last.

      A Patent is a monopoly that is coercively protected by the state. If the state decides that patents should be extended, because the patent-holder brib- er, donates to re-election campaigns of office holders, then they sure as hell do last.

      --

      These are my friends, See how they glisten. See this one shine, how he smiles in the light.
    59. Re:What Are They Talking About? by jafac · · Score: 1

      The vast majority of the pharm money is not spent on R&D. It's wasted on marketing, administration and inefficient production.

      You misspelled "executive compensation" and "donations to political campaigns". Though the marketing is at least as significant as these.

      --

      These are my friends, See how they glisten. See this one shine, how he smiles in the light.
    60. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      >>If you accurately check your history books before Netscape was what Tim Berners Lee wrote, before WordPerfect was Wordstart and the list continues.

      *Sir Tim Berners-Lee wrote mosaic, not netscape. Netscape was based on mosaic, but it was a different animal.

      If you use a confrontation tone about checking accuracy, you'd do well to do it yourself 8 )

      Other than that your argument is sound. Software is already protected by copyright. Patenting it too is dual protection. You can't patent a chord change in a song, or the brush strokes you use in a painting, why should you be able to patent a compound structure in software? It's ludicrous and it's the same thing.

      I am against patents because of this dual protection. Dual protection is having your cake and eating it too and isn't fair to the rest of the people in the industry. Pick copyright or patent, not both.

      Imagine if 12 bar blues chord change structure had been patented, by one person, or the method and process of making a 3d piece of artwork from clay.

      Software industy and congress needs to make up it's mind...

      l8,
      AC

    61. Re:What Are They Talking About? by tambo · · Score: 1
      The main idea behind patents was that companies don't hold the ideas secret so that other can build further inventions upon them.

      Yes, the idea is to compel a public disclosure of the invention so that others can built on it - eventually, i.e., after the patent expires. That's exactly how it works - even in the pharmaceutical industry. Now that the patent for Prozac has expired, world+dog is making variations on it.

      But none of this happens unless you can compel the inventors to disclose the invention. That's what a patent does: a patent must be sufficiently clear and detailed to teach the public about the invention and how to use it. But you have to give the inventor something to compel that disclosure. If the reward doesn't exceed what he could make by keeping it as a trade secret, he won't disclose it.

      So the question is: How do you reward inventors? The drafters of the Constitution stridently debated this point. The best competing idea was that the government would pay some kind of reward fee, but they realized that the federal government couldn't afford to give sufficiently large incentives. They settled on the patent monopoly - a protected right to have the only product on the market for a few years, and charge higher prices as a result.

      Now, let's get back to your suggestion. If we institute a compulsory licensing scheme, where patentees must grant licenses to an invention, then we essentially short-circuit the reward system of patenting. Companies will stop applying for patents, and will instead keep the formula for Zoloft as a trade secret - giving them an monopoly on it until someone else happens to reverse-engineer it. And those companies will then waste resources by creating reverse-engineering methods, e.g., adding a thousand inert materials to their pills in order to frustrate analysis. That is inefficient and arbitrary.

      - David Stein

      --
      Computer over. Virus = very yes.
    62. Re:What Are They Talking About? by antonrojo · · Score: 1

      (One common but flawed Slashdot comment that I'd like to head off at the pass: the ridiculous notion that taxpayers are somehow "paying for the invention twice" by first funding the research, and then paying monopoly prices for the drugs. That reasoning is specious, because the public is paying once for two discrete steps. First, an institution creates an idea for curing a disease, like "let's inhibit this protein as a cure multiple sclerosis." Taxpayer dollars cover that step. Second, a company takes that idea and spends $$$$$$$ to develop a drug that executes this principle. That's paid for by customer purchases and health insurance. They're two distinct steps - not "the same thing" being bought twice.)

      It sounds like you're not including the 'monopoly tax' that medical manufacturers can add. The fact that company investment costs are paid by insurance companies and customer purchases does not avoid the 'paying twice' problem because there is no reason for monopolies to limit drug prices to cover investment costs plus a 'fair profit'.

      To the extent that a company can retain it's patent-based monopoly over drug/device manufacturing (difficult for phama companies in many third world countries) they are charging American taxpayers an additional monopoly tax for products that they already subsidized (where do you think the insurance $ originates from?). Sounds like paying twice to me.

    63. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      Really bad argument... 5 billion (or whatever) is money... You believe that a hard core capitalist corporation will burn money just because it is sooooo easy to get more...

      You expect others to believe it too...


      No, they'll pocket it, and claim it was "expensives".

      Capitialism is run on creative accounting. It's all about the tax dodge -- you pay out $5 million for a private island for the CEO to use, and the company writes it off as a "business expense", but the CEO never technically "owns" it, so it's not income, either.

      Companies don't burn money. They just lie about where it comes from, and where it goes.

    64. Re:What Are They Talking About? by russellh · · Score: 1

      By necessity, this is a lengthy, complex, costly process.

      In your bullet points you forgot marketing (including courting the doctors), on which is spent more money than all your other bullet points above combined.

      And you know, they don't really care all that much if the drugs actually work. They lobby to abolish the FDA. They want to sell their drugs for massive profits and have the federal government protect them from lawsuits (eg the thimerosal controversy). Yay.

      --
      must... stay... awake...
    65. Re:What Are They Talking About? by orgelspieler · · Score: 1

      I don't think Dr. Stein is a management type at all, judging from his lab. Just because you disagree with him does not mean you should resort to name-calling.

    66. Re:What Are They Talking About? by antonrojo · · Score: 1

      Read my lips. Patents don't last. No form of IP lasts. Monopolies that are not coercively protected by the state do not last. If you rely on a patent to make you money, you will shortly go out of business or spend most of your monopoly profits fighting legal battles in court.

      Generally I agree that this is how patents can and do in most cases and in most industries. However, the system only works if 1) the patent is specific enough to allow for innovation and relatedly 2) that alternative technoliges that satisfy the patent can be created

      As numerious, often sensationist, slashdot stories point out, point #1 is far from guaranteed, especailly in the IT world. Point #2 is much more pertinent to medicine since it is quite possible that either there is only one effective method for curing a virus or solving other medical problems and that finding alternatives that don't violate patents can take decades in exteme cases. The facts show that many pharma companies don't license based on a financial assessment that the short term profits from licensing are far smaller than the monopoly profits created by cornering the market on a high-demand drug, medical device, etc.

    67. Re:What Are They Talking About? by tambo · · Score: 1
      Heh - thanks for the support, but that's not me. David Stein isn't exactly a unique name!

      In fact, I do have two advanced degrees - but neither one confers the title of "doctor," unfortunately. I'm a patent attorney, and I have a masters in computer science. I'll probably go back and earn a PhD in artificial intelligence, if only out of curiosity, but that's down the road.

      But I do appreciate the support. The ad hominem stuff is out of place, of course - but this being the Internet, I'm used to looking past it. I usually write it off as the last refuge of the defeated pundit. ;)

      - David Stein

      --
      Computer over. Virus = very yes.
    68. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      Perhaps someone should come up with research reality television shows.

    69. Re:What Are They Talking About? by tambo · · Score: 1
      In your bullet points you forgot marketing (including courting the doctors), on which is spent more money than all your other bullet points above combined.

      I didn't forget it - I just didn't consider it a necessary precursor to putting a drug on the drug store shelf. Certainly there are a hundred similarly extraneous costs: follow-up research (including Phase IV clinical research), administration, facilities, scientific publications, legal support for the process.

      I agree that pharmaceutical marketing is pretty egregious. It's a weird trend that I don't fully understand.

      The typical drug company TV spot usually sounds like this: "Take Plavitor! It will improve your life! - Warning: Do not take Plavitor if you have any of the following 36 conditions..."

      What are they accomplishing with this? They're not informing their customers of what the product actually does. And it's not like they're successfully brainwashing patients into ambling down to the local Walgreen's and buying a prescription of Plavitor - it's a controlled substance. I guess they might be creating an army of zombie patients who wander into doctors' offices moaning, "Plavitor... must have Plavitor..." But presumably (hopefully) the doctors know that Plavitor specifically cures gout, and declines the requests of the 99.999% of patients who don't have gout. So presumably, this tactic doesn't really increase sales.

      I have a very strong objection to pharmaceutical companies lobbying doctors, congressmen, and insurance companies. That has a clear risk of biasing the system, and at the very least reeks of the "appearance of impropriety." This needs to change.

      However, I've never seen metrics for the amount of money spent on pharmaceutical advertising/lobbying vs. drug development, and your suggeston that the former outweighs the latter is a little hard to believe. Can you cite some figures? If this is true, I'd like to have them on hand.

      - David Stein

      --
      Computer over. Virus = very yes.
    70. Re:What Are They Talking About? by tambo · · Score: 1
      If your premise is correct, why were new drugs and treatments coming out before 1980?

      Because rather than licensing a novel idea from a university (which wasn't an option), pharmaceutical companies conducted their own in-house research. This was expensive, slow, unreliable, and generally incompatible with the business realities of for-profit companies like those in the pharmaceutical industry. It was a bad fit, and as a result, drug development was slower.

      - David Stein

      --
      Computer over. Virus = very yes.
    71. Re:What Are They Talking About? by NeutronCowboy · · Score: 1

      You still haven't read the article.

      It claims that new drugs (not old drugs repatented under a different formula and target) have come on the market less frequently than before the Bayh-Dole act. Thereby showing that pharma has become less productive since the inception of the act.

      You make a number of other mistakes in your posts (besides just pulling numbers out of your ass and making unsubstantiated claims like doctors recommending echinacea as a cure for cancer), but I'll focus on just one more. The costly experimentation in cell lines and animals that you think corporations do is actually done by the research scientists receiving those grants. At least, if you're still in the context of the article. Since this is a) the riskiest aspect of the business, and b)one of the most expensive aspects of drug development, it is accurate to say that the pharma companies are using tax dollars to do the hardest part of their work, and then simply go into management and marketing mode once they have something that looks useful.

      In short, the only thing you've proven so far is that you didn't read the article mentioned and are prone to absurd exaggerations to prove your point. Once you show some hard data that the Bayh-Dole act lead to an increase in productivity, we'll talk again. Until then, the evidence points firmly to an unintended consequence of stifling innovation by reducing the incentive for scientists to collaborate.

      --
      Those who can, do. Those who can't, sue.
    72. Re:What Are They Talking About? by tambo · · Score: 1
      You still haven't read the article.

      I like how "RTFA" has become the defacto "STFU N00B" comment. It has about the same amount of persuasiveness, too.

      It claims that new drugs (not old drugs repatented under a different formula and target) have come on the market less frequently than before the Bayh-Dole act.

      Did you see any metrics supporting that claim? No. Go back and look at page 6 - they dance around the issue, discussing life expectancy and pharmaceutical company revenue. The closest data that they provide to show that pharmaceutical development is unchanged is... wait for it... a suggestion that it's "worse." They make a hand-wave reference to charts that they don't cite. Notice that?

      Why would Fortune fail to include some numbers that support its core point? I spent some time this afternoon looking for metrics on the number of new drugs, or (as a different metric) approved NMEs, over the past decades. I didn't find any. It's suprisingly unavailable. Go ahead, look for yourself.

      There's a reason for that. This article attempts to analyze the rate of new drug developments (in order to answer an unrelated question about the FDA approval process.) From his article:

      "There is considerable variation across diseases--even diseases in the same broad disease groups--in the extent and timing of increases in the stock of available drugs. This is illustrated by Figure 6, which shows, for two conditions--diseases of the thyroid gland and diseases of other endocrine glands--the number of drugs available to treat the condition in year t, as a percent of the number of drugs available to treat the condition in 1979.23 Between 1979 and 1984, the number of drugs available to treat diseases of the thyroid gland increased 29%, while the number of drugs available to treat diseases of other endocrine glands increased only 13%. However, between 1984 and 1998, the number of drugs available to treat diseases of the thyroid gland did not increase at all, while the number of drugs available to treat diseases of other endocrine glands increased 33%."

      In a nutshell - it's difficult to measure the rate of new drug development, because the results vary depending on how you define key factors. Does this not raise some suspicion about Fortune's vague conclusion that drug development has gotten "worse?"

      The costly experimentation in cell lines and animals that you think corporations do is actually done by the research scientists receiving those grants.

      You're either being ignorant or clever. This preclinical research is done by academics - but under industry sponsorship, not under federal grants. Federal grants do not pay for drug validation. You couldn't get funding from the government to do that. The for-profit companies pick up the costs at that stage.

      Before your next post, try googling "industry-sponsored research."

      Once you show some hard data that the Bayh-Dole act lead to an increase in productivity, we'll talk again. Until then, the evidence points firmly to an unintended consequence of stifling innovation by reducing the incentive for scientists to collaborate.

      Again, nice trick. You're faced with two unproven assertions, and you choose to believe one without proof unless I can prove the other. That's not very rational.

      - David Stein

      --
      Computer over. Virus = very yes.
    73. Re:What Are They Talking About? by laughingcoyote · · Score: 1

      So, in other words, even by YOUR logic, things still worked, just a bit more slowly. I submit, then, that you've refuted your own "Wikipedia article" premise.

      Now, let's clarify. I have no problem with a pharmmaceutical company who looks at an idea from a university and develops a drug based on it being allowed to patent (and thus profit from) -that specific drug-. However, they should not be able to patent (and nor should publicly funded universities be able to patent) general knowledge, pure research knowledge, parts of genetic sequence, manipulated gene sequences, or similar. SPECIFIC drug formulas only, and only if the discovery of that formula is totally privately funded (aside from looking at the general idea from a university), please. This would not remove the profit motive, simply restrict it to the proper degree-while ensuring that basic scientific knowledge remains available to all, rather than locked away behind a patent, as is also the proper way to do things.

      I don't see it as "everything is patentable" or "nothing is patentable"-a specific drug formula is patentable (although MUCH stricter laws on required availability and price-fixing need to be in place if this is to continue), but a general knowledge principle (gene sequence x behaves differently then modified gene sequence y, modification is performed by procedure z) is not.

      --
      To fight the war on terror, stop being afraid.
    74. Re:What Are They Talking About? by NeutronCowboy · · Score: 1
      RTFA is indeed a STFU n00b statement.I'm not sure what else it would be - or would you like to argue that you can debate the validity of an article without knowing what it says?

      Hey, some data. Too bad it took a beating to get you to support some of your assertions.

      You're completely right - there's no smoking gun that points to a decrease in productivity in pharma development. Conversely, the smoking gun that the act has increased productivity is missing as well. What we do know though is that IP lawsuits have increased dramatically as a result of this enactment, and that the focus of universities has shifted from fundamental science to immediately profitable science. In my book, that's bad. And while 4 years are too short a time period to evaluate its impact, I doubt we'll see many benefits from it.

      Federal grants do not pay for drug validation.
      And exactly how do you think you get to that stage? By just picking a random drug? No - there's research involved to get to that stage. Academics remove the biggest cost pharmaceuticals face - risk.

      You're faced with two unproven assertions, and you choose to believe one without proof unless I can prove the other. That's not very rational.
      I see. Your implication would be, however, that it is impossible to deduce anything about these assertions. You also wouldn't happen to subscribe to the theory that only a-priori knowledge is true knowledge? Probably not. From the effects that we know the Bayh-Dole act had, we can deduce the likelyhood of it increasing or decreasing scientific productivity. Again, so far, signs point to a decrease, not an increase. Wake me up when you have evidence to the contrary.

      --
      Those who can, do. Those who can't, sue.
    75. Re:What Are They Talking About? by russellh · · Score: 1

      However, I've never seen metrics for the amount of money spent on pharmaceutical advertising/lobbying vs. drug development, and your suggeston that the former outweighs the latter is a little hard to believe. Can you cite some figures? If this is true, I'd like to have them on hand.

      here's one. it has an obvious agenda.

      My biggest problem with the pharmaceutical companies is fundamental; they have to be profitable like any other company, they need recurring revenue, and being public, they have to grow. We have to need their drugs, we have to remain sick for them to be successful. They don't win by curing diseases. So they need a different business model in which they win when diseases are eradicated. Putting everyone in maintenance mode should be the worst thing of all.

      Oh and btw, thanks for your level headed reply. it's... so refreshing here...

      --
      must... stay... awake...
    76. Re:What Are They Talking About? by cyberon22 · · Score: 1

      You clearly haven't read the article.

      No-one claimed that the patent system changed. The 1980 change allowed private researchers to patent inventioned funded with federal grants. It did this by eliminating the existing bureaucratic approval process for these types of applications.

      You can spin theories of how this is supposed to be wonderful for innovation. Anyone can. The point of the article is that there has been a striking DROP in innovative drug creation. This is hard evidence, and its particarly striking if your claim of increased federal funding for drug research is true.

      Strong evidence of a slow-down in innovation in drug research exists, and it exists regardless of whether you like it, or bother to read the article before trolling in response to someone who has.

    77. Re:What Are They Talking About? by tambo · · Score: 1
      The point of the article is that there has been a striking DROP in innovative drug creation. This is hard evidence, and its particarly striking if your claim of increased federal funding for drug research is true.

      What is the "hard evidence?" The fact that Fortune wrote that it's true, and that you want to believe them? I'm guessing you're a fan of Fox News.

      "Hard evidence" involves facts and data, not buzz-clips and cursory conclusions. Point to some realistic data that shows that "innovative drug creation" is dropping. If you go back and review the Fortune article, you'll find very little in the way of data. It's just not that kind of magazine.

      - David Stein

      --
      Computer over. Virus = very yes.
    78. Re:What Are They Talking About? by cyberon22 · · Score: 1
      If you want to keep making yourself look like an ass by saying things about the article which are obviously dead wrong to anyone who's read it, I'm happy to help:


      Or you could forget such squishy "knowledge indicators" and go to the hard stuff: drugs. FDA scientists have an entire vocabulary for describing new compounds that come into its office. When something is considered truly novel and innovative, the FDA calls it a new molecular entity, or NME. Many of the other drugs regulators see are reformulations, old compounds with new indications for use, or "me too" drugs that are similar to several on the shelf. But even the label NME doesn't mean a drug necessarily fills a critical gap in health care.

      When regulators see promising clinical data for a drug that really is needed by patients right now--as with the HIV drug Emtriva in 2003--it gives the drug a "priority review." The idea is to get it out to doctors as quickly as possible. So those who want to measure the performance of the world's drug manufacturers should look not only at the total number of FDA-approved compounds and biologics in a current year, but also at how many priority NMEs are making it through. By both measures, the productivity picture is much worse than it was in 1996 (although 2004 seems to have had a bumper crop). From 2000 through the end of 2003, the average number of priority NMEs each year was eight; in the previous four years, it was twice that.

      For a number of common diseases, it seems that progress has stalled. Since the advent of genetically engineered human insulin in 1977, there has been relatively little new help for diabetics. Age-adjusted death rates for those with the disease have gotten worse, not better, during the past 25 years. Patients with Parkinson's, Alzheimer's, and multiple sclerosis have waited anxiously for anything promising to appear in the pipeline. And in cancer, one remarkable study led by the FDA's cancer czar, Richard Pazdur, seems to say it all: A full three-quarters of the 71 cancer drugs approved by the agency from 1990 through 2002 did not show any survival benefit over the old, standard care.


      Fortune didn't run a regression analysis, but if you want to claim that their data is wrong and misleading it helps to at least know what that data is.

      The Fox label is also laughable -- I'm not the one talking out of my ass in this discussion. Why don't you read the article before reflexively spasming for the "reply" button this time.

    79. Re:What Are They Talking About? by tambo · · Score: 1
      It might help if you read what you copy-and-paste before you draw conclusions about it.

      Look at that snippet. What does it involve?

      • Metrics contrasting 1996 vs. 2003, which are pretty much useless for drawing conclusions about the consequences of the Bayh-Dole Act - which was passed in 1980 and took effect in 1981. In case you're really not following this, I'll spell it out for you: they might have instead compared the period before the Bayh-Dole Act took effect vs. the period after the Bayh-Dole Act took effect. That would have been a little more insightful.

      • Some unrelated metrics about the death rates for diabetics in 1977 vs. today. Last I checked, diabetes was not the kind of disease that we control with drugs, but with supplements of the natural hormone called "insulin." Weight loss and diet are also crucial factors, and coincidentally, both weight and diet have gotten much worse in America over the past 25 years. My point is that death rates for diabetics have little or nothing to do with the productivity (or any facet) of the pharmaceutical industry.

      • A spurious quote about patients with neurological conditions anxiously awaiting new drugs. This is where Fortune really loses its grip on reality. Consider:

        • Alzheimer's: link - "For some people in the early and middle stages of the disease, the drugs tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne, previously known as Reminyl) may help prevent some symptoms from becoming worse for a limited time. Another drug, memantine (Namenda), has been approved to treat moderate to severe AD, although it also is limited in its effects."

        • Parkinson's: link - here is a list of 16 drugs that are useful for treating Parkinson's. Many of these are pretty recent, if my memory is correct.

        • Multiple sclerosis: link - five new drugs are on the market for treating MS. In fact, these drugs are amazing - a weekly injection of Avonex essentially halts and reverses the progression of MS. I have personally witnessed this with a family member.

        In other words, we have great new drugs for all three conditions. The fact that Fortune tried to bolster its argument with a comment that is so demonstrably false is indicative of its overall sloppiness.

      • A factoid about the efficacy of new cancer drugs. This doesn't change the fact that we have 71 new cancer drugs on the market since 1990, which, in fact, seems like quite a brisk pace of inventing new drugs. More importantly, the factoid suggests that 53 of the drugs don't have improved survival benefits - might they have other benefits, like reduced side effects, easier administration, etc.? (If not, then why is the FDA approving them?
      So I stand by my earlier statement that Fortune's "data" is paper-thin and provides precious little support for its conclusion. If you'd actually read the excerpt with an ounce of objectivity before pasting it here, you'd have seen that yourself.

      - David Stein

      --
      Computer over. Virus = very yes.
    80. Re:What Are They Talking About? by tambo · · Score: 1
      RTFA is indeed a STFU n00b statement.

      I'm glad you agree. Hopefully you'll also agree that it really doesn't belong in any substantive discussion. If I missed something from the article, you can fairly cite what I missed in a counterargument; but accusing me of not having read the article adds nothing to the discussion, and really just adds a distracting confrontational edge.

      Too bad it took a beating to get you to support some of your assertions.

      I'm not actually here to make any assertions, since it's not my article. I'm here to discuss the amazingly weak assertions in the Fortune article. When I write my own article about the benefits of the Bayh-Dole Act, then you can ask for, and fairly expect, some data to back up my assertions.

      What we do know though is that IP lawsuits have increased dramatically as a result of this enactment...

      Frankly - so what? These lawsuits are just disputes between pharmaceutical companies, or between universities and pharmaceutical companies over licenses. How does the presence or absence of lawsuits affect the rate of technology development? You can't just imply a link here.

      ...and that the focus of universities has shifted from fundamental science to immediately profitable science.

      Where did you get that notion? The whole point of basic research is that it's not "immediately profitable," or even certain to be profitable in the long run. If it were, pharmaceutical companies would trip over themselves to do it in-house. The fact that we rely (hugely) on the federal government to fund it disproves your point.

      And exactly how do you think you get to that stage? By just picking a random drug? No - there's research involved to get to that stage. Academics remove the biggest cost pharmaceuticals face - risk.

      I think you fundamentally misunderstand how these inventions get made.

      Usually, it goes like this:

      • A researcher observes something interesting about a mechanism in molecular biology - something like, "protein X appears to activate protein Y, which causes a disease; maybe we can stop the disease by preventing the expression of protein X." The end result may be some data showing that the deactivation of this protein in an animal model of the disease seems to prevent the disease. All of this "basic" research is wholly funded by the federal government.

      • The observation is licensed to a pharmaceutical company, which finds or synthesizes a drug that successfully implements the concept in humans. All of this "drug discovery" research is performed in-house by the company, and the company bears all of the expense.

      • The drug is given to academic researchers and clinicians who want to test it. The pharmaceutical company pays 100% of the outside researchers' costs in testing the drug for the company.

      In your previous post, you were trying to assert that drug testing, the third step, is performed by academicians under their federal grants. You were wrong. It is performed by academicians, but is wholly funded by the companies that own the drugs. In fact, the academicians host no "risk" whatsoever at this stage. They get paid whether or not the study works; they get to publish the results no matter what those results show; they bear no liability for the effects of the drug.

      - David Stein

      --
      Computer over. Virus = very yes.
    81. Re:What Are They Talking About? by tambo · · Score: 1
      By having the university be the license seller, it puts universities and researchers in competition with each other.

      It does? Really?

      They probably do compete when two groups independently discover the same thing. But that's been true of science since the days of ancient Greece. Nothing about patents, pharmaceuticals, or the Bayh-Dole Act changed that aspect of science one whit.

      Now consider the normal case, not involving a conflict over priority of a single invention. When a researcher and university find a potential drug target, they spend the following months and years talking to pharmaceutical companies about licensing. The struggle here is solely between the university and the pharmaceutical company to establish a fair license price. There is very little interaction or competition with other universities, which are licensing other drugs for other purposes. I'm not sure how that "competition" would even work.

      ...which means they don't want to share interim results...

      Not really. Researchers still publish and present their results all the time. The only difference is that the university makes them tell their technology transfer office about it beforehand, and help them get a patent application on file. It's really a pretty minor effect.

      Even where the researcher doesn't want to publish the results yet, they still get to share their data and materials with other institutions. It's done under a pretty standard contract, like a confidentiality or materials transfer areement, that explicitly prohibits the receiving institution from running off with the data. In fact, this is nothing new - it's just that instead of having unwritten rules of decorum about using each other's data, now the rules are written up in a contract.

      ...sue each other...

      Universities and researchers sue each other? Show me where they do that. Most IP lawsuits in this field are contract disputes between universities and their licensees, or patent disputes between pharmaceutical companies.

      ...act like corporations...

      Academic institutions have been gradually acting more like corporations for the last 100 years. Has nothing to do with IP. Has everything to do with an increased emphasis on efficiency in academia.

      And researchers don't act like corporations. They still act like researchers. They do everything that researchers did 30 years ago: spend time in the lab, write up grant applications, publish, travel to conferences. Their lives have not really changed.

      - David Stein

      --
      Computer over. Virus = very yes.
    82. Re:What Are They Talking About? by Anonymous Coward · · Score: 0
      If you spent $5 billion developing and testing a new drug, would you let your competitors buy the rights to sell their own versions?
      Don't forget the $10 billion spent on PR and marketing on same drug.
    83. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      Tim Berners-Lee didn't write Mosaic, he wrote WorldWideWeb.

    84. Re:What Are They Talking About? by cyberon22 · · Score: 1
      Look at that snippet.


      Why stop with the snippet? Why not read the whole bloody article?

      Asserting that we have "great new drugs" is no basis for your ignorant attacks on a piece that does a great job (1) describing and attempting to statistically document a slow-down in biomedical innovation, (2) describing how a small change in federal law has aversely affected biomedical research while driving up the costs of medical care.

      Your early criticisms of the piece showed complete ignorance of its argument. Now that you're presented with some actual figures, you're trying to squirrel out of facing them. Of course there are ways to critique the data, which makes it surprising that all of your critiques are responses to data in the snippets of article that I've posted. The fact that you've misinterpreted some of them suggests you still haven't bothered to RTFA.

      And in cancer, one remarkable study led by the FDA's cancer czar, Richard Pazdur, seems to say it all: A full three-quarters of the 71 cancer drugs approved by the agency from 1990 through 2002 did not show any survival benefit over the old, standard care.


      Although this translates into 1.5 new drugs per year, the author wasn't attacking the slow pace of invention. He was using the quote to illustrate the nature and growing commercialization of biomedical research -- while simultaneously showing much of its futility. 71 drugs a year is not an improvement over 18 drugs a year if the remaining 53 don't do anything.

      On the other hand, I *do* remember the article going into great length discussing how some of the most effective new drugs have resulted from collaborative community science, and resulting in enormous commercial and legal battles because they became patented and locked-off from further research in ways which would have previously been impractical or impossible.
    85. Re:What Are They Talking About? by tambo · · Score: 1
      Why stop with the snippet? Why not read the whole bloody article?

      Let me refresh your memory for how we got here. I indicated that the article presented virtually no evidence to support its conclusion. You posted a snippet, indicating that that's where the evidence was. I shredded it. Now you want to just make a blanket hand-wave gesture toward the rest of the article and say, "It's somewhere in there."

      It's not in there. Just like it wasn't in the excerpt you posted. Go ahead - prove me wrong.

      Of course there are ways to critique the data, which makes it surprising that all of your critiques are responses to data in the snippets of article that I've posted.

      That's because these are the only pieces of "evidence" in the entire article to support the notion that the Bayh-Dole Act is slowing down research. The rest is anecdote, supposition, dramatic quotes, and unrelated material. Again - I challenge you to prove me wrong.

      71 drugs a year is not an improvement over 18 drugs a year if the remaining 53 don't do anything.

      Incredible. Apparently, you can make a serious reading comprehension error even in a single sentence.

      That sentence doesn't indicate that they "don't do anything." It indicates that they "did not show any survival benefit over the old, standard care." In other words:
      1) They prolong life of cancer patients just as well as previously known therapies. That's a damn site better than "not doing anything."
      2) Drugs have lots of properties - survival rate is not the sole feature of a cancer drug. They may have reduced side effects, like less hair loss or nausea. They may have fewer adverse drug interactions. They may be administered in a more convenient form, like a tablet instead of a horse pill.

      Now you're 0/5 in terms of reading comprehension, having made five serious errors in four posts. Jesus, that's amazing. Zoloft, buddy - seriously.

      - David Stein

      --
      Computer over. Virus = very yes.
    86. Re:What Are They Talking About? by Znork · · Score: 1

      True, I was using the more common terms such things are usually hidden behind. But like you say, those posts hide everything from lobbying to ski-resort trips for doctors.

    87. Re:What Are They Talking About? by N3wsByt3 · · Score: 1

      "Hopefully you'll also agree that it really doesn't belong in any substantive discussion."

      That would depend on the question whether or not the person in question has RTFA. ;-)

      "and really just adds a distracting confrontational edge."

      If one actually read the article, this is true. In that case, the claim isn't litteraly about reading the article, but more like "you missed the point of the article". But the argumentational value of that is rather limited, I concur.

      "How does the presence or absence of lawsuits affect the rate of technology development? You can't just imply a link here."

      Alas, one can. At least with software-patents there already has been research that showed the link: when companies started to patent software in the USA, the litigation and lawyercosts rose dramatically *at the expense of R&D*. I'm sure ypou'll want to know the sources for that, so I'm going to direct you to the FFII; if I remember correctly, they have a whole page with links to scientific research about the detrimental effect patents can have (with, indeed, also a decline in R&D and new products as a result).

      "I'm not actually here to make any assertions, since it's not my article."

      But you do. Or at least, did, in one of your posts to me. You came up with a whole theory of why it was actually beneficial - but without providing any evidence, not even the meager evidence you claim Fortune is using.

      "The fact that we rely (hugely) on the federal government to fund it disproves your point."

      No, it doesn't. His point was, that without the strong emphasis on commercialisation that is rampant today (and to which the amendment of the law contributed) universities were more inclined to do fundamental research, while now they are more and more inclined to do 'rapid-potential-profit' research. This is not difficult to understand, after all; once you view universities (or they see themselves as such) as a mere extension of business, the driving force will be profit, not the pursuit of knowledge on itself.

      It is, in fact, hardly a disputable fact that this happens.

      And, indeed, even that profit-driven research is heavily sponsored by the government (and thus, our taxes), which is why several posters have indicated we're being screwed.

      Anyway, the question remains, if it is the job of the university to concentrate on profit-driven research. In my book, it isn't: companies can do that just fine of their own. I'm not paying universities my tax-money so they can do the work the company would otherwise have to do. There is nothing wrong with profit-driven research... but that's the main objective of corporations, not universities. The latter should stick to academic research, and especially that kind of research which isn't meant to be profitable (basic research)... because companies will not do it, and universities ARE sponsored by the state, after all. Thus, let each do what they do best: short-term profit-research for companies, and long-term knowledge driven basic research for universities.

      Now, refrain from a rebutal with claiming that it can be both. Perhaps, but only to a limited extend. There can be little doubt, that, when you concentrate on making profits, it goes at the expense of research that is deemed to be not profitable. And in reality, this is exactly what happens: the more universities are focussed on profit, the more they are inclined to neglect basic research which is doubtfull to bring them any profit.

      Ofcourse, when you consider monetary income als THE goal of businesses and and universities alike, then this consideration may hold no value for you. One could even claim the extra income is used for basic research, or for the tuition...but the article shows that even this isn't true.

      --
      --- "To pee or not to pee, that is the question." ---
    88. Re:What Are They Talking About? by tambo · · Score: 1
      That would depend on the question whether or not the person in question has RTFA. ;-)

      'k... I think we've beaten this side-issue into the ground, so let's part amicably on it and move on to more central issues.

      At least with software-patents there already has been research that showed the link...

      If you're arguing that software companies are diverting reseach funds, then I have to agree with you. I also think it's non-analogous.

      With software companies, you have the same group developing the software (potentially creating a software invention) and also selling it. If one pot of research money has to fund both activities, then it's quite logical that legal costs derived from the latter activity would entail a reduction of funds for the former activity.

      But software and biotech are very different industries. The key difference here is that the "inventing" group is a wholly different entity than the "selling" group. The inventors actually have very little concern about infringement; it's tough to envision a scenario where they could get sued. They can't even be sued if their inventions infringe others: every IP license on the planet shifts 100% of infringement liability to the licensee. (The only potential liability for the inventors/university is whether the inventors failed to conduct due diligence - i.e., if they know the invention infringes a patent, they can't fraudulently license their claimed IP as non-infringing. But that's a contractual issue between the inventors and the licensee.)

      I'd like to suggest a closer analogy. Have software patents impacted academic computer science research? I don't think it has, and I haven't seen anything to that effect. (If anything, it's increased such research, as CS academicians can now publish articles on the evil software patent system. ;) )

      You came up with a whole theory of why it was actually beneficial - but without providing any evidence, not even the meager evidence you claim Fortune is using.

      Sure, but the context is totally different. I'm not writing an article. I'm posting some off-handed comments in a web forum. When I write articles on this (or any other) topic, you can expect that they are supported by dozens of citations to federal government statistics.

      His point was, that without the strong emphasis on commercialisation that is rampant today (and to which the amendment of the law contributed) universities were more inclined to do fundamental research, while now they are more and more inclined to do 'rapid-potential-profit' research.

      I'm having trouble with this notion of "rapid potential profit," because very few technology licenses embody anything of the sort. Yes, the once-in-a-lifetime, "oh my god this is awesome" kind of invention involves a large up-front payment to the university. (That's what happened in the case of Emory - as described in TFA - which, yes, I did read. ;) To be fair, I'd read about Emory a few weeks ago.)

      But most cases of university technology licensing involve much-delayed profit, in the form of a royalty stream from ongoing product sales. It usually takes a year or several to get the product on the shelf, and even then, the royalties start small and slowly build over time. There is nothing "rapid" about this.

      The author of that comment had some notion that university researchers were being turned into product-development guys. Based on my experience, nothing like this is happening. The primary source of pressure on researchers is to get federal grant money - not to invent valuable IP.

      Ofcourse, when you consider monetary income als THE goal of businesses and and universities alike, then this consideration may hold no value for you.

      I don't view money as THE goal. I view money as the fuel for the process that achieves THE goal, which is to maximize technological progress. I want to see new, useful treatments for every known disease. My

      --
      Computer over. Virus = very yes.
    89. Re:What Are They Talking About? by jafac · · Score: 1

      . . .everything from lobbying to ski-resort trips for doctors.

      Argh! Thanks for ruining my Friday by giving me yet another reason why I'm in the wrong fucking profession.

      --

      These are my friends, See how they glisten. See this one shine, how he smiles in the light.
    90. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1


      I don't do credentials. You're the one bragging about yours.

      The reason management manages the stock price is to ensure their own holdings are up there. If you can't see that, you're clueless about ANYTHING having to do with business - or humans in general.

      I hope the universities using your services get at least some money back from your negotiations, since you obviously know nothing about economics or making money.

      "it works, even if they have distorted it in several ways for personal gain."

      What's wrong with this picture?

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    91. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1

      "In a TRUE free market, monopolies exist and bleed their customers dry."

      This is so stupid it isn't worth replying to, other than to refer the moron to the obvious fact that monopolies are NOT POSSIBLE except under state controlled economies (which thoroughly includes the US.)

      As for pharma IP being distributed due to law, then what is the point of the patent wars referenced by the article? What's wrong with this picture?

      As for the nonsense of "without patents", that has been dealt with repeatedly elsewhere. IP has absolutely no demonstrated effect on the production of inventions historically, exclusive of the general issue of state controlled markets. I am not aware of ANY study indicating such benefit. It's an excuse for greed, nothing more.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    92. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1

      Thank you for repeating exactly what I said.

      Your post should be modded "Redundant".

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    93. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1

      "I'm a patent attorney,"

      If I'd known that, the ad hominem would have been much, much worse. Permit me to correct my mistake.

      You're not just a clueless management type. I apologize for saying that.

      You're complete slime.

      Have a nice day.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    94. Re:What Are They Talking About? by Master+of+Transhuman · · Score: 1


      I think we can separate the general issue of monopoly-breaking power of alternative technologies from the specific issue of how difficult it is to produce same in the bio world due to the current level of bio technology.

      I think the cost of finding alternative treatments that don't violate patents is directly related to issue #1 that you raise.

      I'm also not convinced that there is only one way to treat a problem (or only one effective way - obviously any treatment can be more or less effective; many drugs are not totally effective, but merely improve the patient to allow either other treatments or natural healing to occur.) I think nanotech will put that to rest in the near future in any event.

      One might also quibble over whether the time and expense it takes to find a cure for something is because of misdirection of research resources. A lot of people have complained that the "disease du jour" gets the research money (AIDS is a classic case), while other research possibilities which might have more far-reaching benefits is considered riskier from a profit, patent and monopoly perspective.

      In other words, I think people should be trying to solve world-class problems, first because the most financial profit comes from solving such, and second, because those are the problems that pay the most benefit in solving OTHER problems. I'm not sure the pharma company management is on that wavelength. If your motivation is on your quarterly bottom line, even if you have long-range research goals (which I assume most companies do or should), you tend not to take excessive risk.

      This is where being a public stock company tends to restrict intellectual advancement in the general case. Privately owned biochem companies I think tend to take bigger risks (Craig Venter comes to mind as an example at least in concept - I don't know if his company was a publicly traded one at the time of the genome breakthroughs.)

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    95. Re:What Are They Talking About? by salesgeek · · Score: 1

      Last I checked, neither NASA, the defense department, nor the department of energy was much interested in manufacturing pharmaceuticals.

      There is NIH and it's suborganizations like NCI - not to mention USDA. I heare they let a few grants last year :)

      You always have the choice of not buying it.

      Don't buy and suffer. Don't buy and die. Not much of a choice, is it? You could also ask Limbaugh about Vicodin....

      Every patent application must demonstrate that the invention is useful for a specific purpose.

      The problem is that is not what is happening in reality. See software patents. See genetic patents. See patents like the ones Eli Lilly & Co applied for in trying to keep the Prozac monopoly going.

      --
      -- $G
    96. Re:What Are They Talking About? by Anonymous Coward · · Score: 0

      And back in time?

      That probably explains all the dupe posts on Slashdot ...

    97. Re:What Are They Talking About? by rtb61 · · Score: 1

      Technically speaking a lot of people only pay once for the patents of the big pharmaceutical companies when they can't afford the drug, it is a shame they pay for those profits with their lives.

      --
      Chaos - everything, everywhere, everywhen
    98. Re:What Are They Talking About? by orgelspieler · · Score: 1

      heheh. oops. I just like to assume the best of people. :-) you should've played along, though. It would have been more fun! Well I don't mind that you're a patent lawyer. At least you're trying to change the system from the inside out, rather than bitching about it all day long. Good luck!

    99. Re:What Are They Talking About? by tambo · · Score: 1
      If I'd known that, the ad hominem would have been much, much worse.

      Thanks for establishing your irrelevance.

      I wholeheartedly encourage you to continue holding your rabid malice. That will ensure that no one will ever take you seriously, and that you remain on the fringe where your unrealistic views can't do any damage to the system. Meanwhile, I'll continue working in the industry and will help shape IP policy.

      - David Stein

      --
      Computer over. Virus = very yes.
    100. Re:What Are They Talking About? by N3wsByt3 · · Score: 1

      "'k... I think we've beaten this side-issue into the ground, so let's part amicably on it and move on to more central issues." ;-)

      "If you're arguing that software companies are diverting reseach funds, then I have to agree with you. I also think it's non-analogous."

      Hmm..well, we already disagree. :-) I think that, while not completely the same (it never is), it's analogous enough to warrant the proposition that the same link may be applicable.

      There is, alas, not as much research done on the specific issue of bio-tech patents by universities as there has been done on 'software-patents' by softwarecompanies, so I'll agree it's not conclusive. Additional research in this area may settle the question, but at least the article hinted at the same detrimental effects as is apparent in the software-patents case.

      Your rationale is not without merrit, but neither is that of the article (or mine), and at least they have *some* data that backs it up (or at least indicates it is right). I know you are not writing a scientific article on slashdot, but still, you ARE using it as an argument. Now, all else being equal, when I'm provided with two sides of an argumentation, I'm rather inlined to go for the one which has at least some data backing it up (meager as it may be), then the argumentation which is not backed up by any data.

      I would be more then interested to see your paper (with data) if you ever make it, however. Be sure to give me an email-note when you do.

      "I'm having trouble with this notion of "rapid potential profit," because very few technology licenses embody anything of the sort."

      I didn't mean 'rapid' in the sense of it being a cash-cow within weeks. I'm just pointing out, that research which has little to no potential for profit (the basic research) will become less appealing for universities to do, since the chances of gaining profit with such projects are less then with more commercially-applied projects.

      Surely you must acknowledge that, when your focus becomes more and more profit driven (and everybody, including universities, like to earn increasing amount of money, naturally) then you are less and less inclined to fund projects which show little profit-potential. This is not a far-fetched reasoning, if you ask me.

      Now, there is nothing wrong with companies shifting their attention to more profit-prone projects and research. In fact, it's what they should do, since it's primarely about making profit that companies are about. But basic research has to be done too, and if universities don't do it, who will? Certainly not the corporations.

      Profit-driven research is all good and well, but we're not paying universities with our taxes to fill, nor even support the role of companies; they can do that job by themselves just fine. Their main focus, thus, should be basic research (since they are sponsored by the state (our taxes) already), so it doesn't matter if it has profit-potential or not.

      "I view money as the fuel for the process that achieves THE goal, which is to maximize technological progress."

      First of all, it is the question whether indeed it fuels any sort of process, exept litigation, as the article has hinted at. The results, exept for some exeptions like MIT, were rather poor - as well for the universities themselves, as for most of the companies, as the article mentionned.

      Secondly, I do not believe any major scientific project can run without money...but universities already get money; from the state, and thus, from the taxes we pay. They don't receive this just for the fun, or to aid or fill in the role of companies, as far as I know. That's not the mandate they receive from the state (at least in Europe).

      Thirdly, we may differ in opinion on what the goal actually should be. "Technological progress" as measured how? In deliverance of products on the free market? This may be the goal of corporations, but is (or should) it be that of universities? The goal of schools and

      --
      --- "To pee or not to pee, that is the question." ---
    101. Re:What Are They Talking About? by tambo · · Score: 1
      I think that, while not completely the same (it never is), it's analogous enough to warrant the proposition that the same link may be applicable.

      Here's why I think it's non-analogous. The primary reason that IP-developing businesses might have their research waylaid is the threat of a patent infringement lawsuit over their IP-containing products. Academic researchers, both in biotech and in software, have no such fears because they create no such products, and are never sued.

      Look at it this way. In order to sue for a patent, a company needs to demonstrate some kind of damages - in most cases, loss of business. The law usually requires this as part of a valid complaint; and much more importantly, profit-driven corporations aren't going to waste tons of money enforcing patents without a commercial advantage.

      Now, what kind of commercial advantage do businesses derive by enforcing their patents against researchers? None. That's why they are almost never sued, even when their research clearly infringes.

      The most recent lawsuit involving patent-infringing academic research (Merck v. Integra Life Sciences, finally settled by the SCOTUS) ended up considerably broadening the "experimental use" exception to patent infringement.

      Surely you must acknowledge that, when your focus becomes more and more profit driven (and everybody, including universities, like to earn increasing amount of money, naturally) then you are less and less inclined to fund projects which show little profit-potential.

      Ah, but here is a very important point. An overwhelming proportion of the money that runs academic research derives from grants, either from a government body (including the NIH or DoD) or from a private foundation (like the American Heart Association.) For all of these groups, the decision of these groups on whether or not to fund a project depends most heavily on the scientific importance of the proposal. The possibility of commercializable results is a consideration, but it's not centrally important.

      By contrast, with a few notable exceptions, universities derive very little profit from technology transfer, licensing, commercialization, etc. Virtually all technology transfer groups are doing well if they just break even. (Like the Fortune article, I have seen supporting data, but I can't cite it. ;) At least I can supply a good excuse: the data derives from a private study conducted by the Association of University Technology Managers (AUTM).)

      In short, any academic group hoping to make tech transfer a profit center (and gear its efforts in that direction) is going to be sorely disappointed. That's not what it does.

      So what is the goal of tech transfer, if not profit? It's threefold:

      • The noble aspect: Academia wants new technologies as badly as you do. When a researcher creates an invention with a useful purpose, the university wants to see that purpose realized.
      • The networking aspect: Tech transfer with other institutions helps foster research collaboration.
      • The "bragging rights" aspect: Universities use their metrics about inventions and patents as a way of showing the collective skill and creativity of their researchers.
      • The regulatory aspect: The Bayh-Dole Act wasn't merely a gift of IP to institutions. Such ownership was made contingent upon a duty to commercialize the inventions. If universities don't actively work to exploit their inventions, they could get sanctioned by the federal government, and may even be denied funding in the future.

      ...but universities already get money; from the state, and thus, from the taxes we pay.

      Sure, and I agree that this would be a poor motivation, since universities derive little or no profit from tech transfer. But rather, I meant that money fuels the product-development process - i.e., pharmaceutical companies. If they didn't have a revenue stream secured by a patent, they wouldn't heavily invest

      --
      Computer over. Virus = very yes.
    102. Re:What Are They Talking About? by N3wsByt3 · · Score: 1

      "Academic researchers, both in biotech and in software, have no such fears because they create no such products, and are never sued."

      "The possibility of commercializable results is a consideration, but it's not centrally important."

      In both instances, I can not share your optimism. In an ideal world, everything would be balanced, no doubt. In reality, thinks go differently. For instance, here too, there has been talk about 'connecting' businesses better to the universities. In fact, the current government is (or at least was) quite fond of the idea that corporations would take part in paying the research. Next thing they said, was that they would reduce the grants given, since the corporations would step in for a considerable part.

      Now, even when the level of money (in total) subsidising the universities stay the same, clearly this will have an impact to the sort of research that will be done. In short, there WILL be a shift towards profit-driven research, since the part that was formerly state-sponsored is now sponsored by companies.

      And well, one can call them ivory towers, but I'd rather have that then universities becomming extensions of corporations. Ivory towers can at least concentrate on their primary goals of education and academic research, instead of commercial profit-driven research.

      In fact, I'm wondering if it couldn't be done far more easy. If taxes pay for universities, their patents belong to us too (well, the state). If a company is interested in obtaining a patent, why not let him simply buy it from the state, with the provision it still can be used freely for academic use? There is no real reason to let corporations influence the direction of universitary research, however. Once they have 'secured the patent', as you say, they can simply research the stuff themselves. The money thus received, would be put back in a general subsidising for all universities (by the state). The advantage would be that universities would remain free of commercial meddling and influences, while as a whole, money would be earned (at least by the state), and new products would be created.

      I gather such a system existed, and that you lament the fact many patents lie unused? Well, then, maybe one should divise a system to stimulate that kind of tech-transfer, instead of letting corporations directly sponsor universitary research?

      (BTW, there was so much protest about the plans of commercialising the universities around here, that the original plans have been severly adapted ;-)

      No one has anything against companies on themselves (in fact, more then one university-rooted corporation in bio-tech has been succesful in my country), but one shouldn't be naive neither. When you mix academic work with commercial profit-driven work, the two are not all that compatible, and seen the capitalistic drive in our western society, it's always the academic integrity that is most at peril.

      Anyway, we're both digressing a bit and divulging into opinions, I'm afraid. I don't think we'll solve this discussion untill a bit more hard data proves the article wrong or right. Though, I have the impression you will never be convinced by any data, if that data indeed indicates a decline in R&D, etc.

      But maybe I'm wrong.

      --
      --- "To pee or not to pee, that is the question." ---
    103. Re:What Are They Talking About? by tambo · · Score: 1
      In an ideal world, everything would be balanced, no doubt. In reality, thinks go differently.

      I understand and share your concerns about universities and corporations becoming bedfellows. But there are checks and balances in place. Some naturally flowing from the circumstances: e.g., corporations want to control the publishing rights of academics (in case a study comes out badly, Merck wants the right to squelch it), but researchers viciously defend this right, and are usually successful. Others are imposed upon the circumstances: e.g., every university has an independent IRB and a conflict-of-interest policy, both of which ensure that the academic center retains plausible objectivity in its dealings with corporate sponsors.

      We have to be vigilant about this, but at present, I think it works OK.

      Next thing they said, was that they would reduce the grants given...

      And I think that would prompt an outcry from the scientific community, the likes of which we've not heard since... well, since the release of Michael Bay's Armageddon. ;)

      The trend has remained steadily in the opposite direction - over the past decade, NIH funding has increased every year. This is likely to continue for the foreseeable future. I think that even our stupid politicians understand that basic scientific research is a critical long-term driver of our economy.

      If a company is interested in obtaining a patent, why not let him simply buy it from the state, with the provision it still can be used freely for academic use?

      They can do that now. Under the Bayh-Dole Act, the federal government retains a license to any invention stemming from federally-sponsored research. I don't think that any law restricts its ability to exercise that right as it sees fit, including by licensing it to another company.

      Well, then, maybe one should divise a system to stimulate that kind of tech-transfer, instead of letting corporations directly sponsor universitary research?

      They did. It's called the Bayh-Dole Act. ;)

      If you're arguing that the prior model was well-grounded but badly implemented, I might agree with you. I don't think there's a systematic reason why government licensing wouldn't work. But I don't think any of us are feeling particularly confident in the federal government's ability to do anything these days.

      I have the impression you will never be convinced by any data, if that data indeed indicates a decline in R&D, etc. But maybe I'm wrong.

      Let ye who is without bias cast the first stone... ;)

      The greatest lesson I learned in law school was not argumentation, but objectivity. When you're designing a solution to a problem, you have to look at the problem as an aggregate, without disproportionate deference to the particular interets any one party. I think I'm doing that, as far as America's drug development model is concerned. If you show me a model that produces better, faster, safer, and cheaper drugs, I'll go for it.

      - David Stein

      --
      Computer over. Virus = very yes.
    104. Re:What Are They Talking About? by N3wsByt3 · · Score: 1

      "...both of which ensure that the academic center retains plausible objectivity in its dealings with corporate sponsors."

      Yeah, well, it would be better ensured by not allowing it at all, IMHO. the only reason why it was allowed in the USA, was because it was supposed to be beneficial in stimulating R&D and new products. It would seem (yes, yes, based on limited data, but still) that this isn't the case. thus:

      1)if it's not working, there is no reason for it
      2)even if it is working, there are maybe alternatives that are better with less risk for losing academic integrity

      "They did. It's called the Bayh-Dole Act. ;)"

      Ermm...no. The system I proposed (if it would be necessary to change our current system, which is debatable on itself) would involve no direct funding/influence of companies and universities. Funding of university research by corporations (in a direct way) would not be allowed.

      "If you're arguing that the prior model was well-grounded but badly implemented..."

      I was. Possibly with some adaptations. Maybe the state needs to promote it better, or something.

      "Let ye who is without bias cast the first stone... ;)"

      I'm searching for a boulder to cast right now!! ;-)

      Anyway, I think this dicussion has reached it's end, for now. This is a fact, because it's now mentioned on my blog. ;-)

      As I said; if you ever make a paper about the issue, I'll be interested to read it. Of course, you'll better make sure you have a lot more of hard data then Fortune, since you so lament the lack of it with them! :-)

      --
      --- "To pee or not to pee, that is the question." ---
    105. Re:What Are They Talking About? by tambo · · Score: 1
      I know this thread is past its sell-by date, and that our conversation has wound down (for now), so I'll keep my comments short.

      Yeah, well, it would be better ensured by not allowing it at all, IMHO.

      Well, it's impossible to completely disallow it. For instance, all phases of clinical trials require patients, which are only (efficiently) available through academic hospitals; and hospitals need money in order to conduct clinical trials. Similarly, companies need highly skilled, completely objective scientists to test their stuff, and universities are perfectly situated for that role.

      For IP licensing, your suggestion may be possible. I don't think it would be beneficial, and I might cite the prior attempt as a counterexample; but your theory isn't unreasonable.

      As I said; if you ever make a paper about the issue, I'll be interested to read it. Of course, you'll better make sure you have a lot more of hard data then Fortune, since you so lament the lack of it with them! :-)

      Heh. Count on it. By sheer volume, it would probably be more citations than substance. I just don't see much point in going to that effort in, y'know, the Slashdot comments section. ;)

      This is a fact, because it's now mentioned on my blog.

      Can't argue with that. And your blog is now bookmarkz0red. I'm always interested in opposing viewpoints; the day I stop learning about a field and questioning my own concepts is the day I switch to something new.

      Thanks for the interesting discussion - this is a great way to end it. See you 'round.

      - David Stein

      --
      Computer over. Virus = very yes.
  2. stand on the shoulders of by Diego+and+Aline · · Score: 2, Informative

    Before waxing philosophical on economics, you could do yourself a service by skimming the academic literature on the subject. There are good, free services like econlit.org and scholar.google.com

    --
    All determinations of time presuppose something permanent in perception and that this permanent cannot be in the self, s
    1. Re:stand on the shoulders of by Daniel+Dvorkin · · Score: 2, Informative

      Actually, the linked article refers to quite a bit of academic literature on this particular subject. Before waxing philosophical on other people's philosophical waxing, perhaps you actually ... oh, hell, I'm not going to say it.

      --
      The correlation between ignorance of statistics and using "correlation is not causation" as an argument is close to 1.
    2. Re:stand on the shoulders of by EEBaum · · Score: 1

      TFA is ten pages long. I'll take your word for it.

      --
      -- I prefer the term "karma escort."
  3. Link by Anonymous Coward · · Score: 1, Informative

    Bayh-Dole amendment: http://www.ucop.edu/ott/bayh.html

  4. The fundamental problem with Bayh-Dole ... by Daniel+Dvorkin · · Score: 5, Insightful

    ... is actually a fundamental problem built into all IP law: the assumption that money is the prime motivator for creative endeavors. (And yes, science is a creative endeavor.) This is a myth successfully propagated by generations of moneymen, but a myth is all it is. Scientists, like artists, certainly want to make a living from their work, but the best ones pretty much always do what they do simply because they want to do it, not because they expect it to make them rich. If your primary concern is making money, OTOH, you don't have the time (or, probably, the brainpower; suits who think of themselves as intellectuals because they have an MBA simplye have no idea what goes into a serious scientific education) to become good at anything that constitutes real creative work.

    --
    The correlation between ignorance of statistics and using "correlation is not causation" as an argument is close to 1.
    1. Re:The fundamental problem with Bayh-Dole ... by kfg · · Score: 5, Insightful

      As I posted on another forum only a short time ago when someone suggested that science and art would come to halt if people didn't think they could get rich by it, I consider that suggestion insulting.

      Beyond the basic necessities of life the primary reason I need money is to pay for science and art supplies. For instance, I've been offered a gig as a cello player, but I don't happen to have a cello. That likely means I'll have to borrow money to obtain one, and get paid to recoup the expense, but I'll play the thing for free. Because. . .well, it's fun. Far from requiring payment to produce art most artists pay to be allowed to do it, and will often pay themselves into poverty if need be.

      Likewise I did not study physics in college because it was the hot hiring field at the time. I did it because I "had to." I fully expected to have to patch the elbows on my tweed jackets out of economic necessity rather than fashion.

      Give me money and I'll just blow it on something stupid like a French Horn or an Oscilliscope, so I can "do my thing."

      I wrote a song awhile ago. It's a pretty good song. People request it and stuff. I didn't do it for money.

      You see, there is this woman. . .

      Aha! Now I think we're onto this motivational thing.

      KFG

    2. Re:The fundamental problem with Bayh-Dole ... by biodork · · Score: 4, Informative

      Problem : I work as a "suit" in a Biotech. I have a Ph.D. not an MBA.

      Yes - scientists (myself included) would do it for the love.

      Problem - in general a proect I work on or am involved with will burn $1 million before we have a good handle on whether it will work or not.

      For a million, you better have the commercial side locked up before you risk it.

      --
      Gavin Fischer
    3. Re:The fundamental problem with Bayh-Dole ... by One+Div+Zero · · Score: 1

      Please, please don't take the above seriously.

      What about all those types of creative endeavors which require massive amounts of money in investment?

      Things like biomedical or physics research take a lot of initial set up. Corporations spend millions of dollars on R&D. Do you think the same amount of research would go on if they couldn't recoup their investment costs?

      Oh! And don't forget that money as a prime motivator is only this idea that.. you know.. is written into the constitution?

      Article I, Section 8:
      "To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries;"

    4. Re:The fundamental problem with Bayh-Dole ... by Anonymous Coward · · Score: 0

      Yes and no. The problem with your assumption is that science can be done in the garage. Unfortunately, most science can only be done with the resources that a corporation can muster. The balance in IP law has been disrupted, but we should not simply do away IP law altogether.

    5. Re:The fundamental problem with Bayh-Dole ... by biodork · · Score: 0

      ....this whole post just annoys me.

      You tar whole classes of people here. Some of the best scientists/smartest people I know DO IT FOR THE MONEY. They like being RICH.

      I am a suit with a Ph.D. I work in a company where the vast majority of the management has Ph.D.'s. (CEO has an MD, but we still count him).

      Even if we restrict this to a discussion of the computer world, you then have to declare the head of all of the computer companies stupid.

      Google chiefs - dumb suits with no idea only doing it for the fun. If true -> why did they leave grad school and start a company.

      Same with Yahoo.

      Amazon, started by Jeff Bezos with NO computer background, can't exist.

      I can't beleive this post is flagged as insightful, but then I remember this is the slashdot comment section and I get over it.

      --
      Gavin Fischer
    6. Re:The fundamental problem with Bayh-Dole ... by Master+of+Transhuman · · Score: 4, Insightful

      "Do you think the same amount of research would go on if they couldn't recoup their investment costs?"

      The problem with this notion is there is NO WAY they can be SURE in ANY case that they CAN recoup their investment costs.

      Even if you produce a cure for cancer, how the hell do you know some geek in some other company hasn't produced a cure for cancer that can be produced cheaper and works better than yours? And isn't covered by YOUR patent? (Which is why they want patents that cover ANYTHING and EVERYTHING.)

      Risk is risk.

      The problem is that most money men don't know how to handle risk. Why? Because money men are primates and risk is scare one for primates. They're money men because they believe money makes them better than anyone else and more able to trash anyone else, and that's the only psychology that matters to them.

      The idea of taking actual RISK in discovering something new is simply anathema to these morons.

      So they bribe the state to attempt to secure their fortunes. Which is what patents and copyrights are. It has nothing to do with "stimulating creativity" - that's bullshit.

      Unfortunately (pun intended) it doesn't always work. Which is why the article discusses all the patent wars that erupted as a result of Bayh-Dole and why researchers now have to clear everything with their legal departments before saying a word about their research. And THAT is stifling creativity.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    7. Re:The fundamental problem with Bayh-Dole ... by Phronesis · · Score: 1
      No. The Bayh-Dole act was not trying to stimulate inventing. Bayh and Dole recognized that there was lots of great inventing going on before they introduced their bill.

      The problem they were trying to address was that lots of these patented inventions were not being produced and marketed because although inventors may invent things for free, companies will only produce and sell something if they can make money.

      The big problem Bayh-Dole attempts to address is that a pharmaceutical company is unlikely invest tens of millions of dollars on clinical trials to verify the safety and efficacy of a newly-invented drug if the company does not have exclusive patent rights.

    8. Re:The fundamental problem with Bayh-Dole ... by daemonenwind · · Score: 1

      OK, so you want to do research.

      Great. Keep in mind that, since there is no commercial value to what you're doing whatsoever, that you have no money to do your research. Which means no equipment, no living expenses, no home for you or for your work, no way to record your discoveries and no way to publish your ideas.

      And, if by some miracle you discover something interesting despite having no food, home, resources, lab, equipment or means of notetaking, who will care? How will you tell anyone, since most major journals only publish useful discoveries?

      So you can either be a scientist in your spare time, or you can accept that money makes the world go 'round.

      In any case, look at all the research lines that sat idle before Bayh-Doyle, according to the article in Fortune. Do you think they sat because they were worthless knowledge, or because they didn't strike a researcher's fancy?

      Which outcome is better for society at large, undiscovered cures or expensive cures?

    9. Re:The fundamental problem with Bayh-Dole ... by Arandir · · Score: 1

      ...the assumption that money is the prime motivator for creative endeavors

      It's a fundamental problem with the Free Software community: the assumption that since money is not the prime motivator for creative endeavors, that money as a motivator must be eliminated. Have you ever thought that the lack of money is an extremely huge demotivator?

      --
      A Government Is a Body of People, Usually Notably Ungoverned
    10. Re:The fundamental problem with Bayh-Dole ... by Goonie · · Score: 1
      You tar whole classes of people here. Some of the best scientists/smartest people I know DO IT FOR THE MONEY. They like being RICH.

      If it was money they wanted, there's any number of easier ways to get rich (medicine, law, Wall Street - at least one of which the typical top scientist would have the talents for). So even in your case I would argue that there is more going on than just the desire for money.

      Personally I always thought scientists did it for the free cocaine and abundant groupies ;)

      --

      Any sufficiently advanced technology is indistinguishable from a rigged demo
      --Andy Finkel (J. Klass?)
    11. Re:The fundamental problem with Bayh-Dole ... by laughingcoyote · · Score: 5, Informative

      Your post makes it sound like that's a requirement, and it is indeed in the Constitution. However, its enumeration is in the "Congress may" section, not "Congress must".

      In context, it reads:

      The Congress shall have power...To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries

      It's not recognized as a fundamental right, like property, free speech, and freedom of religion-only as a power granted to Congress to exercise, and only GIVEN THAT the exercise of that power does indeed promote the progress of science and useful art. That point can (and will) be debated here, but I felt compelled to point out that the ability to exclusive control of an idea is not considered a right-it is enumerated as a fully revocable privilege which Congress -may- grant.

      --
      To fight the war on terror, stop being afraid.
    12. Re:The fundamental problem with Bayh-Dole ... by jhoger · · Score: 1

      Did you read the article? The point is that the basic science would have gotten done anyway.

      The knowledge engine that is our university system, funded by government grants does a fine job of producing innovation. Money makes the world go round alright, but it doesn't take as much as Bayh-Dole has caused it to take in pharma. How much does it really cost to keep a reasonable number of scientists motivated, clothed, fed? Keep in mind that scientist types are not all that motivated by money anyway. Given enough of it, they could decide rationally to spend all of it on leisure time and sit on their brains all day.

      Every manager understands that you need to keep folks a little hungry to keep them motivated.

      In fact the article is making the point that all of the complex licensing agreements and formalities is slowing down the pace of research. The lines of implication are not clear, but it's still a fascinating hypothesis.

      I'd guess that a lot of the unlicensed patents were unlicensed because they weren't worth all that much. And it's really hard to see how NOT sharing knowledge is good for science.

      So, fund science by taxes. Let everyone own the resulting technology. Simple and effective.

    13. Re:The fundamental problem with Bayh-Dole ... by TwentyLeaguesUnderLa · · Score: 1

      Well, there's certainly more than money. I don't blame them for being much more interested in science than in those other things ;-) But if there was no money in science, I also wouldn't blame them for keeping it at a level of a hobby and finding another profession.

    14. Re:The fundamental problem with Bayh-Dole ... by Pseudonym · · Score: 1

      I agree. A better way of putting it is that scientists have the following priorities:

      1. Make enough money to eat.
      2. Do what I love to do.
      3. Profit!

      When you're talking about millions of dollars, you'd better have the "eat" part worked out first.

      --
      sub f{($f)=@_;print"$f(q{$f});";}f(q{sub f{($f)=@_;print"$f(q{$f});";}f});
    15. Re:The fundamental problem with Bayh-Dole ... by Jah-Wren+Ryel · · Score: 2, Interesting

      For a million, you better have the commercial side locked up before you risk it.

      I disagree. For a million, or $10M or whatever, you better have the equivalent amount of money locked up before you risk it. But you do not need to have a guarantee of patent-protected commercial exploitability, or even patent-protected profitability in order to acquire that funding. Because of the environment you've been exposed to, that's what you see as the primary way to do business, but there are alternatives.

      --
      When information is power, privacy is freedom.
    16. Re:The fundamental problem with Bayh-Dole ... by mOdQuArK! · · Score: 2, Insightful
      The big problem Bayh-Dole attempts to address is that a pharmaceutical company is unlikely invest tens of millions of dollars on clinical trials to verify the safety and efficacy of a newly-invented drug if the company does not have exclusive patent rights.

      Ah yes, the big problem of big companies not willing to adopt a new product unless they can make obscene profits without doing any work. I'm so glad that Congress saw fit to solve this problem at the public's expense.

      If Congress _really_ wanted to do the public some good, they would've provided massive amounts of seed money so that those academic researchers could take their new discoveries & competitively kick big pharma in the nuts (metaphorically of course). Once big pharma got over the shock of actually having to compete for their profits, they'd find motivation for developing new drugs - like not going out of business. Of course, they might have to accept some slimmer profit margins.

      I have really little sympathy for any industry where the main players are making huge profits. Anyone who understands Economics 101 supply & demand knows that huge profits means that there isn't enough competition in that market.

    17. Re:The fundamental problem with Bayh-Dole ... by dwater · · Score: 1

      Why doesn't the government go one step further and fund a org that will market the products of government funded research?

      --
      Max.
    18. Re:The fundamental problem with Bayh-Dole ... by nietsch · · Score: 1

      Or you might try to develop a way to predict the succesfullnes of your project with a lot less money. The fact that you spend it (or burn through it as you put it) does not mean that it is the only way to do a feasability study.
      If you have money you always need more, if you have not you devise other ways to acheive your goals.

      For when the revolution comes: you have approximately number (13/17)*10^6.5 (you openly admid to wearing a suit and work for an evil company).

      --
      This space is intentionally staring blankly at you
    19. Re:The fundamental problem with Bayh-Dole ... by Znork · · Score: 3, Interesting

      "... is actually a fundamental problem built into all IP law:"

      Actually, the even more fundamental problem is the assumption that a monopoly is an appropriate means to grant a return on investment.

      The IP monopolies have many consequences; they have the same effect as taxes on specific products, slowing the economy, they create a disincentive for the adoption of newer technology, the create a disincentive to combine and join different research, they create a strong risk and roi based incentive to waste money on marketing instead of R&D, thus increasing economic waste in society and diverting money from wealth creating activities. They increase costs for the consumers, making the citizens globally less competetive, they increase costs for companies, making them globally less competetive, they increase costs for the state, making it less competetive, etc.

      The larger the part of the economy that consists of monopoly powered industries, the more apparent the damage will become, leading to exactly the kind of consequences one can expect from the history of other monopoly-heavy economies.

    20. Re:The fundamental problem with Bayh-Dole ... by mtdenial · · Score: 1

      Very well said. You can extend it into athletics as well. I make money to spend it on bicycles and bike parts so I can spend a large amount of my free time tooling around under my own power.

      Recently, I was talking to a non-athlete type, who, upon learning that I raced, asked whether I was making money at it. I was so surprised by it, I wasn't terribly sure how to respond. Looking at your post though, there does seem to be a portion of the population that cannot comprehend why a person would do something without a (perhaps sizeable) monetary reward. I think that is kind of sad.

      --
      I assert reality.
    21. Re:The fundamental problem with Bayh-Dole ... by Phronesis · · Score: 1
      If you take Econ beyond the freshman level, you'll discover that intellectual property is nonrival, so it doesn't satisfy the supply-demand relations that characterize the market for steel. This means that you can't apply a simplistic supply-demand argument about the profits at equilibrium. The whole point of a patent system is to prevent these nonrival goods from becoming nonexclusive and hence public. In other words, the monopoly status of a patent-holder is not a bug, but a feature.

      Indeed, when patents expire competition drives the cost of generic drugs down so they're much cheaper in the US than in Canada or Europe. Most people don't need super-expensive brand-name drugs. There are lots of effective, safe generics out there.

      Big pharma is not always involved anyway. Where the new technology is clinical tests rather than drugs, a small startup can usually market the invention itself. Some of these startups are criticised in the Fortune piece. It's a small startup company, not a big pharma, that's getting more than $2000 in royalties for each patient tested for BRCA-1 and -2 mutations; Another small company, Chiron pretty much owns the Hepatitis C genome, so it has a lock on tests for Hep-C infections, which is why they're so expensive.

      The main restriction to new players entering the drug market (as opposed to the clinical test market) to compete with big pharma is the cost of doing clinical trials to determine safety and efficacy. The best way to open the market up would be to remove government (FDA) regulation of drugs.

      We tried it back before the FDA existed and too many people were dying from taking unproven drugs.

      In any event, the main beneficiaries of Bayh-Dole are not big pharma but little pharma---small startups who take the ideas from the university lab and develop them into potentially useful drugs. There is a very active venture-capital market to invest in these small startups (Techno-Venture Management, etc.)

      If the initial tests are promising, then even with a healthy dose of VC, the small players are not set up to do massive phase-III clinical trials, large-scale manufacturing, and marketing, so at this point, they usually sell out to a big pharma house and collect a large paycheck for the VC investors.

      How would this change if Congress, rather than the private market, supplied the capital to the startups?

    22. Re:The fundamental problem with Bayh-Dole ... by Phisbut · · Score: 1
      As I posted on another forum only a short time ago when someone suggested that science and art would come to halt if people didn't think they could get rich by it, I consider that suggestion insulting.

      Beyond the basic necessities of life the primary reason I need money is to pay for science and art supplies.

      There is a world of difference between "making a living out of" and "getting rich".

      If you like playing the cello, you would probably enjoy having a job as a cello player that would pay enough for your instrument, food and rent, and a little extra to buy you a beer with the buddies every now and then. You would then be quite happy, since you make a living, and you are doing what you love.

      However, if you think "I can get rich by going in the music industry", you could. However, you might not get rich by playing the cello. You'd have to learn to "dance" (or just do choregraphies) while singing à la Britney Spears. You'd probably suck, but you'd be successful and you'd become rich. However, you wouldn't be doing what you love to do, which is playing the cello. You would be rich, but you wouldn't be happy (I really don't think all the rich Spears & al. of this world are happy).

      In science and arts, the best are the ones that do what they enjoy doing. Mozart loved music, the Backstreet Boys got rich with music. Which one will our great-grandchildren remember 75 years from now? Which one is truly great?

      You won't become a gazillionaire playing the cello, but if you really love it, you will be great at it.

      --
      After 3 days without programming, life becomes meaningless
      - The Tao of Programming
    23. Re:The fundamental problem with Bayh-Dole ... by Phisbut · · Score: 1
      What about all those types of creative endeavors which require massive amounts of money in investment?

      What about when those massive amounts of money in investment come from tax-dollars? How come Joe Taxpayer has to pay for both the R&D and the pill?

      --
      After 3 days without programming, life becomes meaningless
      - The Tao of Programming
    24. Re:The fundamental problem with Bayh-Dole ... by Anonymous Coward · · Score: 1, Insightful

      What these people are saying is that if there wasnt profit in it, "they" wouldnt be doing it. I am sure if the money was given to the people who wanted to help people (as opposed to the people who only want to help themselves $$$), we would be seeing a whole different situation. As it stands our health care industry is basically funded by the government already, but only a few elite get to take advantage of it. It is very harmful to society as a whole to have such profit centric people in charge of our health.

    25. Re:The fundamental problem with Bayh-Dole ... by biodork · · Score: 1

      Please... spell it out.

      We NEVER have the cash on hand to just "fund" projects indefinatly. Further, please introduce me to this large sum of money people that don't care if we make money back. I haven't met them. In general, people who give you money want some form of return on their investment. The risk they take with us (and others) is that we are smart enough to take that money and return more money to them.

      --
      Gavin Fischer
    26. Re:The fundamental problem with Bayh-Dole ... by jafac · · Score: 1

      In other words;
      Necessity is the mother of invention. (as opposed to greed).

      --

      These are my friends, See how they glisten. See this one shine, how he smiles in the light.
    27. Re:The fundamental problem with Bayh-Dole ... by Jah-Wren+Ryel · · Score: 1
      --
      When information is power, privacy is freedom.
    28. Re:The fundamental problem with Bayh-Dole ... by angle_slam · · Score: 1

      That may be true of, e.g. an individual scientist at Pfizer. But it is not true of Pfizer as a corporate entity. They don't develop drugs because it's fun or cool. They develop drugs to make money.

    29. Re:The fundamental problem with Bayh-Dole ... by bill_kress · · Score: 1

      That which costs $100m today will cost $10m in 5 years, and could be done by highschool kids in the garage in 10.

      Not that this is an absolute law or anything, but as knowledge and tools are refined, the whole process becomes less expensive.

      If science were slowed down a little bit, it wouldn't really bother me much at all, in fact I might encourage it.

      People who lose relatives, government and people with some degree of empathy will continue to fund research in areas like cancer, aids, etc. This is what taxes should go for, this is a great way to do this kind of work.

      At this point, using private research to build a product based mostly on people and work who have come before you and given freely to build a drug that you use to monopolize a type of health care is borderline criminal.

    30. Re:The fundamental problem with Bayh-Dole ... by enderwig · · Score: 1
      That which costs $100m today will cost $10m in 5 years, and could be done by highschool kids in the garage in 10.

      Not that this is an absolute law or anything, but as knowledge and tools are refined, the whole process becomes less expensive.

      If science were slowed down a little bit, it wouldn't really bother me much at all, in fact I might encourage it.
      But you need to spend capital (money, time, effort) in order to advance things and reduce their costs. If you don't, then it will remain $100m forever (plus the cost of inflation/deflation). Things do not magically decrease in price so that high school kids can do "science."
    31. Re:The fundamental problem with Bayh-Dole ... by bill_kress · · Score: 1

      > But you need to spend capital (money, time, effort) in order to advance things and reduce their costs. If you don't, then it will remain $100m forever (plus the cost of inflation/deflation). Things do not magically decrease in price so that high school kids can do "science."

      Of course! In some cases money is spent in parallel since existing products that are similar get improved and the techniques reduce the cost of other products.

      In other cases it should be government funded (All of us getting together to solve a common problem, exactly what a government is for!).

      Nobody looked at an 8086 and said "Hmm, this needs to be 3ghz! We took small steps and produced products along the way that funded further efficiency improvements.

      In fact, what made computers advance so fast was IBMs inability to prevent others from copying their design, this revolutionized everything.

      If IBM had been as "Smart" as apple about trying to recoup their costs by making their firmware uncopyable, we'd be running on dozens of completely incompatible PC brands now--probably at a 386 speed eqivilent. Or worse yet, there would be few PCs outside offices (Since IBM would have never let the price drop like it has).

  5. Biotech isn't computer tech by ReformedExCon · · Score: 5, Insightful

    While there are certainly areas of crossover, like the algorithms to filter through the volumes of data that biotech firms have, the fundamental difference between bio companies and computer companies is that biotech produces *something*. Computer technology is basically ephemeral. But Biotech leads to medicines and other discoveries that are both difficult to discover and inherently valuable.

    It makes sense to cover biotech with patents, as it took significant effort to research and develop those things.

    Computer tech, on the other hand, is primarily focused on automating processes. Computers are inherently faster than humans at doing repetitive tasks, especially in regards to calculations. But it is difficult to find a program that implements a process that doesn't exist already in another form, or that isn't blatantly obvious to everyone. Something like developing "a secure mechanism by which encrypted media data is stored on a device and available for playback when read and decrypted by the client application" would probably be a good candidate for a patent. "Users can click once and purchase an item without having to load the shopping cart menu" is both obvious and not really that far removed from the systems that preceded it.

    That people get greedy and innovation slows down when companies are competing is just a small side-effect of the patent process.

    --
    Jesus saved me from my past. He can save you as well.
    1. Re:Biotech isn't computer tech by Daniel+Dvorkin · · Score: 4, Insightful

      There's a lot of software out there which was neither trivial nor obvious. Just because most computer "R&D" work (in quotes because most of it is almost entirely "D" without a whole lot of "R") offers only minor improvements on existing systems doesn't mean all of it is that way.

      That being said, neither algorithms nor genes should be patentable. Ever. By anyone.

      --
      The correlation between ignorance of statistics and using "correlation is not causation" as an argument is close to 1.
    2. Re:Biotech isn't computer tech by Austerity+Empowers · · Score: 1

      I don't buy the quality of innovation argument, it sounds elitist in addition to being wrong. Computers innovation enabled biotech research. The reearch could have been done, but it would be very hard to do given the sheer mass of data involved.

      Computers get to market fast, biotech takes a long time. 20 years on computer technology is way too long, but as /.'ers have convinced me, for biotech it's not so easy. That's really the only difference, I haven't heard a good solution yet.

    3. Re:Biotech isn't computer tech by Quirk · · Score: 2, Informative
      "Computer technology is basically ephemeral. But Biotech leads to medicines and other discoveries that are both difficult to discover and inherently valuable."

      Do you know the definition of ephemeral?

      "Function: adjective
      Etymology: Greek ephEmeros lasting a day, daily, from epi- + hEmera day
      1 : lasting one day only
      2 : lasting a very short time
      synonym see TRANSIENT

      How do you come to term computer technology ephemeral?

      Computer technology encompasses concrete inventions and abstract inventions.

      Speaking to abstractions, it's likely some computer algorithms will be around much longer than some of the hardware.

      "Biotech leads to medicines and other discoveries that are both difficult to discover and inherently valuable"

      Do you think sound algorithms are somehow less difficult to discover?

      As to "...inherently valuable... I'm schooled in Economics and Commerce, along with other areas. I've read deeply in the subject of value from Aristotle on up, and, to say biotech discoveries are inherently valuable is to state the trivial. Any discovery is "inherently valuable". It is the nature of information that it is valuable, to speak of it as "inherently" valuable is some kind of voodoo.

      --
      "Academicians are more likely to share each other's toothbrush than each other's nomenclature."
      Cohen
    4. Re:Biotech isn't computer tech by Master+of+Transhuman · · Score: 1


      Nanotech will alter that equation. Nanotech will allow biotech research to be sped up by orders of magnitude. And combined with advances in computer hardware via nanotech, the vast amounts of data produced by nanotech-enabled biotech research will be processable.

      Some people have suggested that we won't make serious progress in understanding the human body and brain for the next 300 years. Wrong. Nanotech will in the next 20-50 years allow massively parallel embedded real-time investigation of body and brain function that will enormously speed up the process. I would expect we would have perfect maps of the entire human body and brain easily by the end of the century, if not sooner - I would guess easily by 2050 to 2075.

      Nanotech will also allow bringing biotech products to market much faster as a result of the overall speedup of both research and development. Manipulation of biotech components will be easier with nanotech tools which will speed development of products.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
    5. Re:Biotech isn't computer tech by Fulcrum+of+Evil · · Score: 1

      Just because most computer "R&D" work (in quotes because most of it is almost entirely "D" without a whole lot of "R") offers only minor improvements on existing systems doesn't mean all of it is that way.

      Just because a particular bit of computer work is obvious and trivial (or at least very simple) doesn't mean it need not be written or that it lacks value. The world needs accounting programs as much as it needs FEA modellers.

      --
      "We returned the General to El Salvador, or maybe Guatemala, it's difficult to tell from 10,000 feet"
    6. Re:Biotech isn't computer tech by NeutronCowboy · · Score: 1

      Completely agree. Dvorkin for President!

      --
      Those who can, do. Those who can't, sue.
  6. Heh by xvx · · Score: 1

    "But in the process innovation and scientific collaboration seem to have been stifled."

    Don't forget spelling. amdendment?

  7. Patent Reform Act of 2005 to hurt innovation more by Anonymous Coward · · Score: 4, Interesting

    Nothing will hurt innovation more than the Patent Reform Act of 2005.

    Why? Because it sets limits on damages for willful and even fraudulent patent infringement so that large corporations will find patents easy to ignore.

    Meanwhile, the limits are still big enough to remain a deterrant for small companies and independent inventors.

    In other words, if you are a big corporations, you might be able to knowingly ignore patents while startups and inventors don't have the same benefit.

    There are some good improvements in the Patent Reform Act of 2005 but this fundamental flaw is going to hurt innovation by making the patent system benefit a small percentage of companies at everyone else's expense.

    Please write to your representatives and respectfully ask them to fix the flaws before it becomes law.

  8. Too much grease by A+nonymous+Coward · · Score: 5, Interesting

    Grease keeps systems working smoothly. Lawyers, money speculators, used car salesman, and a zillion other occupations are society's grease. In a frozen static society, you could get rid of them once you had polished the system to the nth degree. But in a dynamic society, these greasers keep the various diverse parts all working together relatively smoothly.

    But too much grease in a gearbox bogs it down. That's what has happened with intellectual property in general. Those idiots in Washington listened to their corporate sponsors and believed what they said about the more the merrier.

    At some point, hopefully sooner rather than later, business and politicians will notice what the true innovators and researchers have long since learned the hard way, and cut back on the flow of grease. In the meantime, the rest of us are stuck with completely counterpdocutive IP legal wrangling getting in our way. It may take a long time to notice the drop in innovation and productivity, but I sure hope not.

    1. Re:Too much grease by ozmanjusri · · Score: 1

      Grease keeps systems working smoothly. Lawyers, money speculators, used car salesman, and a zillion other occupations are society's grease.

      Nice analogy because, where I come from, we put grease between two large abrasive objects and grind it as flat as possible...

      --
      "I've got more toys than Teruhisa Kitahara."
    2. Re:Too much grease by A+nonymous+Coward · · Score: 1

      I was smiling as I wrote it. It's especially nice when it just happens, without any special effort :-)

  9. Monopolies on problems vs. patents on solutions by FlorianMueller · · Score: 4, Insightful
    The difference between life science patents and patents on programming logic is fundamental:

    • A patent on a medical agent is, generally speaking, like a recipe that anyone in that industry can use to produce something useful. That's why such a patent advances knowledge in the field, and potentially has some value after its expiration.
    • Patents on programming logic are, again generally speaking, just some extended descriptions of the task at hand, of the problem that is to be solved. They outline a rather general approach to solving the problem, but if you read such a patent document, you're not really closer to a functional solution than if you don't. Most of the work is still ahead of you: the actual implementation.
    • Also, if someone wants to question the patent system in biotech, then what's the alternative? Patents have, despite a few cases of misuse, been proven to be the suitable intellectual property rights regime in that field. In contrast, today's leading software companies like Microsoft, Oracle and SAP needed no patents at all during the first 10+ years of their existence. SAP only had a total of four patents a few years ago. It would be too simplistic to say that copyright law alone protects software because it's actually a combination of copyright, trade secrets, complexity, trade marks, and the possibility of converting a technological lead into sustainable economic value (by selling products, acquiring customers, building the brand identity of an innovator). That form of protection is much more dynamic than patents because it requires someone to actually market a product, as opposed to just sitting on a patent and waiting for others to unwillingly and unknowingly "infringe" upon it.

      The other issue is who should own the outcome of the research work that is performed with tax money. I don't think it's reasonable to let the public pay twice for the same work, upfront by employing many such scientists for decades in each case (the fewest of which ever come up with something that can be commercialized on a large scale) and subsequently through patent royalties.

    1. Re:Monopolies on problems vs. patents on solutions by top_down · · Score: 3, Insightful
      The difference between life science patents and programming logic is not fundamental. The final products of life science might be more tangible but from an economic point of view they both produce products that have high sunk cost and low marginal cost.


      Also, if someone wants to question the patent system in biotech, then what's the alternative?


      Patents are government backed monopolies, so the alternative would be a free market. Research would
      be payed for by the government. The government would be financed by taxing the products in the free market. Another option would be allowing patents but forbidding exclusive licenses.


      Patents have, despite a few cases of misuse, been proven to be the suitable intellectual property rights regime in that field.


      The main point of the article is that it been a disaster. Did you read it? In fact the article is still pretty mild, it doesn't mention the many thousands of people that have died and are dying because of the high prices for drugs that can be cheaply produced (after the research has done).

      The results of this 'suitable intellectual property rights regime' are at least as bad as those of Katrina. They just happen over a longer period of time and most of the dying is in far away places.

      --
      Anyone who generalizes about slashdotters is a typical slashdotter.
  10. Ummm... Article argues against itself by biodork · · Score: 4, Insightful

    From the article.
    " A 1979 audit of government-held patents showed that fewer than 5% of some 28,000 discoveries--all of them made with the help of taxpayer money--had been developed, because no company was willing to risk the capital to commercialize them without owning title"

    To all those in this thread that argue "scientists will do it for the love" or any of that crap. That sentence above says it all. Scientists might do it for the love, but companies won't pay to develop it. I work at a biotech company - we won't do stuff that won't make us money. We have to pay our salaries. If we do something that we DON'T have patent coverage on, our competition will just copy it at no cost to them... oh yeah - we will have spent A LOT of money to do the development. If we can't get an exclusive license, then for the most part we won't touch it. It WONT make financial sense to do so.

    You can preach about "greater good of man" and all that. At the end of the day I just want to send my daughter to college and be able to go surfing. To do that, we have to make tools that help people, and I enjoy being part of that. I love solving the problems. I enjoy working on the projects. BUT - I have to eat and the company has to make money.

    --
    Gavin Fischer
    1. Re:Ummm... Article argues against itself by EzInKy · · Score: 1


      I work at a biotech company - we won't do stuff that won't make us money. We have to pay our salaries. If we do something that we DON'T have patent coverage on, our competition will just copy it at no cost to them... oh yeah - we will have spent A LOT of money to do the development. If we can't get an exclusive license, then for the most part we won't touch it. It WONT make financial sense to do so.


      So essentially what you are saying is the your company can not make a profit if it does not have a legal monopoly on the products that it sells. Whatever happened to making things better, faster, and cheaper to get a leg up on the competition?

      --
      Time is what keeps everything from happening all at once.
    2. Re:Ummm... Article argues against itself by Anonymous Coward · · Score: 0

      If we do something that we DON'T have patent coverage on, our competition will just copy it at no cost to them

      I just realized the contradiction in this reasoning. So you are saying if you DON'T have a patent on something, you WON'T make money... but then how could your competitors make money by copying you, if THEY don't have a patent on it, either?

      Wouldn't they say, "we can't make money on it," and then NOT copy it? Then you wouldn't have to worry about it.

      Of course you will make up some excuse, because patents are simply not necessary to make money. Patents are for making OBSCENE profits. If you make a useful product, you can make money selling it, but you have to compete on price, quality, etc. A patent says, "no competition!" That's what this is really about.

    3. Re:Ummm... Article argues against itself by Patrik_AKA_RedX · · Score: 1
      Whatever happened to making things better, faster, and cheaper to get a leg up on the competition?
      They still do that. Just replace "things" with "lawyers".
    4. Re:Ummm... Article argues against itself by TwentyLeaguesUnderLa · · Score: 1

      The difference between you making money on it and them making money on it - YOU spend 500 million dollars developing the drug, testing it for safety, tweaking it to make it usable, doing more testing. To "Make Money" on it, you have to recoup those 500 million. THEY copy it, spend ten or so thousand dollars basically looking at what you did. To "Make Money" on it, THEY have to recoup 1000 times less money than you to turn a profit. Since it's a free market society, and it cost them less to make the product than it does you, they can afford to sell it for a lower price. So of course, if they can do that, nobody is ever going to buy the original developer's product, since it'll be more expensive because that much more work went into making it. So effectively, all that development work that was done doesn't benefit the company that does it. THAT's why they claim that it's hard to make money without a patent.

    5. Re:Ummm... Article argues against itself by rolfwind · · Score: 1
      Ummm... Article argues against itself

      From the article.
      " A 1979 audit of government-held patents showed that fewer than 5% of some 28,000 discoveries--all of them made with the help of taxpayer money--had been developed, because no company was willing to risk the capital to commercialize them without owning title"


      Word of advice - don't just read the opening paragraph of an article and then claim it argues against itself BECAUSE IT THEN GOES INTO DETAIL WHY THINGS AREN'T SO CUT AND DRY.

      The author already said it seemed counterintuitive that the Bayne-Dole law didn't improve things and explored that issue.

      Also at issue in this article that you have missed:

      Why should publicly funded research end up as patents in the private domain?

      This article had nothing to do with patents that companies got by researching things on their own time and money.

      You might as well quote that section of the article and come up with the conclusion - Well schucks, if publicly-funded research isn't being further developed and isn't helping anyone, let's complety cut public funding everywhere!
    6. Re:Ummm... Article argues against itself by tqft · · Score: 1

      So this means that there exists a vast(?) body of research on chemicals and processes (not drugs yet) that could help humanity but won't be touched?

      Does it ever become economic to take all that research and make a library/guide of it?

      Maybe some student looking for a research project - maybe funded by one of the big foundations - or a government - could document at least some of it so people can see what are and aren't blind alleys.

      --
      The Singularity is closer than you think
      Quant
    7. Re:Ummm... Article argues against itself by PetoskeyGuy · · Score: 3, Interesting

      Amendments could still be useful. If the data suggested by the article is true, then they've identified a problem, and a possible solution that didn't work.

      In today's terms you could say the problem is trying to help the US GOV to better leverage it's patent portfolio. We have the technology now to handle so much more information that it should be possible to amend the law to say that the US does own patents on research it funds, then it could have an aution of patent rights. The whole problem was businesses were hesitent to create prodcuts without patent protection.

      The current system instead GIVES AWAY ALL PATENTS that were previously owned by the governemtn and says we'll pay you to do the work, if you discover something good for you, keep the patent and make your millions. Imagine instead if the government kept the patent ownership but auctioned off potentially profitable patents for AT LEAST the cost of the funding, and split part of the profit with the scientists. Extermely useful or critical patents could be kept instead of being sold off if deemed necessary.

      Suddenly scientists are back doing science, businesses get ownership of already completed research with patent protection, scientists get a nice bonus check every once in a while, and the fed actually makes money on scientific research getting potential profit from the sale of the patent instead of sitting on the patents rights until they expire.

      Instead you create a new feedback loop where investing in science generates new discoveries that can be sold to businesses for at least the cost of the discoveries and you could turn that money into more funding for schools and more discoveries.

      Then maybe we could move away from the current USPTO cash cow that creates such worthless patents lately.

    8. Re:Ummm... Article argues against itself by Moridin42 · · Score: 1

      There is a concept called the Free Rider problem.

      Without an exclusive license, free riders become a problem. Companies who did no work developing a technology can copy it. And they can produce it cheaper, because they didn't lay out any money to develop it. Their costs are only production costs. Whereas any company that actually did R&D has both the R&D costs -and- roughly the same production costs.

      There's no competition there. The free riding companies have fewer costs, so they sell their product cheaper. The innovating company, at this point, can choose to either match the lower price and accept their development costs as losses or maintain their higher price and probably go out of business.

      In either case, that company is no longer going to be creating new stuff. There's no money in it.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    9. Re:Ummm... Article argues against itself by Jah-Wren+Ryel · · Score: 1

      Without an exclusive license, free riders become a problem.

      Only if your funding model is stuck in "venture capital" mode.

      Today, in the USA and most of the Western world, biotech development is funded by people who do not care about the end result. All they care about is that the end result is marketable, that somebody, somewhere, will pay for it, regardless of what it does. It is kind of the "money for money's sake" approach to business rather than a "money for beneficient results" model.

      One possible alternative is to enable the people who would directly benefit from the development fund the development. As an illustration consider if everyone in the nation who was at risk AIDS infection were to put up $100 to fund the development of an AIDS "vaccine."

      Ignoring the logistics problems (which can be solved, but are not the point of my post) if the cost for R&D plus a "decent" profit margin could be paid for up front by the people who directly benefit from the end result then free riders are not a problem. The company benefits by reducing its risk of losing money on the project to near zero. The people putting up the money benefit from whatever vaccine is produced. If no vaccine is produced, if all the pre-paid money gets burnt up with no tangible result, the cost to the individuals who fronted the money is relatively small - they've only put up $100 each, so losing a $100, while sucky, isn't anywhere near as catastrophic as one company losing $30B.

      That's just one approach, there are other "non-traditional" business plans out there. Federally funded development isn't really too different from that example, except that nowadays they are trying to eliminate the original "free riders" via IP law. while letting the corps be free riders on the tax payer's dollar.

      --
      When information is power, privacy is freedom.
    10. Re:Ummm... Article argues against itself by klui · · Score: 1

      What you say is true only if a group invents something that is unique without any external help or influence. The article says that most--indeed, if not all--progress is done on top of others. Truth is probably in the middle, but the article's examples of those who have patented were in a way "free riding" off the works of others as well as leveraging the funds of the government.

    11. Re:Ummm... Article argues against itself by top_down · · Score: 1

      Without an exclusive license, free riders become a problem.

      For this very reason much of the research is either payed for or heavily subsidized out of public means.
      This is a much better solution than giving up on the free market.

      Another policy that has been successful is non-exclusive licences. Take a look at the well organized electronics industry where patent pooling and non-exclusive licences are common and a lot of R&D is done.

      The market is what makes companies depend on their customers. If we voluntary deny ourselves the option of buying some drug from another company, we get what we deserve and what the article describes: high prices and stagnating innovation.

      --
      Anyone who generalizes about slashdotters is a typical slashdotter.
    12. Re:Ummm... Article argues against itself by Moridin42 · · Score: 2, Insightful

      Actually.. under your example, there would still be free riders. You just change who they are.

      Say 80% of people at risk for an AIDS infection put up $100 for development. Some firm takes this money and successfully produces a medicine that eliminates the AIDS condition. Do you only sell it to the people that dropped the money on development? Or do you sell it to everybody. Including the 20% of people who paid no money for its development.

      You could grant the investors a discount, certainly. But in that case you'd be granting a protection. It isn't a patent, certainly, but I can't say that its any better. Nor can I say its worse. I just don't know enough about its feasability.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    13. Re:Ummm... Article argues against itself by EzInKy · · Score: 1


      There's no competition there. The free riding companies have fewer costs, so they sell their product cheaper. The innovating company, at this point, can choose to either match the lower price and accept their development costs as losses or maintain their higher price and probably go out of business.


      But you have to admit, there is no competition when the government grants a monopoly preventing it, right? Also there are a couple of things that you seem to be ignoring and that is that the innovating company has a natural advantage over future competitors by being first to market and having a deeper understanding of its products.

      --
      Time is what keeps everything from happening all at once.
    14. Re:Ummm... Article argues against itself by Moridin42 · · Score: 1

      I am not, in any way, arguing that we should do away with free markets. Or the semi-free markets that are in operation.

      I -am- saying, however (and I'll grant I may not have been as accurate as I could've been), that the post I was originally replying to was a little too black and white to be viable.

      I can't really see why most/all university-held patents couldn't be licensed using non-exclusive licenses. But I haven't studied the situation a lot, so take that with a pinch of salt.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    15. Re:Ummm... Article argues against itself by Moridin42 · · Score: 2, Insightful

      Sure, there's not likely to be competition under a patent-based production. So what?

      Lacking patents entirely, there wouldn't be production of the new product at all, because the risk of losing money is high and returns are low.

      I think you overestimate the natural advantage of being first to market. It won't much matter that you were first, if your competitors can match you on quality and beat you on price. And a deep understanding of a product isn't necessary to the copying company. They only need to understand the science enough to reproduce it. Sure, they probably won't be able to produce any new, next step in that line of technology.. but they won't need to do that either. They'll wait for someone else to do it, and copy that product too.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    16. Re:Ummm... Article argues against itself by EzInKy · · Score: 1


      Sure, there's not likely to be competition under a patent-based production. So what?


      Without competition producers have little incentive to control prices.


      Lacking patents entirely, there wouldn't be production of the new product at all, because the risk of losing money is high and returns are low.


      People were inventing products long before patents were created.


      I think you overestimate the natural advantage of being first to market. It won't much matter that you were first, if your competitors can match you on quality and beat you on price. And a deep understanding of a product isn't necessary to the copying company. They only need to understand the science enough to reproduce it. Sure, they probably won't be able to produce any new, next step in that line of technology.. but they won't need to do that either. They'll wait for someone else to do it, and copy that product too.


      If your competitors can beat you on price while matching your quality then your company is not being run very efficiently and if a deep understanding of the science behind the product is not necessary to produce it then the product is most likely not worthy of a patent in the first place.

      --
      Time is what keeps everything from happening all at once.
    17. Re:Ummm... Article argues against itself by Anonymous Coward · · Score: 1, Interesting

      You're just wrong.

      because no company was willing to risk the capital to commercialize them without owning title"

      If it was IMPOSSIBLE for ANYONE to "own title", the companies would not be at a disadvantage. It's only because titles CAN BE OWNED,that the market is unfair and unfree.

      This is discussed at http://libertariannation.org/a/f31l1.html#4:

      In his autobiography, Herbert Spencer tells a story that is supposed to illustrate the need for intellectual property rights. Spencer had invented a new kind of hospital bed. Out of philanthropic motives, he decided to make his invention a gift to mankind rather than claiming a patent on it. To his dismay, this generous plan backfired: no company was willing to manufacture the bed, because in the absence of a guaranteed monopoly they found it too risky to invest money in any product that might be undercut by competition. Doesn't this show the need for patent laws?

      I don't think so. To begin with, Spencer's case seems overstated. After all, companies are constantly producing items (beds, chairs, etc.) to which no one holds any exclusive patent. But never mind; let's grant Spencer's story without quibbling. What does it prove?

      Recall that the companies who rejected Spencer's bed in favor of other uses for their capital were choosing between producing a commodity in which they would have a monopoly and producing a commodity in which they would not have a monopoly. Faced with that choice, they went for the patented commodity as the less risky option (especially in light of the fact that they had to compete with other companies likewise holding monopolies). So the existence of patent laws, like any other form of protectionist legislation, gave the patented commodity an unfair competitive advantage against its unpatented rival. The situation Spencer describes, then, is simply an artifact of the patent laws themselves! In a society without patent laws, Spencer's philanthropic bed would have been at no disadvantage in comparison with other products.

    18. Re:Ummm... Article argues against itself by ooze · · Score: 1

      Huh? Companies being run on the base of actually understanding what they do? That would make economy degrees useless (and everyone knows that people with economy degrees are useless in the first place), and noone could actually want that.

      --
      Just because I can imagine doing a hippopotamus, doesn't mean I'd like to do it.
    19. Re:Ummm... Article argues against itself by Znork · · Score: 1

      "So, the whole thing really seems like a big corporate well fair racket, whereby companies have been essentially gifted valuable IP by the American tax-payers."

      All IP is per definition corporate welfare. It can be compared to temporary taxation rights, given as a subsidy for otherwise unprofitable industries.

      Of course, as far as welfare programs go, this one is neither under democratic control, nor do we get a receipt for taxes paid. Not even a small label like '95% of the price of this product is monopoly taxation, of which 15% is development costs'.

    20. Re:Ummm... Article argues against itself by biodork · · Score: 1

      Look at Malaria research.

      There is a ton of work out there on it. However, the patient population that it would apply to is poor.

      Therefore no drug companies really get in to it.

      That work is just sitting there. Hopefully all of the posters on slashdot will take that and make a product out of it....

      --
      Gavin Fischer
    21. Re:Ummm... Article argues against itself by biodork · · Score: 1

      As you point out - the truth is in the middle.

      Pretty close to nothing that comes out of University research labs is ready to sell. For the most part, it goes in to the lab for 1-2 years before you know if you will get a product.

      Universities produce ideas, not products.

      If there is no protection on those years of work, it wont happen.

      --
      Gavin Fischer
    22. Re:Ummm... Article argues against itself by biodork · · Score: 1

      "If your competitors can beat you on price while matching your quality then your company is not being run very efficiently and if a deep understanding of the science behind the product is not necessary to produce it then the product is most likely not worthy of a patent in the first place"

      This just demonstrates a fundamental misunderstanding of the world.

      Production is, relativly speaking, easy. You lay down some specs and engineers hit them. SPecs being clear, and engineers being bright - this should move forward.

      For most of biotech - the production part is pretty trivial. We all drive on our production costs (see discussions about off-shoring work that also make Slashdot fly in to a tizzy...)

      The "deep understanding" is laid out by someone. Other bright people, once shown the solution, immdiatly will get it. There are few ideas in te world (none that come to mind) that once lain out CANT be understood by others. Thus - your statement about deep understanding falls down. Every company has bright people. They sit down with competitors products and get to understand them. It may take a longer or shorter time, but it happens.

      --
      Gavin Fischer
    23. Re:Ummm... Article argues against itself by biodork · · Score: 1

      Speaking here as someone who does this evil licensing thing for a biotech company. The Universities most certainly do NOT give away licences. We spend a LOT of money on licenses every year. We pay multi-millions in royalties every year.

      Not sure where "GIVES AWAY ALL PATENTS" comes from, but reality is not involved. The bench scientists get part of the money. Universities are getting money. Biotech/pharma is spending money.

      --
      Gavin Fischer
    24. Re:Ummm... Article argues against itself by Jah-Wren+Ryel · · Score: 2, Insightful

      Actually.. under your example, there would still be free riders. You just change who they are.

      Note, I did not say that they would go away. I just said that they are not a problem any more.

      Essentially, when the people funding the work are the ones who need the results, then as long as they get the results, it does not matter who else gets the results too. Because a drug design is just a bunch information, it costs nothing to give the design to everyone once its creation has been paid for.

      --
      When information is power, privacy is freedom.
    25. Re:Ummm... Article argues against itself by Moridin42 · · Score: 1

      I'm not sure I would say that they don't become a problem.

      You say that as long as the initial investors get the results, it doesn't matter who else gets the results too. I don't see how exactly this is true.

      There are going to be people who, knowing the development time for new medicines, will forego investing because they're already terminal. There will be plenty who will forego investment so that they can simply buy the resulting product later on. There are very probably some who will figure that the chances of actually finding a cure aren't likely and not invest for that reason. There are actually a lot of reasons for a person to be a free rider in this situation.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    26. Re:Ummm... Article argues against itself by Moridin42 · · Score: 1

      Without competition producers have little incentive to control prices.

      This isn't true at all. Being in a patent-based monopoly doesn't give you any sort of control over the demand for what you're selling. The producer is concerned about profit. So under high prices, people drop out of the market. This reduces revenues.. and profits. Note here that although I am saying nothing about what I think the life of the patent should be.

      People were inventing products long before patents were created. ... I sorta fail to see how this is relevant. People were inventing before patents. Sure. Good observation. Would you also care to compare the number of inventions per year before patent law and after? I'll grant you that probably isn't a fair comparison. But then neither is your suggestion of comparing 600 year old markets and production to modern day markets and production.

      If your competitors can beat you on price while matching your quality then your company is not being run very efficiently and if a deep understanding of the science behind the product is not necessary to produce it then the product is most likely not worthy of a patent in the first place.

      Your competitors have the cost of production plus the minor cost of the time to clone your technology. The innovators have the cost of researching the entirely new technology, designing a product, and then the production costs on top of it. That is a vastly larger cost.

      Any level of quality the innovating company can product, a competitor can clone for much cheaper. It isn't about one company being run more efficiently. And as I said before.. it takes a lot less understanding of a science to copy than it does to innovate.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
    27. Re:Ummm... Article argues against itself by Jah-Wren+Ryel · · Score: 1

      You still have not demonstrated how free riders hurt the company doing the development.

      Remember, the point of patents is to guarantee a monopoly market in order to provide (but not guarantee) a better chance of showing a return on investment for the developer.

      If the developer is instead guaranteed payment for their work ahead of time, the presence, or lack of, free riders has zero impact on the developer's profitability.

      --
      When information is power, privacy is freedom.
    28. Re:Ummm... Article argues against itself by Moridin42 · · Score: 1

      I have. I just didn't state it in a single sentance.

      In this case, the developing company is hurt by lack of funding. Either they lay out their own cash for development, then we're back to the current model on patents, or we rely on those who need/may need the product to fund development.. in which case, I don't see enough people kicking in enough money to actually make it happen. For good or ill, its been my observation that a lot of people just don't care until something directly impacts their lives.

      --
      I don't expect morality, equality, consistency, or justice from the law. I expect only legality.
  11. insider perspective by goodminton · · Score: 3, Insightful

    First of all, this article is well-researched but poorly written and the author fails to achieve a coherent voice and statement. IMHO, this was a waste of 10 pages. Secondly, I have worked in the biotech industry for last 6 years, 2 years of which have been with THE largest biotech company and the remaining 4 years with various start-ups. From this insider's perspective, I can tell you that the number one challenge of innovating in the biotech industry has less to do with IP law and more to do with the lack of management experience amongst life scientists. When you have industry where start-ups can get $90 million in venture capital and ballon to 150 employees without have a commercial product, that's not an IP issue... it's business 101 issue... think 1990's dot.com reduex

    1. Re:insider perspective by Anonymous Coward · · Score: 0

      FYI - "Between the time research begins to develop a new prescription medicine until it receives approval from the Food and Drug Administration (FDA) to market the drug in the United States, a drug company typically spends $802 million over the course of 10 to 15 years."
      http://csdd.tufts.edu/NewsEvents/RecentNews.asp?ne wsid=4

    2. Re:insider perspective by bananasfalklands · · Score: 1
      Indeed, the comment on page 10 about a 'foriegn' firm buying 'american know how' seemed cut off in it prime - 'commies ahoy?'.

      But look at it from a republican viewpoint. parents pay large college fees, poor sick people still die, and lawyers still get rich.

      You are working from the approach it's got to a product (a good approach it appears to me)

      the patent process today seems to assume that the patent is worth more than the product (whether or not it it is released) to begin with.

      --
      Send Peter Clifford Francis Macrae comdoms to 23 Bedford St, St.Neots, PE19 1AX, England
  12. Patenting programs by fragmer · · Score: 4, Insightful

    The problem with patenting algorythms and functions is in the very concept and purpose of computers. Programming languages are basically tools for expressing thoughts. As human toungues are used for expressing speakable words, programming languages are used to implement thinking processes of the mind. Data is non-material, and computers merely receive, process and output data, as human nervous system does. Algorythms are same as thoughts - they are ways of analyzing and processing data.

    Patenting physical devices (ever computer hardware) is fine by me, but patenting algorythms is comparable to patenting and restricting ways of thinking. Imagine what would happen if a law ordered people to think (or avoid thinking) in a certain way...

    I am not saying that everything on the computer must be completely patent-free. I believe that only unique, sophisticated and unparalleled applications should be allowed to be patented by the US Patent Bureau, for a limited time.

    - Matvei M.S

    --
    09 f9 11 02 9d 74 e3 5b d8 41 56 c5 63 56 88 c0
    1. Re:Patenting programs by nameer · · Score: 1
      Patenting physical devices (ever computer hardware) is fine by me, but patenting algorythms is comparable to patenting and restricting ways of thinking.

      A (sort-of) hypothetical. I come up with a new process for manufacturing goods. This new process is unique, non-obvious, and useful. The embodiment of the process is a machine that executes the process. The rules for the machine - the control logic etc. - are implemented by a large electronics cabinet holding a bunch of opamps and relays all hard wired together.

      Is this patentable?

      Now, for the sake of power consuption, flexibility, etc. I replace my huge electronics cabinet with a computer and some I/O cards. It's the same invention, just a slightly different embodiment (and very slightly at that). Is the process still patentable?

      I think this is the problem with arguing that all software patents are not O.K., while all hardware patents are O.K. The line is too blurry for me, since the point of a method patent is that the method is protected, regardless of the embodiment of the method. I don't patent the machine, I patent the method of executing my new manufacturing process (something that is vaugely tangeble, but I think worthy of patent protection). The implementation of this process would have been done with the "magnetics cabinet" 50 years ago, but today it's done with PLC's (simple industrial computers) running software to emulate the magnetics cabinet. Does that change mean that the process is no longer patentable? The SCOTUS of course said that the computer embodiment is patentable , and I agree with the decision. I think the USPTO f'd it up by allowing what are fundamentally "obvious" software patents, and software patents that are not implementations of patentable processes, but I don't think that all software should be exempt from patent protection.

      --
      "Uh... yeah, Brain, but where are we going to find rubber pants our size?" --Pinky
    2. Re:Patenting programs by fragmer · · Score: 1

      I agree. I, personally, define algorythms as application-nonspecific programming structures. For example, patenting a unique 3D-renderer library is fine by me. But patenting the very mathematical processes involved is not. Imagine a patent for "computer software that utilizes sines and cosines to draw dots in 3D space". I'm hoping that such "inventions" will not become abundant. I hope my wording wasn't too blurry... - Matvei M.S.

      --
      09 f9 11 02 9d 74 e3 5b d8 41 56 c5 63 56 88 c0
  13. The real problem as I see it by ShatteredDream · · Score: 3, Interesting

    Is human nature. Greed is a vice, not a virture, for a reason. Greed causes people to do evil and harmfull things and should not be confused with ambition. The ambitious man wants to build a business that is rich and successful, the greedy man wants to build an empire that will rule the economy with an iron fist and drain every last drop of wealth out of it that it can.

    One of the things that never ceases to amaze me is how accurate Judao-Christian scripture is about teaching about human nature. We see the result of greed in the dotcom bubble burst and we see the natural lack of general altruism all around us from the greedy bastards like Andrew Fastow that tanked Enron to the people now trying to scam FEMA and Red Cross by claiming to be refugees. Human nature toward economics is greed, not altruism and not enlightened self-interest. That is why both pure Capitalism and essentially all forms of Socialism have utterly failed.

    The problem I have with long patents is that they subject the economy to the control of lazy, greedy men and women. I and other fiction bloggers are proof that you don't need a long monopoly on your ideas to want to produce literature, music and discover new ideas. I have probably about 25-30 pages worth of just fiction material up for free for the other Christian sci-fi fans that read it, yet I don't really care right now about making money off of it. My muse is Christ, what is your muse?

    Shorter monopolies will light a fire under the asses of these people and force them to create new things. I hate to break it to the laissez faire purists, but the security afforded by these long monopolies breeds **sloth**, not creativity. Too many seem to have forgotten that old saying: necessity is the mother of all invention.

    1. Re:The real problem as I see it by Phroggy · · Score: 3, Informative

      You're forgetting that greed is the reason the patent system was created in the first place. By awarding a temporary monopoly to the inventor of some new bit of technology in exchange for publishing their designs, greedy people are encouraged to invent new bits of technology and publish their designs, so that when the patent expires, the rest of society benefits.

      Software patents lack a critical part of this deal: reading the patent doesn't make it any easier to reimplement the idea. It's trivially easy to violate Amazon's One-Click patent without reading the patent, or even using Amazon's implementation - just saying "hey, wouldn't it be nice if customer billing information were stored so they could make a new purchase without re-entering anything?" should not be patentable, but currently, just about anything that satisfies that idea will probably violate the patent. The public gains nothing by being able to read the patent. With traditional patents, reading the patent tells you what you would need to know to reproduce the invention.

      Sorry if that was a little incoherent; I'm tired.

      --
      $x='S24;r)>63/* h@<5+oZ)32"5cz';$me='phroggy'x$];
      $x=~y+ -xz+\0-Tx+;print$_^chop$me for split'',$x;
    2. Re:The real problem as I see it by Infamous+Tim · · Score: 1

      Regarding your perl sig: It was a very pleasurable experience to figure that bastard out =).

      In looking at it, you can trim the ,109 at the tail end if you change your input string and tack on an ì. Why didn't you? There was also a typo in there (ending the phrase with a , instead of a period).
      Also, I tried looking it up my three O'Reilly Perl books, but I didn't see the for @_ method you used. Where'd you dig that up from?

      push @x,ord()-32 for split'','Z=!;g&7?oO&:;- aì';split'','phroggy'x4;print chr^shift @_ for @x

      --
      checking for libvirus... no
      ERROR, libvirus.so not found, terminating
    3. Re:The real problem as I see it by Phroggy · · Score: 1

      The problem with ì is that it's not a lower ASCII character (0-127), so its value will depend on what character encoding is used - for example, ì is 236 (0xEC) in ISO-8859-1, 147 (0x93) in MacRoman, and 0xC3AC in UTF-8. When I try to copy and paste your code from Safari into Terminal on Mac OS X, it comes out like this:

      push @x,ord()-32 for split'','Z=!;g&7?oO&:;- a\303\254';split'','phroggy'x4;print chr^shift @_ for @x

      0303 and 0254 in octal are equivalent to 0xC3AC in hex, but of course you wanted to use ISO-8859-1, not UTF-8.

      The comma is not a typo; see Wikipedia.

      Remember that foreach is just a synonym for for, and the two may be used interchangeably.

      --
      $x='S24;r)>63/* h@<5+oZ)32"5cz';$me='phroggy'x$];
      $x=~y+ -xz+\0-Tx+;print$_^chop$me for split'',$x;
    4. Re:The real problem as I see it by Infamous+Tim · · Score: 1

      Thanks for clarifications and link. Twas informative! I bow to your perl hacker prowess

      --
      checking for libvirus... no
      ERROR, libvirus.so not found, terminating
    5. Re:The real problem as I see it by Phroggy · · Score: 1

      #!/usr/bin/perl
      use strict;
      use warnings;

      my $q='XyLEoNgGmGjkrhPrrJtctlhe,auesenaoOmCnEfc';
      for(sort split''=>substr$q,11,22,'Kfkz'){my$d=ord
      substr$q,0,1,'';print"\e[".(ord uc chr $d^64).chr
      (($d&32)/32+67)if($d<122);print}print"\n"#phroggy


      Note that this uses ANSI escape sequences, so may not work on some platforms.

      --
      $x='S24;r)>63/* h@<5+oZ)32"5cz';$me='phroggy'x$];
      $x=~y+ -xz+\0-Tx+;print$_^chop$me for split'',$x;
  14. Meme Pool Circulation by Doc+Ruby · · Score: 3, Interesting

    One fascinating phenomenon is how long it takes for the rough consensus of the "innovation community" (much of which is represented by many Slashdotters), that patents interfere with innovation, to begin to be reported in the "finance community" which depends on the innovators. That such reporting happens at all is really a testament to the relative freedom of the press - relative to all human history, that is. That such reporting will have little to no effect on patent interference with innovation is a testament to the relative slavery of politics, which controls the patent system, to corporations, which care solely about property, and not at all about "innovation" (so long as it's not necessary to profits). Perhaps relative to human history our politics is not so bad, but "not as bad as thousands of years of tyranny" isn't good enough.

    --

    --
    make install -not war

    1. Re:Meme Pool Circulation by Otter · · Score: 0, Flamebait
      As part of the "innovation community", I can tell you that:

      1) There is an absolute consensus that the IP system, while needing reform in certain places, is the engine of innovation.

      2) The rough consensus of the Slashbot community is utter contempt for real innovation. The only thing respected here is copying someone else's innovation as cheaply as possible.

    2. Re:Meme Pool Circulation by Doc+Ruby · · Score: 3, Insightful

      I'm not talking about Slashdot - though those people have their selfserving reasons to agree. I've been part of the innovation community for over 15 years. I can tell you that most people I know who invent things - software, hardware or protocols/architectures - have contempt for patents. And for the lawyers/financiers who value them. We work in that environment, so we derive value from them, as lawyers/financiers are the gatekeepers on the money we want for our value. But the patent system is broken enough that it impedes more than it promotes.

      The main complaint we have is that the PTO offers too many, too broad patents. Which forces innovators to work with too many lawyers for our productivity. Either to get one of those "paper patents" or be left behind, or to spin our wheels ensuring that someone else's paper patent doesn't interfere with our real invention. We feel that most patents we deal with are paper tigers with real teeth.

      Most of us agree that hardware patents should require at least a testable working model, that software should be covered by copyright, not patents, and that business or procedure patents are a travesty. And that practically all patents last too long for the purpose of recouping investment, the basis of their artificial monopoly, while copyright lifetimes threaten not only innovation, but the sustainability of our culture.

      That's what I mean by "the consensus". Not that no IP should be protected, but that the patent system currently threatens much more than it protects. And even the lawyers and financiers who read and write _Fortune_ magazine are starting to think that way.

      --

      --
      make install -not war

    3. Re:Meme Pool Circulation by Infonaut · · Score: 1
      The only thing respected here is copying someone else's innovation as cheaply as possible.

      I've been on Slashdot for a while (obviously not as long as you), but I don't see copying innovation as the dominant meme here. Slashdotters tend to disagree on most things, with a few exceptions, which are:

      Microsoft is generally a force that has become too powerful for the good of the computer industry, except when they provide viable competition for Google.

      Apple is generally an innovative (therefore good) force, except when their Open Source licensing doesn't sit right, or when they sue the crap out of people.

      Google is the cat's meow, except now they're more like a lion, and they have the potential to own the world, so Slashdotters are more watchful of them now.

      Those (CherryOS) who take the work of others and try to present it as their own should be served heaping piles of dogshit.

      Those who reverse-engineer or modify existing technology in some way not forseen by or approved of by the manufacturer are renegade heroes.

      Linux is awesome. Linus is awesome. RMS is a pain in the ass, but he came up with the GPL, so he deserves to be listened to.

      Companies that innovate should do so in a fashion that doesn't preclude other companies and individuals from creating their own innovations. This is where your notion of contempt for innovation arises. My take on it is that the Slashdot community in general gets pissed off when companies produce crippleware, or use patents to unfairly shut off competition. It's not because people here don't want to award innovation; it's because by the Slashdot definition, innovation does not include exclusion.

      --
      Read the EFF's Fair Use FAQ
    4. Re:Meme Pool Circulation by Omnifarious · · Score: 1

      Actually, I'm a member of that community as well, and I think claim 1 is utterly preposterous. The patent system, at least for computer science, is a huge hinderance. I live in fear that some random thing that I've done will get me sued for a patent violation if it ever gets popular. They most definitely do NOT serve their purpose of 'promoting science and the useful arts'. At least, not for computer science, which is what I have the most personal experience with.

      If people here really thought copying things cheaply was so great, then Microsoft would have a lot more respect than it does.

      I really hope you get to live in a world where absolutely everything (including ideas) has an owner. It'd probably be the ideal hell for you given a lot of your other comments.

    5. Re:Meme Pool Circulation by Omnifarious · · Score: 1

      Yeah, Otter's comment get's him dropped from my friend's list because it's false and mean spirited beyond all reason.

  15. oh no! by Anonymous Coward · · Score: 0

    Not the patent poster boy again!

  16. Money IS the prime motivator, but not the only one by FlorianMueller · · Score: 1
    I don't agree that it's a fundamental mistake to assume that money is the prime motivator for creative endeavors. Money has the advantage of being the most convertible form of reward. The triumph of the free market economy, in which the pursuit of profits is seen as a key motivation, is undeniable. In my view, there's empirical evidence that money is the prime motivator.

    However, it's also true that any policy, be it in intellectual property or any other field, is bound to fail if it's based on the exclusive assumption of everyone being a homo oeconomicus. There are people out there who'd rather win the Nobel Prize than make 10 or even 100 million dollars, provided that they already have a level of security and a standard of living that they're comfortable with. And some are even fine to be "poor but proud".

    Lawmakers simply have to understand the diversity of motivations. This is a pluralistic world in which people can seek their individual happiness in different ways.

    In life sciences, there is usually a lot of money involved (for laboratories etc.) to do research. Many inventions in that field simply couldn't be made by someone at home who has no substantial funds. Consequently, the IPR system in the field has to be particularly investor-friendly. Since university researchers usually aren't investors, it's doubtful that they should reap the rewards for what the public has paid for.

    In computer software, there can be no reasonable doubt that a lot of innovation happens every day without the motivation on someone's part to publish software or take out patents. Open source is the best example. Key open source projects were started by people who had to make no capital investment beyond the computer they already had. The entire code base of open source has been developed by a diverse group of people, and in that group you probably find any mix of commercial and non-commercial motivations, literally everything from 0% to 100% of a profit motive.

  17. On Academia and Innovation by Nutty_Irishman · · Score: 5, Insightful

    From TFA


    Universities have evolved from public trusts into something closer to venture capital firms. What used to be a scientific community of free and open debate now often seems like a litigious scrum of data-hoarding and suspicion. And what's more, Americans are paying for it through the nose.


    And who's to blame for that? Yup, the good old American system.

    The fact of the matter is, America doesn't care about science. We worship things like actors and singers and sports figures and then snub our nose at scientists in academia and pay them crap. Business is the most popular major, not because it provides the most to society, but rather it is the most profitable. In other countries, scientists are looked up to and admired (for example, India).

    In the US, the budgets have been cut drastically for academia (most grants are getting a 8% cut straight across the board this past year). Adjusting for inflation, the NIH and NSF budget's have actually shrunk over the past 10 years-- which is ridiculous considering the massive amounts of improvement in technology that have occured. With such a drastic decrease in available funds, researchers need to tighten their projects, search for alternative funding, and be wary of who they tell people what they are doing. Sharing data with someone you aren't collaborating with or on unpublished work is a sure way to find yourself out the door in academia. This is further being complicated by the fact that tenure reviews are starting to shift from the old paradigm of how many papers you published, to a newer paradigm of how much grant money you bring in (while this is usually correllated, it is not always the case).

    It's not the scientists that have created the environment, it's the environment that has created the scientists. There's a reason why College Professors were listed as one of the top 5 undervalued professions in America. Patents are the one bone that academia gets and the writer seems to think that scientists are exploiting America. Academia is already losing a lot of great talent (and henceforth, progress) as it is in America due to lack of funding-- how do you think it would be if patents didn't exists?

  18. Why they want patents (put spaces for readability) by TwentyLeaguesUnderLa · · Score: 1

    The difference between you making money on it and them making money on it -

    YOU spend 500 million dollars developing the drug, testing it for safety, tweaking it to make it usable, doing more testing.

    To "Make Money" on it, you have to recoup those 500 million.

    THEY copy it, spend ten or so thousand dollars basically looking at what you did.

    To "Make Money" on it, THEY have to recoup 1000 times less money than you to turn a profit.

    Since it's a free market society, and it cost them less to make the product than it does you, they can afford to sell it for a lower price.

    So of course, if they can do that, nobody is ever going to buy the original developer's product, since it'll be more expensive because that much more work went into making it.

    So effectively, all that development work that was done doesn't benefit the company that does it.

    THAT's why they claim that it's hard to make money without a patent.

  19. Adjusted for Inflation? by PetoskeyGuy · · Score: 3, Interesting
    I wonder if these numbers are adjusted for infation?
    From Page 8, Paragraph 2
    Whatever the answer, it's clear who pays for it. You do. You pay in the form of vastly higher drug prices and health-care insurance. Americans spent $179 billion on prescription drugs in 2003. That's up from ... wait for it ... $12 billion in 1980. That's a 13% hike, year after year, for two decades.
    Assuming they already adjusted for inflation, 12 Billion in 1980 to 179 billion in 2003 would be about 12.5%

    Assuming those numbers are NOT adjusted for inflation, then 12 billion 1980 dollars = about 29 billion in 2003 dollars. Growing 29 billion to 179 billion is an 8% increase per year.

    I also wonder if this is a linear increase or if there was something sudden jump at some point. Taking two data points and trying to make some sort of comparison other then "this one is bigger" seems rather dumb.

    In 1980 I was single, but in 2003 I had a family of four. That doesn't mean I was reproducing at a rate of 6.2% per year.

    Can someone point to a data source that has amount spent on drugs each year? I searched the web, but so far I don't see any sources I would trust, mostly stories similar to this.
    1. Re:Adjusted for Inflation? by kahei · · Score: 1


        I wonder if these numbers are adjusted for infation?

              From Page 8, Paragraph 2
              Whatever the answer, it's clear who pays for it. You do. You pay in the form of vastly higher drug prices and health-care insurance. Americans spent $179 billion on prescription drugs in 2003. That's up from ... wait for it ... $12 billion in 1980. That's a 13% hike, year after year, for two decades.

      Assuming they already adjusted for inflation, 12 Billion in 1980 to 179 billion in 2003 would be about 12.5%


      Hmm... well, according to my calculations and allowing for rounding to the nearest integer, it looks like they _did_ adjust for inflation, doesn't it?

      HTH.

      --
      Whence? Hence. Whither? Thither.
    2. Re:Adjusted for Inflation? by PetoskeyGuy · · Score: 1

      Hmm... well, according to my calculations and allowing for rounding to the nearest integer, it looks like they _did_ adjust for inflation, doesn't it?

      Maybe - they don't really say. 12 billion to 179 billion over 23 years is indeed 13%. What is not clear is if they already adjusted the 1980 numbers to account for inflation.

      For instance if I made $12,000 in 1980, that would be comparable to making over $25,000 in 2003. So you can't compare the amount spent each year directly. You need to adjust the numbers to account for inflation to be sure youre comparing the ... spending power so to speak .. of each dollar in the same way.

      It's still an increase, but when you count the aging population of baby boomers and the fact that we now have medicine that can keep you alive longer, allegy medicine that people take daily and other factors it may have nothing to do with the law her mentioned.

      It's easier to think of it if you increase the time scale. Lets say the White House in DC was remodeled in 1800 for $50,000. Then again in 2000 for $300,000. Which cost more? Adjusting for inflation, the 1800 remodel would cost about $180,000 more in 2000 dollars.

      You sometimes see that kind of thing in the numbers thrown around by politicians. I remember some congressman said something like "My daddy never made more then $30,000 a year." Of course adjusting for inflation, his dad brought home quite a bit 60+ years ago when he was growing up. It's all just numbers. This is the same reason people form India can work for $5,000 a year. They are doing quite well, and it's the International Exchange rates that makes it seem they are working for nothing from our point of view. It would be like hiring people from the past working 40 hours a week for two dollars a day.

  20. Why patent at all, a Copyright notice is cheaper. by OutOfFocus · · Score: 3, Informative

    "Photon Bounce -- Breaking the laws of physics, but not that of probability & statistic," by, 'Photon Vu' (This entire article copyrighted 9/14th/2005 by Mr. Photon Vu ). This application for patent is applied for by Mr. Photon Vu, dated September 14th, 2005 (11pm, Indianapolis Time, EST) for the design and use of the Photon Bounce and for the design and use of the uniformly distributed electron cloud whose statistical probability is at 0.5 throughout the layer and whose thickness is defined to be width of one electron whose statistical probability is at 0.5. [Begin of target description of patent concept] Patent is for the configuration and use of photon per the non-classical physic bounce to accomplish simultaneous computation via a statistical presence of data formed beneath an electron cloud with statistically uniform region whose probability is of 0.5 to achieve consolidated probability of 1.0 which designates simultaneously solved solutions and consolidated probability of 0.0 which designates unsolved solutions ( which represents region of theoretically-proven unsolvable problems as posed by the data that parameterize the simultaneous equations to be solved ). Details of this configuration are described below from item 1 through item 4: Item 1. Photon have no mass, thus can not cause a physical deflection in physical media, so the phenomenon being used is a statistical bounce in which a photon whose statistical probability is at 1.0 is directed at a region whose statistical probability is uniformly distributed throughout and whose statistical probability is at 0.5 . Item 2. A 'bounce' is defined as the statistical influence of the photon whose statistical probability is 1.0 on the region whose statistical probability is at 0.5 such that when there is a presence of a data point, representing one of the parameter of the simultaneous equation to be solved, all simultaneous computation occur for all data points represented in the computational region, formed by the evenly distributed layer of electrons whose probability was stable at 0.5 at the moment prior to the impact of the photon against it. Item 3. Multiple photons whose statistical probability of 1.0 can be used simultaneously against the uniform layer of electrons whose statistical probability is at 0.5 through the layer, with the requirement that not more than one photon can occupy the same space/time within the uniform layer of electrons. Item 4. Data points are represented by beams of photons of varying energy levels (frequencies) directed at the electron cloud. [End of target description of patent concept] Page 1 of 1 and only 1 page, final. BTW3. the key is not in the document above. It's something that every little kid already know, 'things that glow in the dark'. a.k.a (read below) [ i prefer the kid's version and wording ;))))) ] Energy levels in stable electron clouds are at specific energy 'rungs' which dance with bypassing photons. That's classical physics. In non-classical physics, the electron is a statistical entity whose distribution goes to infinity in space/time. However, even photons have statistical significance, of 1.0. So, when a photon that exist in physical space as a quanta hits an electron (which is really a statistical entity) it converts onto a wavelet, a statistical distribution that we can control. Thus, the statistical significance of an electron whose energy level is quantized already; and thus, a statistically significant computation event occur (not a physical event). Data of a simultaneous equations can be parameterized by electrons that are 'pumped' to a specific set of rungs ( yet again by photons, prior to the computation event ). If you layer this data set with a layer of electrons whose statistical probability is at 0.5 and whose thickness is exactly 1 electron (whose statistical probability is 0.5), you get a region of time/space that can convert the bounce of photons above it into an instantaneous computing event of all simultaneous equations, using the presence of the electron

  21. I would have read the article... by SilverspurG · · Score: 1

    but Fortune's writing style is absolutely unreadable. It's 95% advertisement and pump, 3% "{and,if,or,not,the}", and 2% information.

    UGH.

    --
    fast as fast can be. you'll never catch me.
  22. Ummm... Article argues against itself by xiaomonkey · · Score: 4, Interesting

    I'm surprised the parent was modded +5 insightful, since I'm not sure the poster actually took the time to read the article. Anyhow...

    Technically, the Bayh-Dole law that the article talks about doesn't really say too much about companies being able/unable to patent the results of research that's been privately funded.

    Even prior to the law, if you want to spend your money on research, you of course had the rights to patent the results. However, Bayh-Dole made it so that your company could spend tax-payer(read 'our') money to do research and development and then still be assured of your company owning the resulting intellectual property. So, the whole thing really seems like a big corporate well fair racket, whereby companies have been essentially gifted valuable IP by the American tax-payers.

    Maybe the NIH or NSF should start acting a little bit like a VC firm in these cases. That is, if companies and/or universities want to profit by patenting the results of publicly funded research, then maybe the funding federal agency should get a proportion of the proceeds. That money could then be funded into other new and interesting research projects.

  23. You don't get rich doing science by Ogemaniac · · Score: 1

    However, you may get rich in the science business, as you apparently have done. Congratulations.

    The reality is that if you work in the lab, your salary will be good, but smaller that it would have been if you had become a doctor, lawyer, MBA, etc, especially when you consider the long time it takes to get your PhD (and post-doc, and second post-doc....)

    Not many Americans are entering scientific fields for a darned good reason, I think. I wouldn't repeat my choice, knowing what I know now.

  24. Re:Another example: totalitarian countries by lahvak · · Score: 4, Insightful

    Just look at art and science in totalitarian countries. In all former communist countries, you definitely couldn't get rich by doing science, not even in relative comparison to general population. Yet they had a lot of excellent scientists, and produced huge amount of research.

    As far as art goes, not only you couldn't get rich, in many cases you could get yourself locked up. Still, all the Soviet block countries had very active unofficial art scenes.

    --
    AccountKiller
  25. Re:Another example: totalitarian countries by kfg · · Score: 1

    Thoreau wrote of poets living from their poetry as a steam plane is powered by the shavings it produces. A bowl of rice now again certainly doesn't hurt, but. . .

    The rewards of art and science are. . .art and science.

    KFG

  26. Useful discoveries? by lahvak · · Score: 2, Informative

    AFAIK, most scientific journals publish discoveries that were classified by peers as "interesting" in some way. It could be commercially useful, useful for further research, or just plain interesting from an "intelectual curiosity" point of view.

    In my field, it is often (usually?) impossible to tell whether a result is going to be useful or not.

    --
    AccountKiller
  27. Real unintended consequences--Mansfield Amendment by joneshenry · · Score: 4, Insightful

    Wrong root cause--the blame lies with the left and their reaction to the Vietnam War, with their one permanent reform the destruction of basic research in United States universities through the Mansfield Amendment. Just go to the musty bookshelves of one's university to the mathematics section and look for books before 1970. Many of them will have an acknowledgement of funding through some agency such as the Office of Navel Research.

    The Mansfield Amendment deliberately destroyed the relationship between the United States military and university basic research, so that instead of getting crumbs from a gargantuan Department of Defense budget, which meant the crumbs were quite substantial, basic research had to rely on the politically castrated National Science Foundation with no important constituency to push for funding.

    Faced with the prospect of basic research almost completely disappearing, the only alternative was something similar to Bayh-Dole, because there was no way anymore to politically push through explicit funding. What an irony that now what were once considered public goods are now the property of the largest corporations and the rich only get richer. Now that is the true unintended consequence considering who initiated the Mansfield Amendment.

  28. Re:Patent Reform Act of 2005 to hurt innovation mo by Halo1 · · Score: 4, Informative
    hy? Because it sets limits on damages for willful and even fraudulent patent infringement so that large corporations will find patents easy to ignore.
    They already do so today. The problem with the willful damages is that they kick in as soon as you read a patent, which means there's a huge disincentive to read any patents, reducing their potential value as knowledge source even further (yes, "even further", it's not like e.g. software patents are written to be understood by developers or scientists).
    In other words, if you are a big corporations, you might be able to knowingly ignore patents while startups and inventors don't have the same benefit.
    Large companies have always been able to do whatever they want thanks to their huge portfolios, see e.g. IBM vs Sun in the eighties.
    There are some good improvements in the Patent Reform Act of 2005 but this fundamental flaw is going to hurt innovation by making the patent system benefit a small percentage of companies at everyone else's expense.
    I doubt it. Afaik we don't have this willful infringement equals treble damages clause in Europe either, and the patent problem here is less bad than in the US for now. Less chance at a huge payoff may in fact reduce the number of court cases and thus benefit innovation, because more is invested in R&D and useful things, instead of in lawyers.
    --
    Donate free food here
  29. I have no idea where you get your data from by Ogemaniac · · Score: 2, Informative

    but I am sure it ain't right. Check the historical budget tables at www.omb.gov. NIH and NSF are doing just fine, thank you very much. Unfortunately, most of the data is not adjusted for inflation but the increases are so large that it is obvious that it is greater than inflation (around 2-3% year, or 25% over ten).

    Also, how precisely are you measuring "provision to society"? If you are making claims about it, you should have a good answer.

  30. Politics this early in the morning? by el_womble · · Score: 2, Interesting

    This is all about the spirit of free enterprise. We need research and development in order to progress as a society, but like all good things R&D involves time and resources and both thoses things cost money.

    Where does that money come from?

    Democrats/Librals believe that if the people pay for it, the people own it the benefit to this is that scientists are free to access the real pay dirt - information.

    Republicans/Red-Necks believe that a grant is just that, a gift of money and that scientists should be free to profit from their innovation - the benefit of this is that you attract brighter minds and the industry can run itself relieving the tax burden of a constant stream of grants.

    The question really is what is more important, a free market or a freedom of information?

    Thats not an easy question to answer. People would say that Russia was a perfect example of why the Republicans are right. Others might say that America is a perfect example of why the Democrats are right. I say the truth is that both sides have fudged the system to a point where neither can be right.

    I would have more sympathy for big R&D companies if I thought for one second that they had stopped asking for research grants or tax cuts to support their work. I would have more sympathy for big R&D companies if they could be trusted to return their products back into the public domain where it belongs. I would have more sympathy for R&D companies if they could be trusted to act with compassion where the bottom line must be second to the saving of lives and removal of people from absolute poverty. The one thing these companies can be trusted to do is protect their investors money, but thats about the only thing they are obligated to do by law.

    --
    Scared of flying, pointy things snce 1979!
  31. Re:Real unintended consequences--Mansfield Amendme by Anonymous Coward · · Score: 0

    Office of Navel Research.
    So they even had an office of researching the belly button?!

  32. Patents? Innovation? No connection... by jandersen · · Score: 3, Insightful

    Well, not quite, perhaps, but...

    I think the debate about whether patents are stifling innovation or not misses an important point: that most inventions don't happen because an inventor suddenly invents a brilliant new gadget. The real way most things are invented is when somebody has a problem and solves it; and most often the person doesn't even think of it as anything special, because it isn't in that situation - it's just a handy solution to a problem, so he/she could get on with the job at hand. Later, perhaps, somebody combines a number of these solutions and it turns out to be a great idea.

    I think people who are just 'inventors' are likely to be some sort of pathological phenomenon; a kind of obsessive tinkerers, perhaps.

    As for patents - they certainly make it difficult for others to make money from their good ideas, and I have no doubt that at some point it will become too cumbersome; then it will change. But since people will always run in to new problems and look for solutions, innovation will happen.

    Perhaps when it becomes clear enough that the patent system, with all the mindlessly stupid patents for trivial non-inventions, simply doesn't work, perhaps then will people begin to 'anti-patent' their inventions by immediately laying them out in the public domain; that way you at least ensure that nobody else can shut you out from making a fair earning from your good ideas.

  33. Re:Real unintended consequences--Mansfield Amendme by OneSmartFellow · · Score: 1
    Are you trying to tell me that the Office of Navel Research paid for my textbook.

    No wonder I spent so much time engaged in ompheloskepsis !

  34. Re:Patent Reform Act of 2005 to hurt innovation mo by thebdj · · Score: 1

    I think you are forgetting that the modern day patent trolls are the primary person that this section of the law are meant to stop. You have to realize that most large companies, including Microsoft do not see the point in going after the tiny companies making items because they aren't important enough, and more then likely don't make enough money to be worth the trouble. Most companies enforcing patents nowadays are companies in the case of Freedom Wireless v. BCGI. If you read this case and look at the background of FW's owners, you start to question if they are not acting like a bunch of cons.

    Remember most patents that big corporations are buying up now are meant to protect them against the tiny patent trolls and I do not expect this part of the law to cause some grand paradigm shift where we see big companies suing small businesses out of existence.

    --
    "Some days you just can't get rid of a bomb."
  35. Re:Why they want patents (put spaces for readabili by Vo0k · · Score: 1

    They spend 500 millions from taxpayer's money. It cost them nothing, they just got the grant. Then the manager decides it won't be quite as profitable as they thought because only one in a million suffers from this particular disease and production of this drug probably won't cover the costs, so the project gets cancelled. But they have the patent already, and even if someone was willing to help these 1 in million, who suffer because there's no drug that would help them, the particular drug is patented, and the owner of the patent doesn't want to sell it. Or sues the fundation that researched the drug independently, for patent infringement.
    As long as patents help fund innovation, they are okay. But more and more often they just help profit from obstructing innovation, instead of getting profit from what you did, and staying ahead, you get profit from directly stopping others from doing what you did. Like a racer who wins a unit of race and gets a bonus, instead of using it to gain further on others or catch a break, they spend extra time to push others, trip them or stand in their way, not letting them pass.

    --
    Anagram("United States of America") == "Dine out, taste a Mac, fries"
  36. I Think some of you Forget by thebdj · · Score: 1

    Without Patents there would be no requirement for an individual to disclose an invention. What would happen under such a system is not open innovation; however, it would turn into an immense system of lawsuits and constant battles of "me first" arguments (though this can still happen under the patent system it isn't as bad).

    There are two scenarios in reality:
    Scenario 1: Company A doesn't invent anything for fear of the second that it is released Company B will clone invention of Company A and then Company C repeats and the market is flooded. Now, here come the "free market" cries, but remember that if inventor/company A doesn't believe they can market product A well, and realize the scenario above will happen they will never release said invention and people may go without...

    Scenario 2: Company A invents. Company B takes and "re-invents". Now under old laws of trade secret stealing, or new laws of the "evil" DMCA, Company A sues company B. Vicious cycle continues, and innovation is stifled because companies don't want to release product because of legal battles...

    Patents guarantee Company A protection to be sell inventions without fear of Company B stealing said inventions. It also forces disclosure making Company B capapble of creating "improved" inventions based on Company A's disclosure. The improved inventions can then be marketed and the cycle continues. This is where innovation occurs, the problem is that most fields move so fast anymore (especially PC and bio-tech) that the patents seem overly restrictive for long times.
    Remember without patents most inventions by small inventors would almost definitely never see the light of day. Also remember that this great fear of patents as a money grab is by and large not a major problem since some 90% or more of patents NEVER COLLECT A SINGLE CENT.

    --
    "Some days you just can't get rid of a bomb."
  37. Simple question by Mostly+a+lurker · · Score: 3, Insightful
    When company A has an exclusive patent on enzyme 1 and company B has an exclusive patent on enzyme 2, how do you achieve the life saving drug based on the combination of enzymes 1 and 2?

    The argument that only granting exclusive use of some specific piece of knowledge can make commercialising products based on the idea viable financially is unconvincing. (Leaving aside that this does not eliminate risk because competitive products based on other ideas may still appear.) If necessary, have a system where the government compensates organisations for development in certain cases (perhaps with tax breaks) to give an advantage to the original developer. But do not prevent others from making improvements.

    The patent system adds huge costs for ephemeral benefits. Creativity and invention prosper in an atmosphere of freedom, not one of bureaucratic control.

    1. Re:Simple question by Anonymous Coward · · Score: 0

      The answer is Country C(hina? makes the stuff, while USA jobs and industry dies in the ass.

      The common theme is lots of bright scientists know this, but as there is no viable reward, they stay silent, as they sure don't have the bucks to contest a patent skirmish.

      Patents are mostly a scam to protect big industry, and Trips a tool to beat wantabees into submission. However judging by the trade balance and deflation, that aint working - too much is being held back, know-how wasted. It would be good to solve this very real problem.

    2. Re:Simple question by Secrity · · Score: 1

      This situation happens quite frequently with new technologies. The usual thing that happens is that the patent holders cross-license or pool licenses among themselselves. This method is very effective at allowing a technology to develop while at the same time keeping a very high barrier to actual competition. See http://en.wikipedia.org/wiki/Cross_license

  38. Re:Real unintended consequences--Mansfield Amendme by Anonymous Coward · · Score: 0

    Of course, that's assuming that you consider it moral and just to forcefully extract revenue from people -- who may fully oppose your agenda -- in order to fund that agenda.

    No thanks, I'll trust freedom over you and your agenda any day. If there is a need for research, then quite naturally, that research will be accomplished voluntarily. If the only way to accomplish that research is through force, then have you considered the possibility that society didn't value that research in the first place? After all, what free people want, free people achieve, and what free people don't want, free people don't bother with. Can you admit that, or are you in denial?

  39. Dude, its true! by Anonymous Coward · · Score: 0

    "You believe that a hard core capitalist corporation will burn money just because it is sooooo easy to get more..."

    Why do you think people were investing billions in .com's that never turned a profit, never could turn a profit, never could do anything except be a huge sinkhole for money.

    Or was that different hardcore capitalists?

  40. Effort? by Lifewish · · Score: 1

    As I understand it, the effort in the cases under discussion in TFA was all supplied by the government. And then industry gets to come in and cream off the patent rights to any areas of research that actually produce something. And, in doing so, commercialise what is supposed to be non-commercial research.

    If a company spends lots of money doing basic research to discover a wonder drug, I have no problem with them getting a patent. However, if research is done on the taxpayer's tab, I strongly feel that the taxpayer should get the benefit.

    --
    For the love of God, please learn to spell "ridiculous"!!!
  41. Comment removed by account_deleted · · Score: 1

    Comment removed based on user account deletion

  42. Comment removed by account_deleted · · Score: 1

    Comment removed based on user account deletion

  43. If Bio Tech by Martin+Spamer · · Score: 2, Funny

    ... had made the same progress as IT, we would all live to be 100,000 year old and be as smaller as an amoeba.

    1. Re:If Bio Tech by Sven+Tuerpe · · Score: 1
      If Bio Tech had made the same progress as IT, we would all live to be 100,000 year old and be as smaller as an amoeba.

      Or maybe die from multiple infections after we missed patch day or forgot to wear our firewall.

      --
      http://erichsieht.wordpress.com/category/english/
    2. Re:If Bio Tech by Dr.Dubious+DDQ · · Score: 1
      Or maybe die from multiple infections after we missed patch day or forgot to wear our firewall.

      That'll only be a problem for ordinary people. Those who migrate instead to OpenSequence/FreeDNA genetics instead will be largely immune.

      The only downside is that members of the BSA ("Biological Sequence Authority") keep changing the "mainstream" DNA in people's language centers so as to make it hard for ordinary people to communicate with OpenSequence people.

  44. Re:Real unintended consequences--Mansfield Amendme by jc42 · · Score: 2, Funny

    ... funding through some agency such as the Office of Navel Research.

    That would be research funded by the Navel Academy, I presume.

    --
    Those who do study history are doomed to stand helplessly by while everyone else repeats it.
  45. You disprove your own arguments by Anonymous Coward · · Score: 0

    "In other countries, scientists are looked up to and admired (for example, India)."

    Yes, and India is a 3rd world country with aspirations of being a 1st world country. Probably because they world people with a "masters" degree in mathematics (which is a friggin' joke), but I digress.

    Great. They've been at it a long time. Maybe they'll get there before the end of this millenia.

    1. Re:You disprove your own arguments by Omnifarious · · Score: 1

      Of course, India has managed to produce one of the most oddly brilliant mathematical geniuses of all time Srinivasa Aiyangar Ramanujan.

      Being a 1st world country does not give you any monopoly on intelligence. Generally speaking (though the US is a strong counterpoint to this) your educational system is better. But I wouldn't go discounting Indians who've gotten an MS in mathematics in their own country. The books needed to learn it aren't exactly expensive.

  46. been coming for a long time now by netwiz · · Score: 2, Interesting

    ha! lessee, we gave the keys to our minds and souls to corporate America, and now we're surprised that a collection of "individuals" possessing all the qualities of a paranoid schizophreniac with a single-minded focus on profit had the wherewithall to screw us over.

    will wonders never cease.

  47. Medicare Drug Benefit by Temkin · · Score: 3, Insightful



    The odd thing about this sad state of affairs.... If I'm reading this right, the Federal Government retains royalty free rights to virtually all the research it has funded. Which means, at least in theory, it could seriously leverage its position to purchase drugs for the medicare prescription benefits. Something that has apparently not occured...

    Which just goes to show who the politicians really represent.

  48. No, really? Patents curb innovation? Go Figure! by Anonymous Coward · · Score: 0

    No, Really? Patents stifle innovation, who would have thought that? Wowsers. I mean look at what the great science of Alchemy has brought us!!! 500 years of super-secret butt-heads keeping all they learned in the cave (don't share, its mine, mine all mine!!!) to themselves. 500 years playing with eye-of-newt and possum giblits. That pesky chemistry with it's shared knowledge, what has it gotten us in a lousy 200 years.... DNA, Pfffft, Superconductors Pffft. I tells ya, that sharing knowledge stuff, it'll never work. 9 out of 10 cave dwellers agree on that one.

  49. Grow up, young people ! by fizteh89 · · Score: 0


    It is natural for a single young person to live in a shack and be hungry every day, but to continue doing something (science, poetry, art, music etc.) just for the love of doing it, without any material compensation.

    But some day you grow older, get married, have kids ...
    Do you want your wife and kids to live in a shack with you and be hungry every day, so you can pursue your dreams of creations?

    Do you want some filthy corporate pigs get rich off your discoveries or creations, so their kids can go to Harvard, and your own kids can go nowhere because you don't have any money to pay for their education?

    Keep living off your dreams, young people, and never get married.
    Because the day you get married, your wife will f****** clean this altruistic nonsense out of your brains, or you will end up being single and broke again pretty soon.

  50. Misread the title by whitehatlurker · · Score: 1
    I have to get caffeine before reading this stuff... otherwise I would not have seen:

    The Law of Unintended Consequences: Parents

    --
    .. paranoid crackpot leftover from the days of Amiga.
  51. Re:Real unintended consequences--Mansfield Amendme by biobogonics · · Score: 1

    Just go to the musty bookshelves of one's university to the mathematics section and look for books before 1970. Many of them will have an acknowledgement of funding through some agency such as the Office of Navel Research.

    Not just mathematics but also computer science, including some of the *big names* in the field.

  52. An Observation by Anonymous Coward · · Score: 0

    Just yesterday I pulled out a little booklet that gives highlights of the year that I was born... 1955. In this book it gives the prices for typical products and services in that year. Most of the items, i.e. cars, homes, gasoline, clothes, etc. were approximately one tenth of the cost that they are today.

    However, there were some very notable differences from this trend. Food prices are only 2-3 times more expensive than in 1955.

    But college expenses and medical expenses are now much higher than 10 times the 1955 prices. For example, one year tuition at Harvard was $800 in 1955. It is now about 36x that amount.

  53. Re:Another example: totalitarian countries by Harinezumi · · Score: 1

    Indeed, the Soviet engineer's salary was so small, it spawned its own genre of humor. And yet they still managed to maintain nuclear parity with the West, get men into space, and build cars that would start (with some coaxing) in -20C cold. All in the face of a crippling bureaucracy that made PHBs look like renaissance men.

  54. Astouding quote... by CaptainPinko · · Score: 1
    According to the provisions of Bayh-Dole, the government gets a royalty-free use, forever, of its funded inventions. It has never tried to collect.

    If this isn't the grossest mismanagement of government funds this side of the Atlantic I don't know what is.

    --
    Your CPU is not doing anything else, at least do something.
    1. Re:Astouding quote... by MrCopilot · · Score: 1
      I was trying to stay out of this discussion due to my aversion to patents and reading them. But then I come across this:

      If this isn't the grossest mismanagement of government funds this side of the Atlantic I don't know what is.

      More mismanagement of govt funds on this side of the atlantic info
      http://www.taxpayer.net/
      http://councilfor.cagw.org/site/PageServer?pagenam e=CCAGW_homepage
      http://www.akdart.com/waste.html

      I could go on all day.

      --
      OSGGFG - Open Source Gamers Guide to Free Games
  55. Patents limit innovation (of course) by Anonymous Coward · · Score: 0

    Patents limit innovation. Of course it's true. Patents do for innovation exactly what trade barriers do for econimics, and also what knowledge hoarding (closing libraries, etc) does for basic human literacy: these devices are designed to kill. If you want more wealth, drop trade barriers. If you want more literacy, build libraries. If you want innovation, kill patents. Note that greed gets in the way of each of these (personal, corporate, national). I could probably tie freedom to demcracy somewhere here too as yet another analogy, but it's early and I haven't yet had coffee.

  56. You mean... by Anonymous Coward · · Score: 0

    "Of course, that's assuming that you consider it moral and just to forcefully extract revenue from people -- who may fully oppose your agenda -- in order to fund that agenda."

    You mean like invading Iraq and Afghanistan...and funding Isreal, and sending funding to churches (er...faith based charities), and using the FBI to make sure the record companies get their profits? Or pissing away zillions of dollars in NO primarily to pocket Bush's campaign contributors?

    Is that what you meant?

    1. Re:You mean... by Omnifarious · · Score: 1

      *chuckle* That's what I hate most about the Republican party. They have captured many well-meaning libertarians by seeming to stand for what they believe in while actually being almost diametrically opposed.

  57. Re:Grow up, young people ! by kfg · · Score: 1

    But some day you grow older, get married, have kids ...

    My daughter is 26.

    You will likely find, if you go around talking to older, "successful" people, that most of them report they and their familes were happiest back in the day when they lived in a shack and went hungry now and then.

    My wife bought her own engagement ring. It was a zircon. She thought it was idiotic to spend money on a rock when we could use it better for a decent car or on heating oil. I bought her a CS degree to go with her Antrhopology degree. Geek girl.

    The most likely time for a couple to get divorced is when they get money.

    KFG

  58. Punished By Rewards by mblase · · Score: 1

    A while ago, I read "Punished By Rewards: The Trouble with Gold Stars, Incentive Plans, A's, Praise, and Other Bribes" by Alfie Kohn as part of a class assignment.

    It hammered home its point, but quite clearly: whenever you offer money, or any other incentive, to people in exchange for something they would ordinarily do for free, they stop being interested in doing it for its own sake and instead focus on the reward.

    This goes for universities and scientists as well as grade school children. By offering scientists millions of dollars in patent rights for something they were already doing just because they were good at it, they've made them lost focus on innovation and discovery.

    (That's a mighty good book, by the way, because it covers not just schoolchildren, but how incentives and motivators in the corporate workplace often end up doing the opposite of what they're supposed to do. Scott Adams would be proud.)

  59. Bad example: nobody was rich in the old USSR ! by fizteh89 · · Score: 0

    Nobody was rich in the old Soviet Union, except, maybe, for a few Communist Party bonzas and a few undercover millionaires.
    This is the principal difference between a communist regime and a modern capitalist society like US.
    It's a question of basic fairness: if you create something new and original, can some other individual get rich off your creation without giving anything back to you?
    In the old Soviet Union the answer was NO: nobody, including you, will make any money off your creativity. Therefore, they didn't even need patents: they had something called
    "avtorskoye svidetelstvo", a document confirming that you are, in fact, the original creator, something without any monetary value just to satisfy your pride.
    In the US the answer is YES: some filthy corporate pigs will certainly try to add to their already substantial wealth without even thinking of providing some compensation for you, the original creator. That is why patents and copyrights are unfortunately necessary in a capitalist society.

    1. Re:Bad example: nobody was rich in the old USSR ! by lahvak · · Score: 1

      Nobody was rich in the old Soviet Union, except, maybe, for a few Communist Party bonzas and a few undercover millionaires.

      False! It is true that Soviet Union didn't have a significant number of millionaires, but there were always those who, for example, at the time of a housing crisis had three large appartments and a "dacha" somewhere on a beach. It may not count as rich when compared to Bill Gates, but it was filthy rich compared to the general population.

      Second, while SU didn't have patents, some other countries (e.g. Czechoslovakia) did, the system being somewhat similar to the american one. The patents even had some, if not large, monetary value. You could even make a living as an independent inventor, although most people who chose to do that had some additional source of income, like a night job or pension or something.

      As for artists, you could become rich (relatively) by doing the right kind of "art" for the right people (why do I have an urge to put the word people in quotation marks, too?) Most artists chose to remain poor, and to even risk their freedom (also relative) for their art.

      As for somebody making money off your creativity, I don't think that any of the people who counted as wealthy in those societies were rich because of their own achievements.

      In short, I was not trying to make case against or for a patent system. I was just pointing out that even in a society in which creativity didn't bring monetary award, and was actually often risky, art and science could fluorish. I don't think the example was that bad.

      --
      AccountKiller
  60. Wrong answer.. by mengel · · Score: 1
    Why doesn't the government do this?

    The government doesn't do this because our Congress-critters are completely beholden to big drug companies and insurance companies to fund their campaigns and political party infrastructure, and doing this would make a dent in the drug company and insurance company profits. This is, in general, the reason the Government doesn't commercialize inventions; business interests make sure Congress knows they'll lose campaign funding if they vote for such things, and companies sue for restraint of trade if government branches do compete with them.

    So no, the legal system is not amenable to this -- the legal system is amenable to the folks with the most cash.

    --
    - "History shows again and again how nature points out the folly of men" -- Blue Oyster Cult, 'Godzilla'
    1. Re:Wrong answer.. by tambo · · Score: 1
      The government doesn't do this because our Congress-critters are completely beholden to big drug companies and insurance companies to fund their campaigns and political party infrastructure, and doing this would make a dent in the drug company and insurance company profits.

      You are entirely correct. There is rampant corruption in government due to lobbying. It's interesting that even Adam Smith, the spiritual icon of the laissez-faire capitalists, warned of grave danger in letting companies get too large, since they would use their profits to corrupt the political system. He was correct.

      The answer to that problem is pretty simple: we need more responsible voters. We need people to pay attention to elections and evict politicians with undue ties to private organizations. Unfortunately, the deep political apathy of most Americans defeats that effort.

      I don't have a solution to that problem. I can only agree with you here, both to the existence of this problem and the terrible consequences.

      - David Stein

      --
      Computer over. Virus = very yes.
  61. I don't think the field is the difference. by pavon · · Score: 1

    I agree with Daniel's post, there is some computer research that does develop significant new advances. The reason that the vast majority of software patents are garbage is not because software research yields less good results than biotech research but because the patent office allows people to patent what they are doing, not how they are doing it (and also because there is no practical, objective way to determine the non-obviousness of an invention).

    But even in the cases where computer research does result in legitimate advancement in the field, I am not at all convinced that granting a monopoly helps the "advancement of arts and science" when it comes to the computer industry. Video codecs are an excellent example of work that does require a good deal of research, and thus fit the traditional criteria of being useful, novel, and non-obvious.

    However, what been the effect of codec patents on the industry? It has devolved the standardization process into a political battle where all parties involved are just trying to get their patented technology included, so that they can get their part of the royalty pie. It has significantly increased the cost of video encoding, and the lack of a truly open standard has complicated the task of getting video to people in a format they can play. Worse, the patents are increasingly being used not to protect their invention, but to force certain behavior on the rest of the industry, by refusing to license patents on "standard" formats to groups that do not comply (for example if they don't implement DRM).

    As for the benefits of patents, I have a very hard time believing that someone somewhere would not have developed quality codecs in the absence of patents. Many of the encoding techniques developed were started by researchers in Universities who then moved onto industry where they refined their ideas. The effect of industry may have initially been to accelerated codec development through funding research. However, in the long term it appears to have also hindered it by locking the results up in patents, thus limiting the ability of researchers to collaborate and improve upon existing designs.

    So all in all, the evidence that codec patents helped the industry is fairly weak, while it has definitely hindered the industry.

    As for the merit of biotech patents, well the entire economic model of the medical field in this country is a mess. I am only beginning to wrap my head around what the sources of the problems are, and am in no position to give suggestions as to how to improve it.

  62. Re:Real unintended consequences--Mansfield Amendme by Omnifarious · · Score: 1

    You possess a vocabulary that is entirely too large for your own good. :-)

  63. May I ask... by cr0sh · · Score: 1

    What exactly is "Christian Science-Fiction"? It seems like an oxymoron to me. I could understand the idea of Christian Fantasy fiction (although, I will admit, a lot of so-called science-fiction should be re-classified as fantasy) - but mixing the ideas of religious faith (which is untestable and therefore unverifiable, by definition) with science (which is testable and verifiable), seems like two topics which would be at odds with each other (however, this hasn't stopped creationists with their approach of "intelligent design", so I suppose such a genre of science-fiction could exist, no matter how laughable it would be to read it with a sceptical mind)...

    --
    Reason is the Path to God - Anon
  64. Oh, "patent trolls" again, just shup up, please ! by fizteh89 · · Score: 0

    Freedom Wireless a "patent troll" ?!!!!!!!!!

    You are just insulting people for no reason.
    And you can be an ex-con and inventor at the same time.
    What is your f****** problem with that ?

    Thomas Edison would be the biggest patent troll nowdays, by the way: he had a bunch of patents
    but never produced anything on commercial scale.

    "Patent troll" myth is being propagated by sleazy
    and filthy rich patent counsels working for big
    tech companies to facilitate the passage of the Patent Act of 2005,
    which will make it legal for them to steal IP from small startups and independent inventors.

  65. Consider the Austrian view by Anonymous Coward · · Score: 0

    For those of you who demand a more principled rigorous intelectual treatment of the general subject of IP, I'd recommend that you consider the Austrian view.

  66. Re:Why patent at all, a Copyright notice is cheape by angle_slam · · Score: 1

    There should be a rule that a post longer than X number of character can't be modded insightful if it lacks paragraph tags.

  67. Re:Real unintended consequences--Mansfield Amendme by Anonymous Coward · · Score: 0

    Read the wiki... "But the resulting brain drain is also credited with boosting the development of the fledgling personal computer industry. Many young computer scientists fled from the universities to startups and private research labs like Xerox PARC."

    some good came of this :)

  68. about reading the fucking article by N3wsByt3 · · Score: 1

    "I have no idea what you mean here."

    I'm sorry, but the two parent posters which already responded to you with a "RTFA" are right: you *should* RTFA.

    "It hasn't impacted research much because [/snip your own unsubstantiated theory]"

    Ermm...once again: RTFA. It clearly indicates that there IS a considerable impact on research. I mean, what, it has two pages which deal with several actual criteria to show the downfall in innovative research, so how can you say exactly the contrary, unless you *didn't* RTFA?

    Or, if you are so convinced of your own theory why it can't be that R&D is in decline, please explain why the facts indicate otherwise.

    "Completely untrue. The amount of federal funding flowing into the academic commons has grown over time - particularly in the last ten years."

    Are you trying to be obnoxious on purpose? He (the parent poster) clearly was talking about research flowing *back* into the *academic commons*. Federal funding isn't flowing back; it's simply payed by our tax-money. what the prent poster was aluding at, was the age-old principle of 'scientific sharing', which is essential to scientific progress as a whole, because one scientist builds on the work of another, etc. By having further commercialised the whole process (especially with patenting), this process has been severely limited and restricted. Which, as I (and others) have said before, has led to less innovation and less academic sharing - hence the reduced flowing back of research to the academic commons.

    --
    --- "To pee or not to pee, that is the question." ---
    1. Re:about reading the fucking article by tambo · · Score: 1
      I'm sorry, but the two parent posters which already responded to you with a "RTFA" are right: you *should* RTFA.

      I did - last night - and I didn't see any mention of some kind of change in the patent process, whereby researchers used to "automatically" receive patents for anything. Show me where the article mentions that.

      RTFA. It clearly indicates that there IS a considerable impact on research. I mean, what, it has two pages which deal with several actual criteria to show the downfall in innovative research...

      Criteria? Try "criterion," singular. The only metric they cited about "impact on research" is a really crappy one: "While the number of journal articles produced by American researchers has risen slightly since 1988, the rest of the world has raced ahead (see chart)."

      The conclusion from this single metric that U.S. research is slowing down due to the Bayh-Dole Act lies somewhere is thoroughly specious. The rest of the world has spent the last 20 years finally getting into biotech. And as any actual scientist can tell you, publication quantity != knowledge quality. Etc.

      He (the parent poster) clearly was talking about research flowing *back* into the *academic commons*. Federal funding isn't flowing back; it's simply payed by our tax-money.

      How was it "flowing back" before? What magical mechanism existed to reinvest money in successful labs that was tragically shredded by the Bayh-Dole Act and the patent system? There wasn't one. Since that number was $0 before 1980, it can't have "sharply decreased," now can it?

      - David Stein

      --
      Computer over. Virus = very yes.
    2. Re:about reading the fucking article by cyberon22 · · Score: 1
      I did - last night - and I didn't see any mention of some kind of change in the patent process, whereby researchers used to "automatically" receive patents for anything. Show me where the article mentions that.


      Its right at the top of page two. But since you apparently didn't catch it either time you read (surely you went back to check before trolling), here it is:

      It was one piece of federal legislation that you've probably never heard of--a 1980 tweak to the U.S. patent and trademark law known as the Bayh-Dole Act. That single law, named for its sponsors, Senators Birch Bayh and Bob Dole, in essence transferred the title of all discoveries made with the help of federal research grants to the universities and small businesses where they were made.

      Prior to the law's enactment, inventors could always petition the government for the patent rights to their own work, though the rules were different at each federal agency; some 20 different statutes governed patent policy. The law simplified the "technology transfer" process and, more important, changed the legal presumption about who ought to own and develop new ideas--private enterprise as opposed to Uncle Sam.


      Your claim that the number of drugs under testing for public release is a "crappy" metric for drug-focused innovation is specious.
    3. Re:about reading the fucking article by tambo · · Score: 1
      Its right at the top of page two.

      No, it's not.

      You're not understanding how this works. Researchers could freely apply for patents before the Bayh-Dole Act, exactly as they could after the Bayh-Dole Act. In each era, the patents were prosecuted in almost exactly the same manner, and would eventually issue in the names of the researchers. Nothing here has changed about how "researchers get patents."

      What changed, and what the snippet you posted mentions, relates to the rights conferred by the patent. The federal government used to own those rights, to the exclusion of the university, but the researchers could ask the government to give those rights back. Now the university initially owns them, subject to certain rights reserved to the government. Who owns the rights to the patent is a wholly different concept from how researchers "get" patents - which has not changed.

      You seem to have this recurring problem of pasting text, and then drawing a summary of it that's completely wrong. You might want to mention this problem to your doctor - he might be able to prescribe something to help your reading comprehension.

      - David Stein

      --
      Computer over. Virus = very yes.
    4. Re:about reading the fucking article by tambo · · Score: 1
      Your claim that the number of drugs under testing for public release is a "crappy" metric for drug-focused innovation is specious.

      What I characterized as "crappy" was the reference to the percentage of academic publications by America vs. the rest of the world, as an indication that U.S. research is slowing down because of the Bayh-Dole Act. I wasn't referring to "the number of drugs under testing for public release" or "drug-focused innovation" when I made that statement.

      Seriously, your reading comprehension is just terrible. You should consider asking your doctor if you have ADHD before posting again. They make drugs for that, you know.

      - David Stein

      --
      Computer over. Virus = very yes.
    5. Re:about reading the fucking article by cyberon22 · · Score: 1
      What changed, and what the snippet you posted mentions, relates to the rights conferred by the patent. The federal government used to own those rights, to the exclusion of the university, but the researchers could ask the government to give those rights back.


      I do not know anyone who has ever taken out a patent for the federal government.
    6. Re:about reading the fucking article by tambo · · Score: 1
      I do not know anyone who has ever taken out a patent for the federal government.

      Who mentioned anything about a patent "for" the federal government?

      Out of three comments this evening, you are 0/4 for reading comprehension. That may be a Slashdot record. Seriously - Zoloft - it will do you some good.

      - David Stein

      --
      Computer over. Virus = very yes.
    7. Re:about reading the fucking article by cyberon22 · · Score: 1

      Look pal, your argument isn't with me. Its with the researchers who failed to take out and commercialize patents because they didn't own the patent rights to work that was government funded.

      If you have issues understanding human rationality you'll have to solve them on your own.

  69. about reading the fucking article (2) by N3wsByt3 · · Score: 1

    "I did - last night - and I didn't see any mention of some kind of change in the patent process, whereby researchers used to "automatically" receive patents for anything. Show me where the article mentions that."

    Where did you get that premisse? Nobody is arguing about a patent reform that automatically grants patents for everything, so I'm inclined to see this as a false dilemma.

    That is entirely not the question. Rather it is about the change (amendment) of the law that made (quote): "The law simplified the "technology transfer" process and, more important, changed the legal presumption about who ought to own and develop new ideas--private enterprise as opposed to Uncle Sam." With as result a declining R&D and innovative products.

    Strange you should have missed that part, if you RTFA: it's already on page 2, paragraph 2 and 3.

    "The only metric they cited about "impact on research" is a really crappy one:[...]"

    Untrue, the decline in R&D and innovative new products have been indicated (1)by the produced articles, as you said (and which they themselves say is difficult to pinpoint, but this IS the way in academic circles to put a value onto it, so it's not like they're making the criterion up). (2)They also use the data of the total number of FDA-approved compounds and biologics in a current year, (3)but also at how many priority NMEs are making it through: by both measures, the productivity picture is much worse than it was in 1996. (4)And lastly, they looked at the university-linked businesses which are using these patents, to see what they actually produce in innovative products, which in most cases have almost nothing to show for.

    It seems, again, curious you should have missed all that, when reading the article: it's on page 5 and 6.

    I agree the causality between this decline, and the Bayh-Dole Act, is not irrefutably proven. I think this is always hard to do, in these matters. But at least there is a strong indication of a correlation, which is more then can be said of your theory. If you're so convinced of the benefits of the law and that it's not true there is a decline of R&D and inovative products (in this case drugs), please explane the data provided by the author that indicates otherwise. And please indicate your data which might substantiate your claim and theory.

    I mean, you may dispute the value of 'produced articles' (even when the academici themselves use it as value-measurement), but what, exactly, do *you* offer to substantiate your claims? And I mean in actual data, not esotheric reasonings or opinions.

    All things equal, surely you will agree he made a far better case about his theory, then you with yours - at least, as yet.

    "How was it "flowing back" before? What magical mechanism existed to reinvest money in successful labs that was tragically shredded by the Bayh-Dole Act and the patent system?"

    Hmmm...I'm beginning to see why you 'missed' so much from RTFA. It seems you have a very selective reading.

    Let's go by this one step at a time:

    Original: "He (the parent poster) clearly was talking about research flowing *back* into the *academic commons*."

    Notice the word research.

    Now, your answer: "What magical mechanism existed to reinvest money in successful labs that was tragically shredded by the Bayh-Dole Act and the patent system?"

    Notice the word money.

    Now, did anyone talk about money flowing back, or research? Well, heck, it was research.

    Is research and money the same thing?

    No, it isn't.

    Thus, is your answer to the point?

    No, it isn't. And that's why you missed my explanation about what is actually meant by the flowing back of research completely. and that's why you missed so much in the article too: the whole thing was about how that law disturbed the age-old process of 'scientific sharing' by focussing on the commercial prospects of patenting tax-funded research, and the decline in R&D and innovatyive drugs that followed, when it was supposed to stimulate it.

    The 'sharply decreased' was never about the incomming money, and if you had read TFA a bit better, we could have spared us this whole discussion.

    --
    --- "To pee or not to pee, that is the question." ---
    1. Re:about reading the fucking article (2) by tambo · · Score: 1
      Where did you get that premisse? Nobody is arguing about a patent reform that automatically grants patents for everything, so I'm inclined to see this as a false dilemma.

      How about this? "Inventions are now patented which would not have been patented previously because researchers could not *automatically* get patents for federally-funded research."

      That was the point I was responded to with "I have no idea what you're talking about." You then saw fit to ride in with a "RTFA" response, which, you should now see was a hasty mistake on your part. Naturally, I won't hold my breath waiting an apology or admission of error.

      (1)by the produced articles, as you said (and which they themselves say is difficult to pinpoint, but this IS the way in academic circles to put a value onto it, so it's not like they're making the criterion up)....

      It might be a way to measure U.S. contribution to science vs. that of the world. It's a much bigger leap to infer that the Bayh-Dole Act or licensing is the cause of that. That was my point.

      (2)They also use the data of the total number of FDA-approved compounds and biologics in a current year, (3)but also at how many priority NMEs are making it through...

      ...which metrics they off-handedly reference but do not cite, and merely suggest are "worse" and cherry-pick a particular fact. No verification; no sources that we can use for cross-referencing.

      I mentioned in another comment why Fortune chose not to report its source for these metrics - because the metrics vary a lot depending on which fields you look at, and how you define your terms. This isn't obfuscation; it's genuinely hard to correlate NME data to pharmaceutical company productivity. See my other comment, and better still the article I referenced there, for more info.

      And lastly, they looked at the university-linked businesses which are using these patents, to see what they actually produce in innovative products, which in most cases have almost nothing to show for.

      That's an excellent circular argument. "As proof of pharmaceutical company productivity, let's look at university business. Oh, hey, it's way up! They earn great licensing revenue and get a lot of patents! Well, that just proves that the Bayh-Dole Act is strictly a distraction; all of that business activity is happening in spite of the proven low productivity of pharmaceutical companies (see above.)"

      He (the parent poster) clearly was talking about research flowing *back* into the *academic commons*." Notice the word research.

      Research "flows?" What an imagination you have. You're using the fanciful part of your mind to envision some magical, intangible substance called "research" that graciously wafts back and forth between the gleaming towers of academia. If you close your eyes, and maybe ingest some hallucinogens, you can almost see the twinkling streams of "research," rippling as if brushed by a light breeze, flowing happily from one university to another. But here comes the big bad cave troll called Business, or maybe Patents, which gobbles up all of the flowing research and leaves behind a charred wasteland. No more flowing "research!" The landscape of research has been forever polluted, twisted into a blackened desert of greed!

      Back here in the real world, "research" is an activity that takes place in a lab. It doesn't "flow" in any way, shape, or form, so it's impossible for "research" to "flow" back into a lab. Money flows in; results flow out - that's about it.

      In other words, the literal meaning of that statement is nonsensical. I was trying to translate the original poster's nonsensical statement into what he probably meant, in order to respond to it. Again, you hastily rode in with a condescending "RTFA" response - without stopping to consider that the meaning you claim I missed is nonsense.

      This was your second mistake. Again, I won't await an admission of error. I will just recommend that you quit while you're... not farther behind.

      - David Stein

      --
      Computer over. Virus = very yes.
    2. Re:about reading the fucking article (2) by N3wsByt3 · · Score: 1

      "That was the point I was responded to with "I have no idea what you're talking about." You then saw fit to ride in with a "RTFA" response, which, you should now see was a hasty mistake on your part. Naturally, I won't hold my breath waiting an apology or admission of error."

      And you shouldn't, or you would turn blue like a smurf! ;-)
      Even the parent poster didn't say 'everything', but in any case, you seem to have a tendency to go for the semantics or your own interpretation of what is said, rather then the obvious meaning of the arguments. In this case, you could keep continue to say 'no new patentlaw has emerged', but someone reading the parent post (without bad will) would realise he was talking about the amended law and what it changed, as is portrayed by the article (this whole discussion IS about what is said in the article, after all).

      Now, in all honesty: did you *really* failed to realise this? Do you actually think it is about patenting everything for everybody...or are you going to be sensible, instead of obnoxious, and agree it's exactly about the issue I've quoted in my former post, where I, as well as the former poster, was talking about. (and which you were well aware off, IMHO).

      "It might be a way to measure U.S. contribution to science vs. that of the world. It's a much bigger leap to infer that the Bayh-Dole Act or licensing is the cause of that. That was my point."

      And your much smaller leap to substantiate your theory is..what, exactly?

      I already agreed that the causality is not proven. But meager as the data may be, the indications rather show some support to his theory. It certainly *does not* show any support for your theory. So, if you claim the contrary; what data do you use (which is, obviously, a lot better then the mere correlation of his data).

      "...which metrics they off-handedly reference but do not cite, and merely suggest are "worse" and cherry-pick a particular fact. No verification; no sources that we can use for cross-referencing."

      Are you suggesting their conclusions or claims in these matters are untrue, or merely inadequately referenced with sources? I'm inclined to think that, if they have looked at those criteria and say it has declined, they are not merely inventing it to be interesting.

      True, it would be nice to see the whole methodology, statistic analysis, and what not, but I doubt the article was meant for scientific peers. And yes, one could be obnoxious again, and claim they don't show proof or sources, but then again, even if they did provide a link as source, one could always claim it's untrue. *Nothing* on the web can be deemed to be true (or untrue) when push comes to shove, so the point remains rather moot. Why, in fact, bother with anything what they say, then? If they lie about the decline in NME's, they can lie about everything... and the sources they might link to, can be complete false too.

      Your explanation why they say 'worse' is intriguing, but remains speculation at best. And, somehow, I doubt you would be more happy if they had said a '20% decline', for instance: I'm sure you would have found something else to dismiss the whole thing.

      Mind you, for someone so keen on having 'hard' evidence, you're rather meager on providing some data for your own claims and theory.

      "As proof of pharmaceutical company productivity, let's look at university business. Oh, hey, it's way up! They earn great licensing revenue and get a lot of patents! [...]"

      Ermm... you are unable to get your capitalistic-orientated mind of anything but money, are you? For the last time: it's about the declining R&D and innovative new products, as an unforseen consequence of the amendment of the law, NOT about what some universities may or may not see in monetary return for their tax-sponsored research. And in those area's, most of those companies have very little to show for, indicating that it's not the breeding ground of R&D and new products which it was claimed the law would provide f

      --
      --- "To pee or not to pee, that is the question." ---
    3. Re:about reading the fucking article (2) by tambo · · Score: 1
      Even the parent poster didn't say 'everything', but in any case, you seem to have a tendency to go for the semantics or your own interpretation of what is said, rather then the obvious meaning of the arguments.

      :shrug: You're focusing on the "everything" part. Since my first response to this guy/post, I have been focusing on the "automatically" part, or as the parent poster wrote it, the "*automatically*" part. As in: "researchers could not *automatically* get patents for federally-funded research" in drawing some kind of before/after contrast vis-a-vis Bayh-Dole.

      I have no idea what that means. Does he think that, at one point, researchers were automatically granted patents upon application? Or that, either before or after, they were not permitted to file for patents for federally-funded research? Or that the federal government "automatically" filed patent applications on their behalf?

      None of these interpretations make any sense. Nothing about patents is "automatic" that was non-"automatic" before, nor vice versa. I honestly can't tell what he meant by this. That's why I asked him to clarify, which is when you stepped in.

      And your much smaller leap to substantiate your theory is..what, exactly?

      I don't have to prove my theory to anyone. I didn't write an article of any kind (though I may in the near future - in a slightly more academic journal than Fortune - as this is a topic of great interest to me.) I'm mainly here to criticize the presumptive conclusions from the article, and from the Slashdot crowd.

      Are you suggesting their conclusions or claims in these matters are untrue, or merely inadequately referenced with sources?

      Yes. I'm suggesting that they have been somewhat sloppy and cursory in the factual backing for the conclusions they have drawn. This is Fortune Magazine - it's like a version of Teen Magazine for the Chief (.*) Officer crowd: very fluffy, mostly op-ed, no real analysis or hard data. That's its reputation, and it has earned it well.

      ...even if they did provide a link as source, one could always claim it's untrue.

      Hardly. Elsewhere in this thread, I (and others) posted data about the percentage of Americans with health insurance, and cited the U.S. Census. I also cited the growing trend in federal funding of research, which I pulled from the NIH website. There are certainly reliable sources out there - Fortune just chose not to cite any, any at all, for the few scraps of data that form the keystone of its argument.

      I doubt you would be more happy if they had said a '20% decline', for instance...

      At least that's a step toward verifiable. "Worse" is so... qualitative.

      Ermm... you are unable to get your capitalistic-orientated mind of anything but money, are you?

      Back up the train of thought a second. As a counter to my complaint about Fortune's lack of data, you referenced their citation on university research. That citation of theirs took the form of money (and patents.) Though I approve of it as a metric, it wasn't my choice to use money here - it was Fortune's.

      A cursory scroll through the posts would make it clear to you that sentence was not from me, but from the parent poster.

      Yeah, but you chose to castigate me over not adopting the literal meaning of the original poster, from which you apparently derived some kind of meaning. My point is that it has no cognizable literal meaning - it's jibberish. "Research" doesn't "flow" anywhere.

      The only one who is completely focused and sees it as the crux of the debate, is you.

      Not really. When I advocate for the patent system, and for the licensing method for drugs, I'm doing so for the sake of innovation. I don't care about the money; I want to see the U.S. push technology forward as fast as possible. The cash flow is an enabling means to that end.

      In reality, he, as well as I, are talking about what the a

      --
      Computer over. Virus = very yes.
    4. Re:about reading the fucking article (2) by N3wsByt3 · · Score: 1

      "So here, at last, we get to the crux of the argument, the difference between your views and mine."

      Indeed, it is, with the difference that it was also what the article was about.

      "The difference between your argument and mine is that you can't tolerate any restraints on that pool of ideas. I believe we have to in order to compel people to perform that other 99%."

      Well, I would rather claim the difference is that you make a personal cause for your opinions of it. You fail to realise that my or your personal preference is (or at least should) be irrelevant in discussing the point raised by the article, which was, alas, not about the flow of money which you keep bringing up (in line with your view).

      I'm not unreasonable about it; I think your question for more sources has some merrit, for instance. But seen the fact it was not meant as a science paper for peer-review, it is not all that uncommon. Now, maybe they did screw up their numbers; it's always possible...but, that remains to be proven, while you seem to act as if it is already proven to be bogus - the basis for which you mainly find in your unsubstantiated personal view about it. And, unless you have data which would contradict what they have (which you don't), the data they provide - incomplete with sources as it may be - do indicate some support for what they claim. Even when one can criticise the article, in any case it surely does *not* indicate that the law was beneficial *in terms of R&D and new products*; which was what the article was about.

      If the main point had been the monetary benefit, then your discussion, while still totally unsubstantiated, would at least have made sense. Instead, you have largely ingored the issue raised by the article, by repeating the (unproven) monetary benefits it brings.

      Your personal belief that one 'has to' restrain the pool of ideas in order to compel people to perform the 'other 99%' is irrelevant (or at least should be) in discussing the point the paper made. Alas, it clearly shows you let your own bias overrule everything else.

      If it *were* about the monetary benefits, even if it would go against my own personal beliefs, at least I wouldn't try to substantiate it by argumenting about the decline in R&D, if the article was about the money instead of the R&D. It may well be that - even though I would probably also mention the decline as an argument against it - I would come to the conclusion, indeed, that it has some monetary benefits for at least some universities, for instance. There is no reason to let your personal beliefs cloud your argumentation, after all.

      It's NOT about your views or my views, it about what the article said. And it didn't deal with the monetary aspect, it dealt with the decline in R&D and new products.

      --
      --- "To pee or not to pee, that is the question." ---
    5. Re:about reading the fucking article (2) by tambo · · Score: 1
      And, unless you have data which would contradict what they have (which you don't), the data they provide - incomplete with sources as it may be - do indicate some support for what they claim.

      But that support is about as minimal as it can be. I can claim to have seen evidence that UFOs landed in Roswell. If I don't tell you what that evidence is, I have eviscerated the assertion, because you can't check it. I guess it adds an iota more support than not claiming to have seen evidence at all... but it's a very small iota. ;)

      Your personal belief that one 'has to' restrain the pool of ideas in order to compel people to perform the 'other 99%' is irrelevant (or at least should be) in discussing the point the paper made.

      Isn't the central point of the article that the Bayh-Dole Act is (a) unnecessarily stifling academic research and (b) not really spurring drug innovation?

      My comment about the 1% vs. 99% exactly bears on both points. The academic research is the 1%; drug innovation is the 99%. It is possible that patenting the use of a particular protein to cure a particular disease may stifle research by other scientists into the use of that protein for that disease. (In fact, I don't see it that way, but let's say it does.) My point is that we have to permit this stifling of the other research - the 1% - in order to compel a pharmaceutical company develop a drug based on the idea - the 99%.

      - David Stein

      --
      Computer over. Virus = very yes.
    6. Re:about reading the fucking article (2) by susasusesume · · Score: 1

      How about you just quit being a troll?

  70. patent revenue and risk by logicpaw · · Score: 1
    Risk is risk. The problem is that most money men don't know how to handle risk.

    Actually, money people have been doing risk arbitrage for centuries. It's one of the reasons for the existance of futures and options markets.

    Patents which can legally enforce massive profits go hand-in-hand with risk. The bigger the possible payoff, the better that funding highly risky R&D looks to the money people. Take away the lotto chance for a massive payola, and the money people go for a much less risky (and interesting) portfolio of R&D.

    1. Re:patent revenue and risk by Master+of+Transhuman · · Score: 2, Insightful


      I agree in general, but my point is that money men need legal protection for their risk - which is then not exactly risk, is it?

      And the effect you mention in the last sentence is exactly the problem of patents - if somebody can claim a legal monopoly, others won't bother investing in the market - which reduces innovation.

      That's the reason legally protected monopolies are bad for the species - in the pure free market case, monopolies which arise (by natural means) are quickly (relative to the existing case anyway) torn down by investment in alternative means of accomplishing the same function. If the monopoly is legally protected - and patents overly broad - there is no incentive to invest in alternative and probably better means of accomplishing the same function; you won't make any money anyway.

      --
      Richard Steven Hack - This sig is TOO GODDAMN SHORT TO DO ANYTHING USEFUL WITH! MORONS!
  71. oh please read the fucking article by cyberon22 · · Score: 1
    Ad hominem attacks on me aren't stopping you from looking like an ass, especially now that you're pretending not to have written stuff like this:

    Criteria? Try "criterion," singular. The only metric they cited about "impact on research" is a really crappy one: "While the number of journal articles produced by American researchers has risen slightly since 1988, the rest of the world has raced ahead (see chart)."


    What you characterized as crappy was clearly a completely bogus claim that the article is based on one measure of research productivity. This was accompanied by vague and unsubstantiated attacks on .

    Frankly, if you don't think that the number of drugs shortlisted for "priority" testing by the FDA is a good metric for biomedical research you need to take some science courses. Proxy variables rarely get much better. Its stuff like this that makes you a shortlist candidate for President.

    Watching you flaggelate from ignorant outrage to ad hominem attacks is starting to be fun. And since you had trouble clicking through to page two (or counting to two judging by your "criteria" comment), you can find the link to that elusive quote below. If paragraph two of eight doesn't count as the "top" of a page, you're a pedant in addition to idiot.

    http://www.fortune.com/fortune/fortune75/articles/ 0,15114,1101810-2,00.html
    1. Re:oh please read the fucking article by tambo · · Score: 1
      Ad hominem attacks on me aren't stopping you from looking like an ass...

      There's nothing ad hominem about what I wrote. You may not like it; that doesn't make it unfair. You have now demonstrated five very basic reading comprehension errors in your posts. I am merely pointing that out.

      What you characterized as crappy was clearly a completely bogus claim that the article is based on one measure of research productivity.

      Now you're just confusing yourself.

      We've had two parallel but distinct arguments here:

      • How the article supports its notion that U.S. academic research has slowed down due to the Bayh-Dole Act - which was supported by one metric that is, at best, very indirect.

      • How the article supports its notion that pharmaceutical company productivity has not grown as a result of the Bayh-Dole Act - which it supported with a few barely-quantitative criteria ranging from poor to flat-out lies (as I demonstrated above.)
      Frankly, if you don't think that the number of drugs shortlisted for "priority" testing by the FDA is a good metric for biomedical research you need to take some science courses.

      Now you're just not reading at all. My criticism wasn't about the correlation between FDA-approved drugs and biomedical research productivity. That's fine. My criticism was that the metric was offered as a comparison, to show the effect of the Bayh-Dole Act - yet the numbers compared were both well after the Act was passed. They show nothing about the impact of the Act, because they fail to indicate what things were like before the Act went into effect.

      - David Stein

      --
      Computer over. Virus = very yes.
    2. Re:oh please read the fucking article by cyberon22 · · Score: 1

      Yes -- this might be a good time to review things:

      Your original post made three basic mistakes on which quite a few people corrected you. These are (1) that Bayh-Dole did not lead to an increase in the patenting of research, (2) it did not result in higher costs to consumers, (3) it did not have a negative effect on research. The fact that you were assailed so broadly with a roundside of RTFAs suggests exactly who has comprehension problems, or simple issues reading articles before commenting on them.

      The article explicitly discusses the relationship between Bayh-Dole and patents, and its revealing that you've shut up about that. Of the two that are left, the second is the weakest. If research and development are separate activites then there is simply no need for drug patenting. Producers will supply materials at their cost of production in competitive markets. Why create monopolies? Thats the theoretical argument anyway. In practice things are more complex and there are heavy financial subsidies for corporate drug development but your assertions about the market are neither practical nor theoretical.

      I'm skipping your third claim because it is counterfactual. Asserting that "they have created a host of new drugs since [1980]" is not a logical contribution to a discussion of the negative influence of a singple policy change on the pace and ease of biomedical research. This is doubtless the reason you've been slammed universally for failing to read the piece. You failed to understand the argument and then posted a "rebuttal" which was completely unconnected with the original argument yet drew the opposite conclusions. When you were called on this your defense was to attack Fortune for having a weak empirical base for its assertions. You aren't making a good argument, but neither are they, right?

      This is a different claim that the earlier one, and its one we can actually address by comparing the actual article to the things you claim it says. And your first salvo of idiocy was arguing that the piece only had a single metric on which to back its generalizations about problems that the Bayh-Dole act created for research. Even disregarding the various case studies, and reducing our scope of scrutiny to the one page of material titled "Measuring Producitivity", therefore it is amazing to find at least FOUR metrics. In review, these are:

      -- publications in key journals
      -- NME identication by the FDA
      -- FDA priority reviews
      -- performance of NASDAQ biotech firms

      Anyone can identify problems with these variables. Which makes it strange that the problems you started fixating on were actually addressed in the article. Your dismissal that "quantity is not quality" when it comes to publication is a case in point. Had you actually *read* the article instead of just searched in Slashdot quotes for something to attack, you would have discovered that the piece focuses on "key journals". Now there are lots of reasons to view this figure with suspicion (ie. the internationalization of science SHOULD result in a relative reduction of American contributions), but you picked the stupidest and most implausible.

      Now you apparently don't want to confront the fact that the article contains information you've denied, and are responding by trying to nit-pick the argument and argue that its various metrics and case studies *really* measure two completely different things: pharmaceutical company activity and basic research. Nevermind that we are evaluating an Act which was supposed to bring these activities closer together -- they are two completely separate activities!

      And its at this point that you've truly slipped the surly bonds and earth and floated into the stratosphere of fantasy. The government does not believe it. Researchers do not believe it. Non-profit organizations pouring money into medical research may do believe it. Small children should not believe it but may come to believe it if they watch enough Fox. I just hope your blinders provide some comfort in sheltering you from the terrors of facing the palace of cognitive dissonance you've created for yourself.

    3. Re:oh please read the fucking article by tambo · · Score: 1
      Frankly, if you don't think that the number of drugs shortlisted for "priority" testing by the FDA is a good metric for biomedical research you need to take some science courses.

      Jesus. Seriously, are we even speaking the same language? Is your browser filtering everything I write through Babelfish's English/Cantonese filter and then back again before displaying it to you?

      My original post argued none of the points you just indicated. Let me tackle each in turn:

      (1) that Bayh-Dole did not lead to an increase in the patenting of research,

      Wrong. I argued that the Bayh-Dole Act did not change the patent system in any way. That's why I wrote: "Before the Bayh-Dole Act of 1980, universities could patent inventions; after the Act, universities can still patent inventions, in exactly the same manner (foregoing the completely unrelated changes in patent law.)"

      If you'd asked me whether the Bayh-Dole Act had increased university patenting, I would have responded, Absolutely! It has certainly increased the number of patents held by my academic research center - we file over 100 applications/year, and this figure grows every year.

      But here's what the Act didn't change: (1) how those patents are obtained through the USPTO, (2) what kinds of technologies can be patented, (3) the scope of enforceability of the ensuing patent, (4) the prosecution and litigation costs of the patent... etc...

      My point, as I originally wrote it and as I write it now, is that the Bayh-Dole Act deals with who gets to commercialize te patent. That is, who owns the rights to the invention, including the rights to any ensuing patents, and what they can do with them. The Bayh-Dole Act only changed ownership rights to the technology, including rights the subsequent patents. This has certainly had an effect on patent activity, but the Act itself did not change anything about the actual patents or the process of obtaining or enforcing them.

      My argument here hasn't changed one bit in the last 24 hours - as it shouldn't have, because I was right. Any perceived shifting is the product of your addled reading comprehension skills.

      (2) it did not result in higher costs to consumers,

      Wrong. Neither my original post nor any of my ensuing posts discussed whether prices have risen. I don't even think that question has meaning, because my argument has been that without the Bayh-Dole Act, they wouldn't have had a product to buy. It's impossible to argue a price differential between one scenario where the product is available, and one where it's not.

      What my original post discussed was the philosophical component of that price - whether the patient has already paid for the drug by way of federal taxes. I don't believe that's true. I believe that federal grants are used to create the idea, and the consumer's payment is for the implementation of that idea as a drug. They are not "paying twice," philosophically.

      Again, that was my original argument, and I have maintained it up to and including this post. As I noted, the assertion that you thought I was making is not only nowhere in my posts, but is nonsensical.

      (3) it did not have a negative effect on research.

      Wrong. Closer, but but still wrong. My original post did not discuss the impact of Bayh-Dole on research in any way. I did mention the impact of Bayh-Dole on pharmaceutical company productivity, which is completely different. And I did mention the effect of Bayh-Dole on academic research in subsequent posts. But again, you're incorrect in summarizing my original post this way.

      And your first salvo of idiocy was arguing that the piece only had a single metric on which to back its generalizations about problems that the Bayh-Dole act created for research.

      You keep making these ridiculous mistakes. It's really getting tiresome.

      I did originally state that the article mentions only a single metric to

      --
      Computer over. Virus = very yes.
    4. Re:oh please read the fucking article by cyberon22 · · Score: 1
      If you'd asked me whether the Bayh-Dole Act had increased university patenting, I would have responded, Absolutely! It has certainly increased the number of patents held by my academic research center - we file over 100 applications/year, and this figure grows every year.
      Congratulations -- your Nth post and you finally engage with the article under discussion and find yourself actually supporting it -- the Bayh-Dole act has increased patent activity in the research sphere.
      These are used for different purposes. They are used to prove different arguments.
      Bullshit. They only work to "prove different arguments" if you assume basic research and the commercial licensing of it are two completely separate activities. They are not, and what make your claim even more specious is that the point of Bayh-Dole was to bring the activities closer than they had previously been. To review, you didn't bother to read the piece, starting making idiotic statements about it using your own and highly questionable assumptions of how the world works, and you got called on them. Cry me a river. You make a boatload of assumptions that no-one else makes and are surprised that people find the stuff you type completely incomprehensible. Case in point below:
      Neither my original post nor any of my ensuing posts discussed whether prices have risen.
      To the extent the rise in prices for services reflects monopolistic production, this is what people refer to when they claim to be "paying twice": once for for the research and one for the privilege of buying a product from a single producer at prices far above the cost of production. At this point, the best defense you've got is that you simply didn't read the article, and have no clue what you're talking about.
    5. Re:oh please read the fucking article by cyberon22 · · Score: 1
      they wouldn't have had a product to buy. It's impossible to argue a price differential between one scenario where the product is available, and one where it's not.
      If you fail to see the objection or believe that it is "impossible" to make this claim I would hazard that you have never taken a course in economics. Or read the article. The question is whether the marketplace for a particular product is competitive or monopolistic. When a market is competitive products are priced at slightly above their cost of production. This earns the manufacturer just enough profit to keep them from making something else. When there is a monopoly (created by patents) however, manufacturers can charge as much as the market will bear. Their profit rates are much higher because there can be no competition. Your misunderstanding seems driven by the personal conviction that UNLESS producers are guaranteed supra-market rates of return on investments, they will simply not commercialize research, even if the research costs have been borne by others. This is counterfactual for two reasons: (1) low barriers to entry have not led to a scarcity of generic drugs on the marketplace, (2) experiences in other industries illustrate that the lack of monopolistic control over technologies does not dissuade producers from making high-cost investments in it (ie. the computer industry). To provide a concrete example of how the article addresses this, and also expose another lie of yours in claiming that the only facts in the piece are on page 4 (possibly because it's the only section you've been forced to read), let us wade out to page 7-8 for a very concrete example:
      In October 1990 a researcher named Mary-Claire King at the University of California at Berkeley told the world that there was a breast-cancer susceptibility gene--and that it was on chromosome 17. Several other groups, sifting through 30 million base pairs of nucleotides to find the precise location of the gene, helped narrow the search with each new discovery. Then, in the spring of 1994, a team led by Mark Skolnick at the University of Utah beat everyone to the punch--identifying a gene with 5,592 base pairs and codes for a protein that was nearly 1,900 amino acids long. Skolnick's team rushed to file a patent application and was issued title to the discovery three years later. By all accounts the science was a collective effort. The NIH had funded scores of investigative teams around the country and given nearly 1,200 separate research grants to learn everything there was to learn about the genetics of breast cancer. The patent, however, is licensed to one company--Skolnick's. Myriad Genetics, a company the researcher founded in 1991, now insists on doing all U.S. testing for the presence of unknown mutation in the two related genes, BRCA1 and BRCA2. Those who have a mutation in either gene have as high as an 86% chance of getting cancer, say experts. The cost for the complete two-gene analysis: $2,975. Critics say that Myriad's ultrarestrictive licensing of the technology--one funded not only by federal dollars but also aided by the prior discoveries of hundreds of other scientists--is keeping the price of the test artificially high. Skolnick, 59, claims that the price is justified by his company's careful analysis of thousands of base pairs of DNA, each of which is prone to a mutation or deletion, and by its educational outreach programs.
      You are claiming that the patent Myriad took out on testing for this gene was necessary, as otherwise there would be no-one willing to offer tests for this gene on a commercial basis. This is simply stupid, and about par for the course for the rest of your logic.
    6. Re:oh please read the fucking article by tambo · · Score: 1
      They only work to "prove different arguments" if you assume basic research and the commercial licensing of it are two completely separate activities. They are not...

      *sigh* As with your tiresome "you didn't read the article" assertions, your attempt to prove that "they are the same" by sheer repetition isn't getting you anywhere.

      I have worked in the commercial licensing arena for over three years. I can tell you from experience that academic research and pharmaceutical research are about as different as they possibly can be, not only at my institution but at every academic institution I've ever encountered. You may as well equate novel-writing and library science, or automotive design and gasoline production, or filmmaking and DVD player design. One process produces a raw material that the other consumes, and that is the extent of the relationship.

      You don't have to believe me. I really don't care, because I'm done arguing with you.

      To the extent the rise in prices for services reflects monopolistic production, this is what people refer to when they claim to be "paying twice": once for for the research and one for the privilege of buying a product from a single producer at prices far above the cost of production.

      Your theory about price doesn't change the fact that my original post didn't address a rise in prices.

      ...another lie of yours in claiming that the only facts in the piece are on page 4 (possibly because it's the only section you've been forced to read), let us wade out to page 7-8 for a very concrete example:

      That's classic. You can't tell the difference between "data" and "anecdote?" No wonder you've had trouble following my arguments.

      If you fail to see the objection or believe that it is "impossible" to make this claim I would hazard that you have never taken a course in economics.

      You're just not following my arguments at all - as demonstrated by your 100% incorrect summary of my first post. Since you can't bother to read what I've written before responding, I'm done with you.

      - David Stein

      --
      Computer over. Virus = very yes.
    7. Re:oh please read the fucking article by cyberon22 · · Score: 1
      your attempt to prove that "they are the same" by sheer repetition isn't getting you anywhere.


      I'm not attempting to prove anything. I'm simply telling you what the article says since you criticize it but don't understand it.

      Your theory about price doesn't change the fact that my original post didn't address a rise in prices.


      Nonsense. You criticized someone suggesting that Bayh-Dole led society to "pay twice" for certain drugs. If you don't see the link between that and higher prices that's because you don't understand the issues at hand. RTFA.

      You can't tell the difference between "data" and "anecdote?"/BLOCKQUOTE

      You can argue that the variables the author uses are not good proxies for what he wants to measure. You can argue that the individual stories he presents are not representative of the biopharm industry as a whole.

      These are methodological issues, and I don't have issues with your raising them. I have issues with your denying the existing of supporting evidence for the author's argument just because you don't like it and disagree with his conclusions. Claiming that an anecdote does not constitute data is just the latest absurdity. If you want to be technical, it constitutes a single data point (N=1). The issues are with its representative sampling and power.

      I suspect the problem is that attacking someone on methodological grounds comes off as stupid when you can't (1) offer better evidence, or (2) suggest a better way of quantifying and analysing the issue. You've got a long way to go before you even start to do either.
  72. Re:Another example: totalitarian countries by varjag · · Score: 1

    In all former communist countries, you definitely couldn't get rich by doing science, not even in relative comparison to general population. Yet they had a lot of excellent scientists, and produced huge amount of research.

    You could do pretty well as an established scientist in USSR; better off than majority of population. There were periods when certain branches of science clashed with state propagandists (genetics, information theory) but in general it was possible to make good living (by Soviet standards certainly - a good car was a luxury back then) off science research. Doctorate paid well, and if you made some real advances recognized worldwide the Party took care to maintain your life at a reasonably comfortable level.

    Aritstic expression was far more problematic, as you were bound by official party line. Socialist Realism in visual arts and silly pop songs for musicians were pretty much all genres available if you wanted to live off it.

    --
    Lisp is the Tengwar of programming languages.
  73. WTF are you talking about ? by fizteh89 · · Score: 0

    >One possible alternative is to enable the people
    >who would directly benefit from the development
    >fund the development. As an illustration
    >consider if everyone in the nation who was at
    >risk AIDS infection were to put up $100 to fund
    >the development of an AIDS "vaccine."

    This is the most idiotic statement I read so far in this discussion.
    Truly a masterpiece of Slashdot idiotism.
    I guess those people at risk would really
    love this proposal of yours...

    1. Re:WTF are you talking about ? by Jah-Wren+Ryel · · Score: 1

      Please explain how letting the people who have a personal interest in the creation of an AIDS vaccine directly pay for that creation is idiotic.

      --
      When information is power, privacy is freedom.
    2. Re:WTF are you talking about ? by fizteh89 · · Score: 0

      There are many private organizations and funds sponsoring AIDS research.
      And everybody is free to donate, of course.

      But to expect that small individual contributions from people
      exposed to AIDS risk can make it possible to bring about new AIDS medicines is naive, to say it politely.
      For one thing, most of those needy people are dirt pour.

      This kind of research needs serious money which can only be provided by the government and by serious private investors, and investors want return on
      their money, although some charity also takes place.
      In particular, people in Africa need this thing badly and
      without charity they will be dying by the millions.

      But charity is charity, it has its limits.
      Serious people sponsoring expensive and risky research want to see a potential to make some
      profit, which can only be achieved with patents.

    3. Re:WTF are you talking about ? by Jah-Wren+Ryel · · Score: 1

      So, your whole point boils down to logistics problems. Kinda stupid on your part since I specifically addressed that point in my original post. Please read more carefully befor flying off the handle next time. That is all.

      --
      When information is power, privacy is freedom.
  74. Re:Why patent at all, a Copyright notice is cheape by OutOfFocus · · Score: 1
    Hi!

    It was meant to be a joke, not to be read, but to be skimmed for humor. If you actually read it, it's just garbage. ;)

    Have a nice day.